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Abstract 
Severe sepsis is a major burden in the intensive care unit (ICU) with persistently high mortality 
rates. Optimization of antibiotic dosing has been suggested as an intervention to improve clinical 
outcomes for critically ill patients with severe sepsis. However, current antibiotic dosing guidelines 
may not be appropriate for these patients, as they rarely consider the altered physiology and illness 
severity associated with this population. Optimizing antibiotic dosing using pharmacokinetic (PK) 
and pharmacodynamic (PD) principles can address these critical illness-related changes and 
promote therapeutic success. Due to their wide spectrum of antibiotic activity and excellent safety 
profile, beta-lactam antibiotics are commonly used for severe infections in the ICU. Two alternative 
dosing approaches to traditional intermittent bolus (IB) dosing, namely continuous infusion (CI) 
and extended infusion (EI), have been suggested to maximize the therapeutic potential of these 
antibiotics in critically ill patients. Collectively, the two dosing approaches can also be referred as 
prolonged infusion (PI). 
 
This Thesis aims to better characterize the pharmacokinetics/pharmacodynamics (PK/PD) of beta-
lactam antibiotics to determine whether there is any therapeutic advantage associated with PI dosing 
(CI and/or EI) as compared to IB dosing. 
 
This Thesis comprises of eight chapters. Chapter 1 is an introductory chapter which provides an 
overview of the published literature on the area of research. The discussion in Chapter 1 presents a 
theoretical framework behind the Thesis objectives. Chapter 1 concludes with the specific aims of 
this Thesis. 
 
Chapter 2 reports the findings of a prospective PK study which aimed to describe the population PK 
of doripenem in critically ill patients with sepsis and perform dosing simulations to develop 
clinically relevant dosing guidelines for these patients. Twelve critically ill participants receiving 
500 mg of doripenem 8-hourly as a 1-hr infusion were enrolled. The volume of distribution (Vd) 
and clearance (CL) of doripenem in this patient cohort were substantially different than those 
usually described in non-critically patients. As current dosing guidelines were mostly derived from 
the non-critically ill, findings from this study suggest that the licensed “one-dose-fits-all” dosing for 
doripenem is unlikely to achieve optimal exposures in critically ill patients. Empirical use of PI 
dosing should be considered to account for PK and illness severity differences, particularly when 
less-susceptible pathogens are involved. 
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Chapter 3 incorporates a published systematic review which compares the PK/PD data and clinical 
outcomes between CI and IB dosing to describe any potential merits supporting either of the two 
dosing approaches for critically ill patients. The findings suggest that beta-lactam CI may not be 
advantageous for all critically ill patients and may be beneficial in patients with severe infections.  
 
Chapter 4 describes the findings of a post hoc analysis on the Defining Antibiotic Levels in 
Intensive care unit patients (DALI) study, which recruited critically ill patients from 68 ICUs across 
10 countries. The analysis aimed to compare the PK/PD target attainment and clinical outcomes 
between PI (CI and EI) and IB dosing of meropenem and piperacillin/tazobactam in 182 critically 
ill patients. In this analysis, PI dosing significantly increased the target attainment for most PK/PD 
end-points. Data from this chapter also suggest that the critically ill patients who are most likely to 
benefit from altered dosing strategies are those with severe pneumonia and not receiving renal 
replacement therapy (RRT). 
 
Chapter 5 is a published review article which scrutinizes the methodology of clinical studies 
comparing CI versus IB dosing of beta-lactam antibiotics. Several issues and problems in the 
interpretation of results obtained from these studies are discussed. This finally led to a proposal of 
how a methodologically robust study should be performed to test the clinical outcome differences of 
CI versus IB dosing of beta-lactam antibiotics in critically ill patients. 
 
Chapter 6 reports the findings of the Beta-Lactam In Severe Sepsis (BLISS) study, which was a 
two-centre, randomized controlled trial of CI versus IB dosing of beta-lactam antibiotics, enrolling 
140 critically ill participants with severe sepsis who were not on RRT. This study aimed to 
determine if CI is associated with better clinical outcomes and PK/PD target attainment in critically 
ill patients, as opposed to IB dosing. In this study, CI of beta-lactam antibiotics demonstrated higher 
clinical cure rates and better PK/PD target attainment than IB dosing. The findings suggest that 
beta-lactam CI may be most beneficial for critically ill patients with severe infections, who are 
infected with less-susceptible microorganisms. 
 
Chapter 7 incorporates a published review article which systematically analyses the relevance of 
PK/PD characteristics of antibiotics and their potential roles in maximizing patient outcomes and 
preventing the emergence of antibiotic resistance. Based on the collated data, dosing approaches 
which are likely to reduce the risk of antibiotic resistance in the ICU were also proposed.  
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Chapter 8 will be the final chapter in this Thesis and summarizes the clinical findings of all the 
work and highlight potential areas of future research. 
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Chapter 1: Introduction and literature overview 
1.1 Introduction 
The mortality rate due to severe sepsis and septic shock in the intensive care unit (ICU) setting 
remains high despite recent therapeutic advances [1]. Source control of the infection, along with 
early and appropriate antibiotic administration, are the most effective strategies available to 
clinicians for the management of critically ill septic patients [2-4]. However, appropriate antibiotic 
administration is not straightforward as critically ill patients may develop pathophysiological 
changes that can alter the antibiotic pharmacokinetics (PK). Indeed, dosing that does not account for 
these alterations may lead to inadequate antibiotic exposure and therapeutic failure [5-8]. Beta-
lactam antibiotics are key in the treatment of severe infections due to their spectrum of antibiotic 
activity and overall tolerability. These antibiotics display time-dependent pharmacodynamics (PD), 
whereby the time which the antibiotic concentration remains above the minimum inhibitory 
concentration (MIC) best characterizes bacterial killing [9-12]. Based on this property, maximal 
beta-lactam activity is likely to be achieved through a continuous infusion (CI) or an extended 
infusion (EI) strategy which maintains concentrations at higher concentrations throughout a dosing 
interval, rather than traditional intermittent bolus (IB) dosing [13-17]. Different dosing approaches 
in critically ill patients with sepsis may lead to better attainment of PK and PD targets potentially 
leading to greater clinical success. 
 
1.2 Applied clinical pharmacology of antibiotics 
Pharmacology is the science of drugs or study of drug actions. The two main areas of pharmacology 
are PK and PD. Knowledge on PK and PD is essential to comprehend the complex effect of 
pathophysiological changes in critically ill patients and how they alter plasma and tissue antibiotic 
concentrations. Furthermore, a personalized dosing regimen can be established for critically ill 
patients by using pharmacokinetic/pharmacodynamic (PK/PD) principles. 
 
1.2.1 Pharmacokinetic considerations 
PK refers to the study of concentration changes of a drug over a given time period. It provides a 
mathematical basis to assess the time course of drugs and their effects in the body. The important 
PK parameters for antibiotics are: (a) volume of distribution (Vd); (b) clearance (CL); (c) peak drug 
concentration over a dosing interval (Cmax); (d) minimum drug concentration during a dosing 
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interval (Cmin); and (e) area under the concentration-time curve over a dosing interval (AUC) or 
over a 24-hour period (AUC0-24) [18]. 
 
1.2.2 Pharmacodynamic considerations 
PD is the study of the relationship between measures of drug exposure and pharmacological effect. 
For antibiotics, PD relates concentration to the ability of an antibiotic to kill or inhibit the growth of 
a pathogen. This can be done by integrating antibiotic PK data with information on pathogen 
susceptibility (e.g., MIC). PD indices include the following: (a) the duration of time (T) that the free 
(unbound) drug concentration remains above the MIC during a dosing interval (fT>MIC); (b) the ratio 
of peak drug concentration (Cmax) to MIC (Cmax/MIC); and (c) the ratio of the area under the 
concentration-time curve during a 24-hour period (AUC0-24) to MIC (AUC0-24/MIC) [18]. Together, 
PK parameters and PD indices describe the dose-concentration-effect relationship. Figure 1-1 
outlines the interrelationship of PK and PD. 
 
 
Figure 1-1: A diagram outlining the relationship between pharmacokinetics (PK) and 
pharmacodynamics (PD) of an antibiotic 
 
1.2.3 Bacterial kill characteristics of different antibiotics 
Different classes of antibiotics have been shown to have different kill characteristics on pathogens. 
These kill characteristics have been determined predominantly from in vitro studies and describe 
the PK measurements that represent optimal bactericidal activity [19]. Generally, antibiotics can be 
classified into three categories based on their modes of bacterial killing: (a) concentration-
dependent antibiotics (e.g., aminoglycosides); (b) time-dependent antibiotics (e.g., beta-lactams); 
and (c) both i.e., concentration and time-dependent antibiotics (e.g., vancomycin and 
fluoroquinolones) [12]. The fundamental concepts of antibiotic kill characteristics are further 
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illustrated in Figure 1-2. As an example, for time-dependent antibiotics such as the beta-lactams, 
fT>MIC is strongly correlated with bacteriostasis and bactericidal activity [12, 20-26]. Thus, for a 
time-dependent antibiotic, the longer the effective drug concentration is maintained over a dosing 
period the greater drug efficacy [25, 27, 28]. 
 
 
Figure 1-2: Pharmacokinetic (PK) and pharmacodynamic (PD) of antibiotics on a 
hypothetical concentration versus time curve 
 
1.3 Sepsis 
Severe sepsis and septic shock are the most common causes of morbidity and mortality in critically 
ill patients [1, 29-35]. In a multicentre point prevalence study involving 1265 ICUs across 75 
countries, 51% of the ICU patients were classified as infected on the day of study with an ICU 
mortality rate of 25.3% [31]. Data from a large European ICU study has further corroborated severe 
sepsis status as a major healthcare burden, whereby severe sepsis accounted for 26.7% of ICU 
admissions with mortality rates for patients with severe sepsis and septic shock were 32.2% and 
54.1%, respectively [33]. Based on the Malaysian Registry of Intensive Care report for year 2011, 
23.2% of Malaysian ICU patients developed severe sepsis within 24 hours of ICU admission with a 
mortality rate approaching 60% [36]. Despite an emerging trend for improved survival in ICU 
patients [32, 37-39], the mortality rate in critically ill patients remains unacceptably high 
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worldwide, ranging from 30-50% in severe sepsis and 40-87% in patients with septic shock [37, 40-
45]. As a consequence, huge hospital resources are spent worldwide on septic patients [46, 47]. 
 
The “older” definition of sepsis [48] has been refined in 2005 by The American College of Chest 
Physicians (ACCP) and the Society of Critical Care Medicine (SCCM) [49, 50] as an infection in 
the presence of systemic inflammatory response syndrome (SIRS) [50]. SIRS has been described as 
a constellation of physiological (e.g., temperature, heart rate, respiratory rate) and laboratory 
abnormalities (e.g., white cell count [WCC]) that accompany inflammation independent of its 
underlying aetiology [48]. Severe sepsis is defined as sepsis complicated by at least one organ 
dysfunction or tissue hypoperfusion. Organ dysfunction can be described using definitions that were 
previously developed by Marshall et al., [51] or a more recent definition used in the Sequential 
Organ Failure Assessment (SOFA) score [52].  Septic shock refers to acute circulatory failure 
characterized by persistent arterial hypotension unexplained by other causes. Specifically, septic 
shock can be defined as sepsis induced hypotension (hypotension is defined as a systolic blood 
pressure of <90 mmHg or mean arterial pressure of <70 mmHg or a systolic blood pressure 
decrease >40 mmHg), which persists despite adequate volume resuscitation in the absence of other 
causes for hypotension [48, 50]. 
 
1.4 Pathophysiological changes in critically ill patients with sepsis that can 
affect drug pharmacokinetics 
Physiological changes that can occur from either pharmacological interventions or the natural 
course of sepsis may alter antibiotic PK and consequently affect antibiotic exposure in critically ill 
patients. Vd and drug CL are the most important PK parameters in terms of calculating a drug 
dosing requirements and both may be significantly altered in critically ill patients with severe 
sepsis.  Table 1-1 describes the anticipated changes in Vd and CL of various antibiotics in ICU 
patients compared to the general population. 
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Table 1-1: Pharmacokinetic characteristics of hydrophilic and lipophilic antibiotics in general 
ward versus ICU patients 
Antibiotic PK parameters General PK Altered PK in ICU patients 
Hydrophilic Vd Low Vd  Vd 
e.g., aminoglycosides, 
beta-lactams, colistin, 
glycopeptides, linezolid 
CL Predominantly 
renal 
 or  depending on renal 
function 
Intracellular 
penetration 
Poor  interstitial penetration 
    
Lipophilic Vd High Vd Unchanged 
e.g., fluoroquinolones, 
lincosamides, 
macrolides, tigecycline 
CL Predominantly 
hepatic 
 or  depending on renal 
function 
Intracellular 
penetration 
Good Unchanged 
Abbreviation: CL, clearance; ICU, intensive care unit; PK, pharmacokinetics; Vd, volume of 
distribution. 
 
1.4.1 Changes of volume of distribution 
The Vd of a drug is defined as the apparent volume of fluid (usually expressed in L or L/kg) that 
drug distributes into to give a total concentration the same as is measured in the plasma. Changes in 
antibiotic Vd have been noted in critically ill patients [6, 53-57], and the contributing factors are 
discussed below. 
 
Sepsis involves release of various inflammatory mediators [49, 58-60] that eventually increases 
capillary permeability [61-63]. This capillary leak syndrome causes fluid shifting from the 
intravascular compartment to the interstitial space, which is commonly described as the third 
spacing phenomenon. This phenomenon increases the Vd of hydrophilic antibiotics, decreasing their 
plasma and tissue concentrations in critically ill patients [64]. Consequently, a higher dose of such 
antibiotics is needed in order to achieve effective antibiotic exposure in critically ill patients with 
severe sepsis. In contrast, fluid shifts have a minimal effect on lipophilic antibiotics as they 
inherently possess a larger Vd due to their greater partitioning out of the blood stream (typically into 
intracellular and adipose compartments). In addition, several medical interventions in the ICU such 
as aggressive fluid resuscitation [65-68], mechanical ventilation [69-72], extracorporeal circuits 
[73], the presence of postsurgical drains [74, 75] and total parenteral nutrition [76] have also been 
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reported to be associated with increased Vd and consequently decreased concentrations of 
hydrophilic antibiotics. 
 
1.4.1.1     Tissue perfusion and target site distribution of antibiotics 
Effective antibiotic concentrations need to be achieved in the interstitial fluid of tissues as most 
infections are thought to occur here [77]. However, critically ill patients with sepsis have shown 
diminished microvascular perfusion, which results in impaired distribution of drugs especially to 
sites of infection such as soft tissues [78-82]. This phenomenon can be attributed to capillary 
leakage, tissue oedema and microvascular failure which are frequently seen in such patients. Using 
an in vivo sampling technique known as microdialysis, the extent of antibiotic penetration into 
tissues of critically ill patients has been described [72, 83-88]. Critically ill patients with septic 
shock are initially managed with large boluses of intravenous (IV) fluids to increase blood pressure. 
However, in the presence of increased permeability, large administration of IV fluids eventually 
leads to extreme volume expansion in the interstitial space which markedly increases Vd for 
hydrophilic antibiotics [56, 89]. In patients with septic shock, antibiotic concentrations in interstitial 
fluid may be 5- to 10-times lower than corresponding plasma concentrations as well as those 
concentrations observed in healthy volunteers [90]. However, in patients with sepsis but without 
shock, there seems to be a less significant effect on tissue distribution and penetration of antibiotics 
[85, 91]. The difference in these findings may be attributed to the level of sickness severity (sepsis 
versus septic shock) whereby septic shock causes greater impairment in microvascular perfusion 
that leads to lower antibiotic penetration than patients with sepsis. 
 
1.4.1.2     Protein binding and hypoalbuminaemia 
Hypoalbuminaemia is a common condition in the ICU with reported incidences as high as 40-50% 
[92, 93]. In critically ill patients, hypoalbuminaemia is usually caused by the increase in capillary 
permeability [94], downregulation of its hepatic synthesis [95] and malnutrition [96]. What follows 
is an increase in the free concentration of drugs that are usually bound to this negative acute phase-
protein. The unbound concentration of such antibiotics is not only available for elimination, but also 
for distribution [97-106]. For moderate-to-highly-protein bound antibiotics, this phenomenon has 
been associated with a 90% increase in Vd [106, 107]. However, tissue concentrations remain low 
despite increased drug distribution, due to significant fluid shifts during the acute phase response 
and the large requirements for IV fluids in critically ill patients [97, 100, 102, 105, 108]. 
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1.4.2 Changes in drug clearance 
CL can be defined as the volume of blood (usually expressed in L/hr or L/hr/kg) cleared of drug per 
unit time. CL measures the irreversible elimination of a drug from the body by either excretion 
and/or metabolism. Changes in drug CL have been noted in critically ill patients [109, 110] with 
contributing factors discussed below. 
 
1.4.2.1     Increase in cardiac output and augmented renal clearance 
Critically ill patients with severe sepsis frequently develop SIRS. A major component of this 
inflammatory response is a hyperdynamic cardiovascular state, which is characterized by an 
increase in cardiac output (CO) and enhanced blood flow to major organs [111-113]. One of the 
major organs affected are the kidneys whereby the increase in renal blood flow associated with 
increases in CO leads to increases glomerular filtration rates (GFR) [109]. Furthermore, therapeutic 
interventions used to reverse hypotension in critically ill patients usually include large boluses of IV 
fluid and administration of vasopressor infusions, which are also associated with an early increase 
in CO and GFR [60, 111, 112, 114, 115]. Consequently, all of these factors lead to increased renal 
CL of some drugs, a phenomenon referred to as augmented renal clearance (ARC, defined as a 
creatinine clearance [CLCR] >130 mL/min). As hydrophilic antibiotics are predominantly cleared by 
the kidney, ARC in critically ill patients usually causes lower plasma concentrations [116-124]. 
Identifying patients with ARC is not easy as critically ill patients may have elevated renal function 
despite normal serum creatinine concentrations [125-128]. Thus, antibiotic dosing in this unique 
patient population is usually flawed as most clinicians fail to address this phenomenon [129]. 
 
1.4.2.2     End-organ dysfunction 
As disease progresses in a critically ill patient, myocardial depression may occur leading to 
decreased organ perfusion and microcirculatory failure eventually resulting in end-organ damage or 
in extreme cases, multiple organ dysfunction syndrome [60, 130, 131]. This syndrome often 
includes renal and/or hepatic dysfunction that consequently results in a decrease in antibiotic CL. 
The resulting accumulation of drugs and their metabolites in plasma increases the likelihood of 
toxicity [132]. It is imperative to note that certain antibiotics can be cleared by other organs when 
the primary eliminating organ (usually the kidneys) is impaired. By way of example, some 
antibiotics such as ticarcillin and piperacillin demonstrate increased biliary CL that causes little 
change in their plasma concentration despite mild to moderate renal dysfunction [133, 134]. 
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1.4.2.3     Extra-corporeal circuits 
Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients and the 
associated mortality rates are higher in septic AKI population compared to those with non-septic 
AKI [135-137]. The PK of antibiotics in this population are highly variable as parameters may be 
altered by both AKI and critical illness. In addition, patients with AKI may be receiving 
extracorporeal therapies including continuous renal replacement therapy (CRRT) or sustained low-
efficiency dialysis (SLED) to remove fluid and wastes from the body, and extracorporeal membrane 
oxygenation (ECMO) to support impaired cardiac and/or pulmonary systems to maintain 
appropriate blood gas concentrations. These interventions may influence antibiotic dosing 
requirements as critically ill patients with CRRT and SLED were reported to have variable 
antibiotic CL [138-142]. There is limited data on the influence of ECMO [141, 143-146]. 
 
1.4.3 Beta-lactam antibiotics and their pharmacokinetic and pharmacodynamic 
properties 
The beta-lactam antibiotics are made up of penicillins, cephalosporins, carbapenems and 
monobactams. This group of antibiotics are generally hydrophilic in nature, demonstrate low Vd 
(0.1-0.6 L/kg), and are predominantly cleared by the kidneys [8]. In relation to protein binding 
properties, most beta-lactams have a moderate (30-70%) to low (<30%) degree of protein binding. 
However, ertapenem, cefazolin, ceftriaxone and flucloxacillin demonstrate high protein-binding 
(>90%) when compared to the other beta-lactams members, highlighting that PK variability may 
exist within the group. 
 
The fT>MIC is regarded as the optimal PD index for beta-lactams and as such, maintaining effective 
drug concentration above the MIC should be the priority when this antibiotic class is used [9, 11, 
12, 24]. Specifically, the percentage (%) of fT>MIC (% fT>MIC) needed for bacteriostasis is 35-40%, 
30%, 20% for cephalosporins, penicillins and carbapenems, respectively and for bactericidal is 60-
70%, 50%, 40% for cephalosporins, penicillins and carbapenems, respectively [10-12, 24]. 
However, emerging clinical data from critically ill patients suggests that these patients may benefit 
from higher and longer antibiotic exposures than those described in in vitro and in vivo studies [22, 
23, 25-28, 147]. In a study specifically investigating critically ill patients with sepsis, McKinnon et 
al., found a % fT>MIC of 100% was associated with higher rates of bacteriological eradication and 
clinical cure than lesser % fT>MIC values [28]. Thus, it has been suggested that maintaining 
concentrations above the MIC for 90-100% of the dosing interval is an appropriate PD target for 
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critically ill patients and may prevent antibiotic resistance [5, 148, 149]. It has also been 
demonstrated that maximal bactericidal activity occurs when drug concentrations are maintained at 
four- to five-times the MIC, with higher concentrations providing little added benefit [23, 25, 26, 
147, 150-152]. Thus, it has been suggested that beta-lactam concentrations should be maintained at 
least four- to five-times the MIC for extended periods during each dosing interval [5, 7, 153]. 
 
Another consideration for optimizing antibiotic exposure is the post-antibiotic effect (PAE), i.e., the 
suppression of bacterial growth even with antibiotic concentrations below the MIC [154-158]. The 
beta-lactams except for the carbapenems, produce minimal or no PAE against Gram-negative 
pathogens. Carbapenems have been found to have a significant PAE against Gram-negative bacilli, 
including Pseudomonas aeruginosa strains [155, 157, 158]. This PAE property of carbapenems 
may explain their faster bacterial killing rate and shorter % fT>MIC for optimal bactericidal activity 
[158-162]. 
 
Maintaining effective beta-lactams exposure for extended periods or increasing % fT>MIC would be 
especially appropriate in immunocompromised patients including critically ill patients [7, 27, 163]. 
Furthermore, achieving an optimal PD index may increase the likelihood of therapeutic success in 
these patients [20-23, 26, 27, 147]. Traditional IB dosing produces antibiotic concentrations below 
the MIC for much of the dosing interval [67, 85, 86, 106, 151, 164-175]. This has prompted 
clinicians to consider several dose optimization strategies that maximize the value of % fT>MIC. 
Research has shown that improved antibiotic exposure can be obtained via three general 
approaches: (1) increasing the antibiotic dose; (2) increasing the frequency of antibiotic dosing or; 
(3) by utilizing EI or CI [67, 85, 86, 106, 151, 164-175]. However, increasing the antibiotic dose 
has been shown to be less effective to adequately maintain effective drug concentration during a 
dosing period. Increasing the antibiotic dose only raises the % fT>MIC for one half-life, which is 
usually short (i.e., 1 or 2 hours) for most beta-lactams. Although study findings have been 
inconclusive, increasing the antibiotic dose could theoretically lead to toxicity issues, which has 
indeed been described in a recent meta-analysis [176] and several case reports [177-180]. Hence, EI 
and CI of beta-lactam antibiotics have been proposed as a means of achieving optimal PK/PD 
targets in critically ill patients without increasing a patient’s total daily dose [85]. These new 
administration approaches may be especially important in patients who develop ARC and/or have 
increased Vd which are common in critical illness [6, 7]. Specific PK changes associated with beta-
lactam use in critically ill patients are discussed below. 
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1.4.4 Pharmacokinetic and pharmacodynamic considerations for critically ill patients 
with sepsis 
It is being increasingly shown that heterogeneity in beta-lactam PK is significant among critically ill 
patients and this phenomenon may affect treatment outcomes [6, 7]. Large Vd and CL differences 
are common [56, 181]. For example, mean Vd for meropenem in severe sepsis can range from 0.3-
0.5 L/kg (healthy volunteers Vd 0.2 L/kg) [86, 182-195]. The increased Vd in critical illness can 
result in sub-therapeutic antibiotic concentrations particularly in the early phase of the disease and 
thus, should prompt clinicians to use higher loading doses to achieve optimal concentrations rapidly 
[57, 196-199]. 
 
Apart from antibiotic Vd, high and variable beta-lactam CL is also frequently noted in patients with 
severe sepsis [181, 200]. For beta-lactams, CL is frequently correlated with CLCR, which may 
increase in critical illness [69, 117, 118, 120, 121, 175, 201-206]. A review by Goncalves-Pereira 
and Povoa reported high CL with variable antibiotic trough concentrations in most clinical studies 
investigating beta-lactam PK in ICU patients [56]. Chapuis et al., found 40-fold variations in 
cefepime trough concentrations in his study and interestingly, 50% of the patients had antibiotic 
concentrations lower than the target concentration (i.e., 4 mg/L) when a standard cefepime dosing 
regimen was used [198]. The low antibiotic concentrations commonly observed are likely to be 
caused by the presence of ARC [117, 121, 129]. To account for this PK change, altered dosing 
approaches for beta-lactams such as the use of higher doses or increased frequency is necessary to 
ensure adequate fT>MIC is achieved [207]. However, drug CL may increase or decrease based on 
patient organ function and reduced beta-lactam CL can occur with renal and/or hepatic dysfunction. 
In this situation, dose reduction may be indicated to prevent toxicity from elevated drug 
concentrations. 
 
Reduction in tissue penetration of beta-lactams has been described in critically ill patients and is 
likely to be caused by microcirculatory failure [66, 72, 80, 83-88, 90, 91, 189, 208]. Emerging 
PK/PD data from critically ill patients suggests better antibiotic tissue penetration and optimal PD 
target attainment can be achieved via CI of beta-lactam antibiotics [79, 81, 82, 85, 86, 167, 209-
212]. 
 
Numerous PK/PD studies have suggested potential flaws in the current mode of beta-lactam 
administration (i.e., IB administration) in terms of achieving optimal PK/PD targets in patients with 
severe sepsis. Generally, IB administration produces high unnecessary peaks, which confer no PD 
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advantage for this antibiotic class and results in low trough concentrations (Figure 1-3) [7]. Lipman 
et al., performed a prospective PK/PD clinical study to describe the PK properties and PD 
characteristics associated with twice daily dosing of cefpirome in patients with severe sepsis [67]. 
Using 60% fT>MIC as the PD target, the authors reported that only 60% and 10% of the patients met 
the PD target for MIC of 4 and 16 mg/L, respectively. In addition, the authors also concluded that 
the standard dosing regimen produces low cefpirome trough concentrations and may not be 
sufficient to treat severe infections in critically ill patients. Apart from this study, numerous other 
PK/PD modelling and dosing simulation studies concluded that an improved beta-lactam PK/PD 
profile is achieved with more frequent dosing or via EI or CI [53, 67, 79, 82, 85, 86, 106, 167-171, 
173-175, 184, 187, 190, 204, 205, 213, 214]. All present in vitro and in vivo animal data also 
support the use of CI compared to IB dosing in patients with altered PK [15]. Therefore, CI and EI 
dosing of beta-lactam antibiotics may be meritorious and may maximize the likelihood of 
therapeutic success. 
 
 
Figure 1-3: The simulated concentration-time profile of cefepime when administered by IB or 
CI dosing 
Abbreviation: CI, continuous infusion dosing; IB, intermittent bolus dosing; MIC, minimum 
inhibitory concentration. 
  
12 
 
1.4.5 Continuous beta-lactam infusion 
CI of beta-lactam antibiotics is likely to offer the greatest advantage over IB administration when 
less susceptible pathogens (e.g., P. aeruginosa) are present [85, 86, 169, 215, 216]. When 
susceptible pathogens are involved, because of a lower MIC, the mode of administration (i.e., CI or 
IB) is likely to be less important. Therefore, CI of beta-lactam antibiotics is unlikely to be 
advantageous for all patients but may be particularly important in specific patient cohorts such as 
critically ill patients with high level of sickness severity, who are also more likely to have less-
susceptible pathogens [217]. 
 
1.4.5.1     In vitro models simulating human pharmacokinetics 
Although results from several animal studies clearly show that CI of beta-lactam antibiotics is more 
efficacious than IB administration, the half-life of these drugs in animals (i.e., rodents) is much 
shorter than in humans and thus, extrapolating the results to patients may not be completely 
representative [15]. In vitro models that mimic human PK may provide better information with 
regards to antibiotic exposure and its effect in humans [218]. 
 
In one of their earlier in vitro PK models, Mouton and den Hollander suggested that continuous 
ceftazidime administration was more efficacious against P. aeruginosa compared to IB dosing 
[152]. After the fourth dose, a marked difference in bacterial counts was observed between the two 
dosing approaches (CI; 2.2 log10 versus IB; 2.8 log10). The authors added that maximal 
bactericidal activity may be achieved with sustained antibiotic concentrations at four- to five-times 
the MIC, with higher concentrations providing little further benefit. Other investigators have 
confirmed these results in their studies [219-225]. 
 
1.4.5.2     In vivo animal studies 
The effectiveness of CI versus IB administration of beta-lactam antibiotics has also been examined 
in in vivo animal studies [226-237]. In one of their leading reviews, Craig and Ebert concluded that 
based on numerous in vitro and in vivo animal studies, CI of beta-lactam antibiotics demonstrated 
many potential advantages, particularly in Gram-negative infections and in immunocompromised 
hosts [17]. Roosendaal et al., found similar results when the efficacy of CI of ceftazidime was 
studied in a cohort of neutropenic rats [231]. In this study, the daily dose needed to protect 50% of 
the animals from death (PD50) was 16-times lower with CI (1.52 mg/kg per day versus 24.37 mg/kg 
per day; p <0.001). However, when the authors studied non-neutropenic rats, the differences 
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between the two dosing methods almost completely disappeared. This interesting finding suggests 
that CI administration may be more beneficial in immunocompromised hosts. Similar findings have 
been reported in several other studies [17, 233, 235]. Importantly, some in vivo models have shown 
more rapid bactericidal activity with IB [232, 234]. However, the administration of a loading dose 
prior to CI will enable faster achievement of effective concentration for CI [238]. 
 
1.4.5.3     Clinical outcomes 
Despite strong in vitro and in vivo PK/PD data supporting the administration of beta-lactams by CI, 
there is currently no “convincing” data on patient outcomes that differentiate the two dosing 
methods. This may be attributed to several methodological flaws in studies that may mask the 
benefits of CI previously observed in pre-clinical studies [13, 14, 217, 239, 240]. Findings from 
clinical trials suggest that CI of beta-lactam antibiotics may have variable efficacy in different 
patient groups [166, 241-243]. It has been suggested that patients who are most likely to benefit 
from CI are critically ill patients with a high level of illness severity [166, 242, 243], but with 
conserved renal function [241, 244, 245]. 
 
Numerous clinical comparative studies have been conducted with beta-lactams testing various 
dosing strategies in various patient populations including critically ill patients [85, 86, 151, 166, 
169, 171, 172, 241-243, 246-252], patients receiving extracorporeal renal circuit [244, 245, 253], 
trauma patients [254], patients with malignant diseases [255], patients with intra-abdominal 
infections [256], patients with chronic obstructive pulmonary disease (COPD) [257, 258] and non-
specific hospitalized patients [173, 259-262] (Table 1-2). These studies have not shown whether 
alternative dosing approaches (i.e., CI and EI) are advantageous nor which patient groups may 
benefit. Most of these trials were conducted in North America and Europe between 1979 and 2015, 
with all but five studies published after 2010 [166, 241, 242, 246, 259]. A number of articles have 
also discussed the potential advantages and disadvantages of CI [13-17, 263-265]. A recent 
systematic review of the published literature by Abdul-Aziz et al., [13] found no statistically 
significant differences in critically ill patients with regards to mortality rate [151, 172, 243, 248], 
clinical cure [172, 243, 266], time to normalization of leukocytosis or pyrexia [248, 254], 
mechanical ventilation [172, 243, 254, 266], hospital or ICU length of stay [172, 243, 254, 266] and 
adverse events [266] between CI and IB dosing. In addition, three meta-analyses have been 
published to determine if any clinical benefits of CI beta-lactams can be found from the combined 
clinical data of the present studies [217, 240, 267]. Again, the analyses have not reported any 
significant difference between CI and IB dosing with regards to clinical cure and survival. 
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However, wide confidence intervals can be observed in the meta-analyses that suggest a clinically 
relevant difference between the two dosing approaches may still exist if more stringent 
methodology was used in the studies [217]. Nevertheless, Kasiakou et al., suggested that fewer 
daily CI doses are needed to produce similar outcomes as IB dosing [267]. Despite these findings, 
there are currently four recent meta-analyses which reported significant patient benefits with altered 
dosing approaches [239, 268-271]. However, the recent findings should be interpreted with caution 
as the meta-analyses have included a significant number of retrospective and non-randomized 
studies in their pooled analysis. A large-scale prospective clinical trial with a robust design is 
required to answer the controversy surrounding the effectiveness of CI versus IB dosing in critically 
ill patients. Future trials need to address the methodological flaws associated with current studies. 
These methodological flaws have been described in detail by Abdul-Aziz et al., in a recent review 
article [13, 14]. Figure 1-4 summarizes the current limitations and flaws associated with the 
available clinical trials. 
 
Figure 1-4: Description of the current limitations and methodological flaws associated with 
current clinical trials 
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It is also imperative to highlight the clinical findings of three recent randomized controlled trials 
(RCT) which demonstrated some clinical outcome advantages favouring CI administration of beta-
lactam antibiotics when only critically ill patients were recruited [166, 242, 243]. In a prospective, 
open-labelled RCT which recruited Australian ICU patients (n = 57), Roberts et al., [243] 
demonstrated higher clinical cure rates favouring CI administration as opposed to IB dosing of 
ceftriaxone (52% versus 20%; p = 0.04). In a prospective, multicentre, double-blind, RCT (Beta-
Lactam Infusion Group [BLING] I; n = 60), Dulhunty et al., [166] showed that participants in the 
CI treatment arm demonstrated higher clinical cure rates (77% versus 50%; p = 0.032) compared to 
the IB arm. In a single-centre RCT which recruited 240 critically ill Czech participants, Chytra et 
al., [242] reported higher microbiological cure rates in the CI treatment arm as opposed to the IB 
arm (91% versus 78%; p = 0.020). However, none of the studies demonstrated significant patient 
survival advantages. 
 
It follows that, CI administration of beta-lactam antibiotics may not result in better outcomes for all 
critically ill patients. This was recently highlighted in a multicentre, double-blind, RCT (BLING II; 
n = 420) [241]. Despite recruiting only patients with severe sepsis, Dulhunty et al., [241] found no 
significant difference between CI and IB participants, in all five clinical end-points evaluated. In 
this study, Dulhunty et al., included patients receiving renal replacement therapy (RRT) (~25% of 
participants) and this inclusion criterion may have reduced PK/PD exposure differences between CI 
and IB dosing because patients with reduced drug clearances, as seen during RRT, are less likely to 
manifest sub-therapeutic antibiotic exposures [211, 244, 245, 253]. Patients receiving RRT are 
therefore less likely to benefit from altered dosing approaches such as CI administration. Based on 
these inconsistent findings and other relevant retrospective clinical data [272-276], we await the 
outcome of future clinical trials that use a more rigorous and stringent methodology to demonstrate 
the clinical outcome differences between CI and IB, if they do exist. 
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Table 1-2: Characteristics of previously published studies of continuous versus bolus dosing of beta-lactam antibiotics 
Study Setting 
(Country) 
Antibiotic Critically ill Population Sample 
size 
Agea Allocation 
sequence 
generator 
Allocation 
concealment 
Masking Concomitant 
antibiotic CI IB 
Angus et al., 
[151] 
Not specified 
(Thailand) 
Ceftazidime Yes Septicaemic 
melioidosis 
21 48 
(29-58) 
43 
(27-73) 
Not specified Not specified Not specified Various 
Bodey et al., 
[255] 
Non-ICU  
(USA) 
Cefamandole No Malignant diseases 
with neutropenia 
204 Not specified Adequate Adequate Not specified Carbenicillin 
Buck et al., 
[173] 
Non-ICU 
(Germany) 
Piperacillin/tazobactam No Hospitalized 
infections 
24 60-88b 32-76b Not specified Adequate No Nil stated 
Chytra et al., 
[242] 
ICU  
(Czech) 
Meropenem Yes Critically ill patients 
with severe sepsis 
240 45±18 47±16 Yes Adequate No Various 
Cousson et al.,  
[249] 
ICU 
(France) 
Ceftazidime Yes Critically ill patients 
with nosocomial 
pneumonia 
16 61 (21-81) Yes Not specified Not specified Not specified 
De Jongh et al., 
[247] 
ICU 
(Belgium) 
Temocillin Yes Critically ill patients 
with nosocomial 
infections 
17 58±8 56±9 Not specified Not specified No Various 
Dulhunty et al., 
[241] 
ICU 
(Australia, New 
Zealand & Hong 
Kong) 
Meropenem, 
piperacillin/tazobactam, 
ticarcillin/clavulanate 
Yes Critically ill patients 
with severe sepsis 
432 64 (54-72) 65 (53-72) Yes Yes Yes Various 
Dulhunty et al., 
[166] 
ICU 
(Australia & 
Hong Kong) 
Meropenem, 
piperacillin/tazobactam, 
ticarcillin/clavulanate 
Yes Critically ill patients 
with severe sepsis 
60 54±19 60±19 Adequate Adequate Yes Various 
Georges et al., 
[172] 
ICU  
(France) 
Cefepime Yes Critically ill with 
Gram-negative 
infections 
50 50±17 46±24 Not specified Not specified No Amikacin 
Hanes et al., 
[254] 
ICU  
(USA) 
Ceftazidime Yes Critically ill trauma 32 33.5±12.5 36.1±12.8 Not specified Not specified No Nil stated 
Jamal et al., 
[244] 
ICU 
(Malaysia) 
Meropenem Yes Critically ill patients 
with severe 
sepsis/septic shock 
receiving CVVH 
16 48 (32-63) 45 (29-61) Not specified Yes No Nil stated 
Jamal et al., 
[245] 
ICU 
(Malaysia) 
Piperacillin/tazobactam Yes Critically ill patients 
with severe 
sepsis/septic shock 
receiving CVVH 
16 44 (34-70) 63 (46-71) Yes Yes No Nil stated 
Lagast et al., 
[262] 
Not specified 
(Belgium) 
Cefoperazone No Gram-negative 
septicaemia 
 
 
45 37-77b Not specified Not specified No Nil stated 
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Laterre et al., 
[259] 
ICU 
(Belgium) 
Temocillin  Yes Critically ill patients 
with intra-abdominal 
and LRTI 
32 68±11 65±15 Not specified Not specified No Various 
Lau et al., 
[256] 
ICU  
(USA) 
Piperacillin/tazobactam No Complicated intra-
abdominal infections 
262 50.4±16.6 49.3±17.8 Not specified Not specified No Nil stated 
Lipman et al., 
[250] 
ICU 
(Hong Kong) 
Ceftazidime Yes Critically ill patients 18 64±9 53±14 Yes Not specified Not specified Nil stated 
Lubasch et al., 
[258] 
Not specified 
(Germany) 
Ceftazidime No Hospitalized patients 
with COPD 
exacerbation 
81 65.3±10.1 Not specified Not specified No Nil stated 
Nicolau et al., 
[251] 
ICU 
(USA) 
Ceftazidime Yes Critically ill patients 34 43±15 51±21 Not specified Not specified Not specified Tobramycin 
Nicolau et al., 
[252]  
ICU 
(USA) 
Ceftazidime Yes Critically ill patients 
with nosocomial 
pneumonia 
24 37±13 45±19 Not specified Not specified Not specified Tobramycin 
Nicolau et al., 
[266] 
ICU  
(USA) 
Ceftazidime Yes Critically ill patients 
with sepsis 
41 46±16 56±20 Adequate Not specified No Tobramycin 
Okimoto et al., 
[260]  
Not specified 
(Japan) 
Meropenem No Elderly patients with 
CAP 
50 80 Not specified Not specified Not specified Nil stated 
Pedeboscq et al., 
[261] 
ICU  
(France) 
Piperacillin/tazobactam Yes Severe sepsis 7 58±12 Not specified Not specified No Ofloxacin 
Rafati et al., 
[248] 
ICU  
(Iran) 
Piperacillin Yes Critically ill patients 
with sepsis 
40 50.1±22.2 48.0±20.7 Not specified Not specified No Amikacin 
Roberts et al., 
[169] 
ICU 
(Australia) 
Piperacillin/tazobactam Yes Critically ill patients 
with sepsis 
16 30 (23-40) 41 (22-65) Yes Yes No Nil stated 
Roberts et al., 
[85] 
ICU 
(Australia) 
Piperacillin/tazobactam Yes Critically ill patients 
with sepsis 
13 25 (19-35) 42 (23-65) Not specified Yes No Nil stated 
Roberts et al., 
[86] 
ICU 
(Australia) 
Meropenem Yes Critically ill patients 
with sepsis 
10 57 (54-63) 55 (48-61) Yes Yes No Nil stated 
Roberts et al., 
[243] 
ICU  
(Australia) 
Ceftriaxone Yes Critically ill patients 
with sepsis 
57 43±19 52±16 Adequate Adequate Adequatec Multiple 
depending on 
indication 
Sakka et al., 
[171] 
ICU (Germany) Imipenem/cilastatin Yes Critically ill patients 
with sepsis 
20 62±16 59±16 Not specified Adequate No Nil stated 
Tamer et al., 
[246] 
ICU 
(Egypt) 
Meropenem Yes Critically ill patients 
with severe sepsis 
100 Not specified Not specified Not specified Not specified Nil stated 
Van Zanten et 
al., 
[257] 
 
Not specified 
(Netherlands) 
Cefotaxime No Hospitalized patients 
with COPD 
exacerbation 
93 65.3±8.4 68.6±5.3 Not specified Not specified No Nil stated 
Abbreviation: CAP, community-acquired pneumonia; CI, continuous infusion; COPD, chronic obstructive pulmonary disease; CVVH, continuous venovenous haemofiltration; IB, intermittent bolus; ICU, intensive care unit. 
aValues are reported according to published results as mean (±SD) or median (interquartile range). 
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bValues are reported as range. 
cOnly outcome assessment was blinded. 
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Table 1-3: Antibiotics dosage and outcome data of previously published studies for CI versus IB dosing of beta-lactam antibiotics 
Study Types of infection Number of patients 
(APACHE II scorea) 
Antibiotic dosage regimen Concurrent 
PK/PD analysis 
Clinical outcome 
measures 
CI IB p-valueb 
CI IB CI IB 
Angus et al., 
[151] 
Septicaemic melioidosis 10 (15) 11 (21) 12 mg/kg LD, then 4 
mg/kg every 1 hr 
40 mg/kg every 8 hrs Yes Mortality 20% 36.4% 0.89 
Bodey et al., 
[255] 
Pneumoniae, UTI & 
neutropenic fever 
167 (ND) 162 (ND) 3 g LD, then 12 g/24 
hrs 
3 g every 6 hrs No Clinical cure 64% 57% ND 
Buck et al., 
[173] 
Pneumoniae, IAI & fever 
of unknown origin 
12 (ND) 12 (ND) 2 g LD, then 8 g/24 hrs 4 g every 8 hrs Yes Clinical response 67% 67% ND 
Chytra et al., 
[242] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
120 (21) 120 (22) 2 g LD, then 4 g/24 hrs 2 g every 8 hrs No Clinical cure 83% 75% 0.18 
Bacteriological cure 91% 78% 0.02 
ICU mortality 12% 14% 0.7 
ICU LOS 10 days 12 days 0.04 
De Jongh et al. 
[247] 
Pneumoniae & UTI 7 (12) 10 (13) 2 g LD, then 4g/24 hrs 2 g every 12 hrs Yes Clinical cure 100% 86% ND 
Survival at day 28 100% 86% ND 
Dulhunty et al., 
[241] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
212 (21) 220 (20) Three different beta-lactams standard ICU daily 
doses 
No Clinical cure 52% 50% 0.56 
Survival at day 90 74% 73% 0.67 
Alive ICU-free days 18 20 0.38 
Organ failure-free days 6 6 0.27 
Duration of bacteraemia 0 0 0.24 
Dulhunty et al., 
[166] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
30 (21) 30 (23) Three different beta-lactams standard ICU daily 
doses 
Yes Clinical cure 70% 43% 0.37 
ICU mortality 93% 87% 0.67 
Days to clinical resolution 11 17 0.14 
ICU LOS 8 days 9 days 0.5 
Georges et al., 
[172] 
Pneumoniae & blood 
stream infection 
24 (45)c 23 (44)c 2 g/12 hrs twice daily 2 g every 12 hrs No Clinical cure 85% 67% ND 
Mortality 12% 13% ND 
Duration of MV 24 days 25 days ND 
ICU LOS 34 days 40 days ND 
Hanes et al., 
[254] 
Pneumoniae 17 (13) 14 (11) 2 g LD, then 60 mg/kg 
every 24 hrs 
2 g every 8 hrs Yes Duration of leukocytosis 8 days 11 days 0.35 
Duration of pyrexia 8 days 4 days 0.06 
Duration of MV 23 days 12 days 0.16 
ICU LOS 27 days 16 days 0.11 
Hospital LOS 41 days 29 days 0.37 
Jamal et al., 
[244] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
with CVVH 
 
8 8 1 g LD, then 125 mg/hr 
every 24 hrs 
2 g LD, then 1 g every 
8 hrs 
Yes Adverse events 0% 0% ND 
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Jamal et al., 
[245] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
with CVVH 
8 (33) 8 (34) 2.25 g LD, then 37.5 
mg/hr every 24 hrs 
4.5 g LD, then 2.25 g 
every 6 hrs 
Yes Adverse events 0% 0% ND 
Lagast et al., 
[262] 
Blood stream infection 20 (ND) 25 (ND) Day 1: 1 g LD, then 3 
g/24 hrs 
Day 2 +: 4 g/24 hrs 
2 g every 12 hrs No Clinical cure 25% 16% ND 
ICU mortality 70% 80% ND 
Laterre et al., 
[259] 
Pneumoniae, IAI, UTI, 
SSTI & blood stream 
infection 
14 (17) 14 (16) 2 g LD, then 6 g/24 hrs 2 g every 8 hrs Yes Clinical cure 93% 79% NS 
ICU mortality 14% 36% NS 
Treatment duration 7 days 6 days NS 
Lau et al., 
[256] 
IAI 81 (8) 86 (8) 2 g LD, then 12 g /24 
hrsg 
3 g every 6 hrsg No Clinical cure 86% 88% 0.817 
Bacteriological cure 77% 88% 0.628 
Lipman et al., 
[250] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
9 (21) 9 (16) 12 mg/kg LD, then 2 g 
over 478 mins, 
followed by 2 g every 8 
hrs 
12 mg/kg LD, then 2 g 
over 28 mins, followed 
by 2 g every 8 hrs 
Yes Adverse events 0% 0% ND 
Lubasch et al., 
[258] 
Pneumoniae 41 (ND) 40 (ND) 2 g LD, then 2 g/7 hrs 
twice daily 
2 g every 8 hrs Yes Clinical cure 90% 90% ND 
Bacteriological cure 90% 88% ND 
Nicolau et al., 
[251] 
Pneumoniae 17 (14) 17 (15) 1 g LD, then 3 g/24 hrs 2 g every 8 hrs Yes Adverse events 0% 0% ND 
Nicolau et al., 
[252]  
Pneumoniae 11 (14) 13 (15) 1 g LD, then 3 g/24 hrs 2 g every 8 hrs Yes Adverse events 0% 0% ND 
Nicolau et al., 
[266] 
Pneumoniae 17 (14) 18 (16) 1 g LD, then 3 g/24 hrsh 2 g every 8 hrsh No Clinical cure 41% 33% 0.592 
Duration of MV 8 days 8 days 0.97 
Days to defervescence 3 days 5 days 0.015 
Days to WCC 
normalization 
7 days 6 days 0.259 
LOS ICU 9 days 9 days 0.691 
Pedeboscq et al., 
[261] 
IAI 3 (ND) 4 (ND) 12 g/24 hrs 4 g every 8 hrs Yes Mortality 0% 0% ND 
Rafati et al., 
[248] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
20 (16) 20 (14) 2 g LD, then 8 g/24 hrs 3 g every 6 hrs Yes Mortality 30% 25% 0.72 
Decrease in illness 
severity 
  CI>ITd 
Duration of pyrexia 2 days 1 day 0.08 
WCC normalization 75% 83% ND 
Roberts et al., 
[169] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
8 (20) 8 (24) Day 1: 4.5 g LD, then 
8g/24 hrs 
Day 2 +: 13.5 g/24 hrs 
 
 
 
4.5 g every 6 hrs or 8 
hrs 
Yes Survival 100% 100% 1.00 
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Roberts et al., 
[85] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
6 (18) 7 (24) Day 1: 4.5 g LD, then 
8g/24 hrs 
Day 2 +: 13.5 g/24 hrs 
4.5 g every 6 hrs or 8 
hrs 
Yes Clinical cure 100% 100% ND 
Roberts et al., 
[86] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
5 (ND) 5 (ND) 0.5 g LD, then 3 g/24 
hrs 
1.5 g LD, then 1 g 
every 8 hrs 
Yes Survival 60% 100% 0.06 
Roberts et al., 
[243] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
29 (19) 28 (16) 0.5 g LD, then 2 g/24 
hrs 
Day 1: 2.5 g/24 hrs 
Day 2: 2 g/24 hrs 
No Clinical curee 52% 20% 0.04 
Mortality 10% 0% 0.25 
Duration of MV 4 days 3 days 0.33 
ICU LOS 11 days 6 days 0.29 
Hospital LOS 42 days 24 days 0.34 
Sakka et al., 
[171] 
Pneumoniae 10 (26) 10 (28) 1 g LD, then 2 g /24 hrs 1 g every 8 hrs Yes Mortality 10% 20% ND 
Tamer et al., 
[246] 
Pneumoniae, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
50 (ND) 50 (ND) 2 g LD, then 4 g/24 hrs 2 g every 8 hrs No Clinical cure  74% 62% 0.198 
Mortality at day 28 26% 38% 0.198 
SOFA at the EOT 3 5 <0.001 
WCC at day 5 of therapy 14 15 0.042 
CRP at day 7 of therapy 109 119 0.035 
LOS ICU 10 days 12 days <0.001 
Van Zanten et al., 
[257] 
 
COPD exacerbation 40 (ND) 43 (ND) 1 g LD, then 2 g/24 hrs 1 g every 8 hrs Yes Clinical cure 93% 93% 0.93 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; CI, continuous infusion; CNS, central nervous system; CRP, C-reactive protein; IAI, intra-abdominal infection; IB, intermittent bolus; ICU, 
intensive care unit; LD, loading dose; LOS, length of stay; MV, mechanical ventilation; ND, not described; PK/PD, pharmacokinetic/pharmacodynamic; SOFA, Sequential Organ Failure Assessment; SSTI, skin and skin-
structure infection; UTI, urinary tract infection; WCC, white cell counts. 
Legend: 
aValues are reported as mean or median. 
bBold values indicate statistical significance at p <0.05. 
cValues are SAPS scores. 
dStatistically significant difference in APACHE II scores on days 2, 3 and 4. 
eA priori analysis. 
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1.4.6 Extended beta-lactam infusion  
Although potential efficacies have been described, there are unfortunately several drawbacks 
associated with CI such as the need for a dedicated IV line (Table 1-4) [13, 15, 264, 277]. 
Furthermore, some beta-lactams lack the physicochemical stability to be continuously exposed to 
room temperatures that may lead to formation of degradation products [278-285]. Thus, extending 
the infusion time, typically for three to four hours, has been suggested as an alternative way to 
maximize the fT>MIC for some of these antibiotics [13, 286-288]. Several observational and 
retrospective studies have suggested potential benefits associated with EI of beta-lactam antibiotics 
particularly in patients with severe infections [164, 165, 286, 289-298]. In a recent multicentre, 
retrospective cohort study, Yost et al., compared the effectiveness between EI of 
piperacillin/tazobactam infusion and IB dosing of comparator antibiotics in 359 patients with 
documented Gram-negative infections [295]. The authors found a decrease in mortality in the EI 
group (9.7% versus 17.9%; p = 0.02) and further analysis confirmed that the dosing approach 
prolonged survival by 2.77 days (p <0.01) in this study. Another non-randomized study of note 
reported a significant lower 14-day mortality rate in patients with an Acute Physiology and Chronic 
Health Evaluation II (APACHE II) score ≥17 favouring EI compared to IB administration of 
piperacillin/tazobactam in critically ill patients infected with P. aeruginosa (12.2% versus 31.6%; p 
= 0.04) [298]. Therefore, it has been suggested that EI of beta-lactam antibiotics is a suitable 
alternative to IB dosing in critically ill patients. However, further prospective, clinical studies are 
required to support the clinical benefits that were reported in these retrospective studies. 
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Table 1-4: Possible advantages and disadvantages of employing CI versus IB dosing of beta-
lactam antibiotics 
Administration 
method 
Advantages Disadvantages 
Continuous infusion Stable and predictable antibiotic PK 
profiles 
Intensive educational effort to 
update clinical staff on the 
administration method prior to 
implementation 
Lower antibiotic daily dose is a 
possibility with this approach 
Requires special infusion pumps 
and infusion bags that are costly 
Reduces drug acquisition costs 
when lower antibiotic doses are 
used 
Some beta-lactams are not stable 
under prolonged exposure at room 
temperature 
   
Intermittent bolus Effective resource consumption 
(e.g., reduce the time required for 
pharmacists or nurses to prepare 
and administer antibiotic) 
Risk of drug wastage is high with 
this approach (e.g., when a patient 
dies during treatment) 
A simple antibiotic administration 
method 
PD targets may not be met 
especially in critically ill patients 
Does not require dedicated line 
access for drug administration thus 
incompatibility with other drugs is 
not an issue 
Neurological adverse effects are 
theoretically more possible with 
high Cmax 
 
Less likely to have unexpected 
device failures and dosing delivery 
rate error 
 
Abbreviation: Cmax, peak drug concentration over a dosing interval; PK, pharmacokinetic; PD, 
pharmacodynamic. 
 
1.4.6.1     Doripenem 
Doripenem is a new member in the carbapenem class of beta-lactam antibiotics, which 
demonstrates broad antibiotic coverage against Gram-positive, Gram-negative and anaerobic 
pathogens including the highly resistant multi-drug resistant (MDR) strains [299, 300]. 
Furthermore, doripenem has enhanced activity compared to meropenem against P. aeruginosa 
(doripenem minimum inhibitory concentration required to inhibit the growth of 90% of organisms 
[MIC90]; 8 mg/L versus meropenem MIC90; 16 mg/L), one of the most frequently isolated 
pathogens in the ICU [300]. With promising results in several clinical studies, doripenem has been 
approved for the treatment of severe infections namely complicated intra-abdominal infections 
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[301], complicated urinary tract infections [302-304] and for nosocomial pneumonia [305, 306]. In 
all these studies, doripenem was reported as effective and non-inferior to its comparator drug (i.e., 
imipenem, meropenem, piperacillin/tazobactam or levofloxacin) and to significantly reduce 
mechanical ventilation and hospitalization days [307-312]. 
 
In the earlier phase of development, doripenem dosing was guided using a PK/PD approach [313-
316]. This approach is especially important for finding the most advantageous dosing regimen for 
the treatment of less susceptible Gram-negative pathogens. Like other beta-lactams, doripenem 
displays time-dependent activity whereby its efficacy is related to fT>MIC [317-319]. Combined with 
its favourable stability profile, administering doripenem via EI to extend the fT>MIC is an appropriate 
and appealing approach compared to CI and IB dosing. Furthermore, several PK/PD modelling 
studies have provided data supporting extended doripenem infusion particularly if severe infections 
are involved [53, 185-188, 313-316, 320-326].  
 
A typical doripenem dose of 500 mg to 1000 mg every 8 hours, administered as a 1- to 4-hour IV 
infusion, is recommended to enhance PK/PD target attainment, especially when dealing with severe 
infections [313, 314, 316, 326]. However, to date, population PK/PD models to describe doripenem 
usage have mostly been developed in heterogeneous patient groups [313, 314, 316, 326-329] which 
are unlikely to address the PK differences and the disease severity of critically ill patients [6-8, 
330]. For example, a doripenem dose of 500 mg every 8 hours as a 1-hour infusion is only effective 
against pathogens with a MIC of ≤2 mg/L. This standard doripenem dose is likely to fail in 
critically ill patients, who may have altered PK and who are commonly infected with pathogens 
with higher MICs [331-335]. In this context, it is important to highlight the recent termination of an 
industry-sponsored clinical trial investigating the use of doripenem in ventilator-associated 
pneumonia (VAP) [336]. This phase III, prospective, multicentre, double-blind RCT aimed to 
demonstrate the non-inferiority of a fixed 7-day course of doripenem (1 g every 8 hours as a 4-hour 
infusion) compared to a 10-day course of imipenem-cilastatin (1 g every 8 hours as a 1-hour 
infusion) in adult patients with VAP. The trial was terminated when interim analyses showed 
greater clinical failure and mortality rates in the doripenem treatment arm. Further analysis (i.e., 
modified intention to treat [mITT] analysis group) also revealed that patients receiving doripenem 
with high CLCR (150 mL/min) had clinical cure rates that were 27% worse than the comparator 
group (doripenem 44.4% versus imipenem-cilastatin 71.4%, 95% confidence interval: -55.4% to 
1.4%). This among other findings [187, 188, 322, 337] indicates that “one-dose-fits-all” dosing 
approach is no longer relevant in critically ill patients due to their possible altered physiology and 
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thus, PK/PD analyses of doripenem are needed to develop clinically relevant dosing guidelines in 
this population. 
 
1.4.7 Summary 
Several important pathophysiological changes in critically ill patients may alter antibiotic PK and 
consequently influence PK/PD target attainment. Use of a standard dosing regimen, which is 
usually derived from healthy volunteers, does not address the altered PK phenomenon and may 
increase the likelihood of therapeutic failure. Furthermore, pathogens that are commonly isolated in 
the ICU differ from the general wards in a way that their MICs tend to be relatively higher [334, 
335]. Altered dosing approaches (i.e., CI and EI) may be needed to ensure effective antibiotic 
exposure and may produce better therapeutic outcomes in critically ill patients. 
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Aims 
This Thesis aims to better characterize the PK/PD of beta-lactam antibiotics in critically ill patients 
and to determine whether there is any therapeutic advantage associated with the PI dosing strategy 
(i.e., CI and EI) as compared to traditional IB dosing in this unique patient population. 
 
The specific aims of the Thesis are: 
1. To describe the population PK of doripenem in critically ill patients with sepsis in a 
Malaysian ICU and to investigate sources of PK variability 
 To determine PK parameter estimates of doripenem in critically ill patients with 
sepsis. 
 To identify potential covariates which would help to explain PK variability in this 
population. 
 To develop clinically relevant dosing guidelines for this population which would 
help to maximize therapeutic efficacy and minimizing antibiotic resistance. 
2. To review the published literature describing the PK/PD and clinical outcomes associated 
with CI versus IB dosing of beta-lactam antibiotics in hospitalized patients.  
3. To perform a post hoc analysis on the Defining Antibiotic Levels in Intensive care unit 
patients (DALI) study data to compare the PK/PD and clinical outcomes associated with PI 
(i.e., CI and EI) versus IB dosing of beta-lactam antibiotics in a large cohort of critically ill 
patients. 
4. To identify the methodological shortcomings associated with current clinical studies seeking 
to compare CI versus IB and to describe the criteria that should be considered for 
performing a definitive clinical trial of this intervention in critically ill patients.  
5. To perform a randomized controlled trial in order to determine if CI administration of beta-
lactam antibiotics is associated with improved clinical outcomes as compared to IB dosing 
in a large cohort of critically ill patients with severe sepsis in a Malaysian ICU setting.  
6. To review the published literature on the relevance of PK exposure and PD characteristics of 
different antibiotic classes on maximizing therapeutic efficacy and minimizing development 
of antibiotic resistance in critically ill patients. 
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Chapter 2: Population pharmacokinetics of doripenem in critically ill 
patients with sepsis 
2.1 Synopsis 
Beta-lactam antibiotics are commonly used to treat severe infections due to their wide antibiotic 
spectrum and overall tolerability. However, inappropriate usage has contributed to increases in 
resistance to many beta-lactams and consequently, threatens the utility of this antibiotic family. 
Furthermore, infection caused by MDR pathogens, such as P. aeruginosa, is significantly 
associated with patient’s morbidity and mortality. Doripenem, the latest addition to the carbapenem 
class of antibiotic, offers a glimmer of hope in the management of severe Gram-negative infections 
as it demonstrates broad antimicrobial coverage against Gram-positive, Gram-negative and 
anaerobic pathogens, including the “troublesome” MDR strains. For this reason, doripenem has 
been approved for several indications, including complicated intra-abdominal infections, 
complicated urinary tract infections and for nosocomial pneumonia. Like other beta-lactam 
antibiotics, the length of time that drug concentrations remains above the MIC of infection-causing 
pathogen is related to doripenem’s effectiveness. A typical doripenem dose of 500 mg to 1000 mg 
every 8 hours, administered as a 1-hour IV infusion, is currently recommended for severe 
infections. However, this dosing recommendation was developed based on the PK of doripenem in 
healthy volunteers and therefore, pathophysiological alterations in critically ill patients were not 
taken into consideration. As reported in previous studies, failing to account for critical-illness 
related changes may lead to inadequate antibiotic exposure and therapeutic failure. Furthermore, 
previous PK/PD analyses of doripenem have mainly been performed in non-infected, heterogeneous 
Caucasian patient groups and therefore, the existing PK data may not accurately characterize the PK 
differences of other population such as in the Malaysian critically ill population. This chapter 
therefore aims to describe the population PK of doripenem in Malaysian critically ill patients with 
sepsis and use Monte Carlo dosing simulations to develop clinically relevant dosing guidelines 
specifically for these patients. 
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2.2 Manuscript entitled “Population pharmacokinetics of doripenem in 
critically ill patients with sepsis in a Malaysian intensive care unit” 
The manuscript entitled “Population pharmacokinetics of doripenem in critically ill patients with 
sepsis in a Malaysian intensive care unit” has been accepted for publication in the Antimicrobial 
Agents and Chemotherapy (2015). 
 
The co-authors contributed to the manuscript as follows: Conception and development of the study 
design was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. 
Jason A. Roberts and Dr. Christine E. Staatz. Literature review was performed by the PhD 
candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. Jason A. Roberts and Dr. Christine 
E. Staatz. Data collection was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, Azrin N. 
Abd Rahman and Dr. Mohd-Basri Mat-Nor. Sample bioanalysis was performed by the PhD 
candidate, Mohd-Hafiz Abdul-Aziz, under the supervision of Dr. Steven C. Wallis. PK/PD analysis 
was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz and Azrin N. Abd Rahman under 
the supervision of Prof. Jason A. Roberts and Dr. Christine E. Staatz. The PhD candidate took the 
leading role in manuscript preparation and all co-authors reviewed and contributed to the final draft 
of the manuscript. 
 
The accepted version of this manuscript is presented and incorporated in this chapter. However, 
some text, tables and figures may have been inserted at slightly different positions to fit the overall 
style of the thesis. Numbering of pages, tables and figures may also change to fit the thesis 
requirements. Manuscript references have been collated with all other references in the thesis. 
 
Permission has been granted by the publisher and copyright owner, American Society of 
Microbiology, to reproduce the manuscript in this Thesis. 
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2.2.1 Abstract 
Doripenem has been recently introduced in Malaysia and is used for severe infections in the ICU. 
However, limited data currently exist to guide optimal dosing in this scenario. We aimed to describe 
the population PK of doripenem in Malaysian critically ill patients with sepsis and use Monte Carlo 
dosing simulations to develop clinically relevant dosing guidelines for these patients. In this PK 
study, 12 critically ill adult patients with sepsis receiving 500 mg of doripenem 8-hourly as a 1-hour 
infusion were enrolled. Serial blood samples were collected on two different days and population 
PK analysis was performed using a non-linear mixed effects modelling approach. A two-
compartment linear model with between-subject and between-occasion variability on CL was 
adequate in describing the data. Typical Vd and CL of doripenem in this cohort was 0.47 L/kg and 
0.14 L/kg/hr, respectively. Doripenem CL was significantly influenced by patients’ CLCR such that 
a 30 mL/min increase in estimated CLCR would increase doripenem CL by 52%. Monte Carlo 
dosing simulations suggested that for pathogens with a MIC of 8 mg/L, a dose of 1000 mg 8-hourly 
as a 4-hour infusion is optimal for patients with CLCR of 30-100 mL/min whilst a dose of 2000 mg 
8-hourly as a 4-hour infusion is best for patients manifesting a CLCR >100 mL/min. Findings from 
this study suggest that for doripenem usage in Malaysian critically ill patients, an alternative dosing 
approach may be meritorious, particularly when MDR pathogens are involved. 
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2.2.2 Introduction 
Doripenem, a member of the carbapenem class of antibiotics, demonstrates broad antibiotic activity 
including against the troublesome MDR pathogens [338]. The PK profile of doripenem closely 
resembles that of other carbapenems. Similarly, this antibiotic demonstrates time-dependent 
activity, where the PK/PD index that best correlates with its efficacy is fT>MIC [317].
 Doripenem has 
been approved for complicated intra-abdominal and urinary tract infections in the United States, and 
is also indicated for nosocomial pneumonia in Europe and the Asia-Pacific. In Malaysia, doripenem 
is commonly reserved for the management of complicated infections deemed to be caused by P. 
aeruginosa and to some extent, Acinetobacter baumannii. As per local antibiotic guidelines, 
patients receiving doripenem in a Malaysian ICU typically receive a standard dose of 500 mg 8-
hourly as a 1-hour IV infusion. However, the appropriateness of this dosing regimen is disputable as 
it is based on PK/PD data derived from earlier studies which mostly recruited heterogeneous 
cohorts of healthy volunteers and non-critically ill Caucasian patients [313, 314, 316, 326]. 
Importantly, results of subsequent PK/PD studies suggest that current recommendations may be 
grossly flawed in critically ill patients and optimal dosing requirements may significantly differ 
from that initially proposed [187, 188, 322]. 
 
Antibiotic dosing in critically ill patients is rarely a straightforward process [6]. Extreme alterations 
in antibiotic PK, particularly increases in Vd and profound increases or decreases in renal drug CL, 
are common occurrences in the ICU and may severely influence drug exposure [56, 121]. To further 
complicate matters, pathogens that are usually isolated in the ICU differ from general wards, as they 
are commonly less susceptible to the current antibiotic armamentarium [334, 335]. Additionally, 
local microbiology and antibiotic resistance patterns may greatly vary across different geographical 
regions affecting antibiotic dosing requirements [332]. In this context, it is imperative to consider 
regional antibiotic susceptibility data whereby in the Asia-Pacific region, the MIC90 for doripenem 
against P. aeruginosa was reported as 8 mg/L [332, 333]. As previously mentioned, the commonly 
administered dose of 500 mg 8-hourly as a 1-hour infusion is reported to only be effective against 
pathogens with an MIC of ≤2 mg/L and its application is therefore likely to fail in such a scenario 
[313, 316].      
 
Current population PK models which describe doripenem disposition have mostly been developed 
in heterogeneous Caucasian patient groups [186, 187, 313, 314, 316, 321, 322]. However, it is 
likely that the PK of doripenem may vary across different races and therefore, the existing PK 
models may not accurately characterize the PK differences in Malaysian critically ill patients [339]. 
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Interethnic differences, such as relatively smaller body size and lower body fat distribution among 
Malaysian critically ill patients as opposed to their Caucasian counterparts, may influence 
doripenem exposure and consequently, dosing requirements may also differ between these two 
patient populations. 
 
In this study, we aimed to describe the population PK of doripenem in Malaysian critically ill 
patients with sepsis and also, to investigate sources of PK variability. With this resulting model, we 
then sought to develop clinically relevant dosing guidelines specifically for these patients.     
 
2.2.3      Materials and methods 
2.2.3.1     Setting 
This prospective, open-label PK study was undertaken in a general ICU of a tertiary hospital in 
Pahang, Malaysia between November 2012 and October 2013. The study was registered and 
approved by the Medical Research Ethics Committee Malaysia (ID: NMRR-12-649-13058). 
Written informed consent to participate in the study was obtained from each participant or their 
legally-authorized representative. 
 
2.2.3.2     Study population 
Patients were eligible for recruitment if they were; (a) adult (≥18 years old) ICU patients; and (b) 
were prescribed doripenem for the treatment of sepsis (defined as presumed or confirmed infection 
with SIRS manifesting in the previous 48 hours). Patients were excluded if they; (a) required any 
form of extracorporeal renal support; (b) were pregnant or lactating mothers; or (c) were known or 
presumed to be allergic to doripenem or any of the carbapenem antibiotics. 
 
2.2.3.3     Doripenem administration and ancillary treatments 
Doripenem (Doribax®; Janssen-Cilag, Raritan, NJ) was administered over 1-hour using a 
volumetric infusion pump controller at a dose of 500 mg in 100 mL of 0.9% sodium chloride as part 
of the patients prescribed course of therapy. All subsequent patient management, including the 
addition of other antibiotics and drugs, was at the discretion of the treating clinician and was not 
affected by study procedures. 
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2.2.3.4     Study protocol 
PK sampling was performed during one 8-hour dosing interval on Day 1 (i.e., representing a 
scenario when patients were presumed to be at their worst clinically) and Day 3 (i.e., representing a 
scenario when patients were presumed to be more clinically stable) of doripenem treatment. Blood 
samples (3 mL) were drawn from a central line and were collected into lithium-heparinised tubes at 
the following times on Day 1 (occasion 1) and Day 3 (occasion 2) of therapy, immediately before 
the first doripenem dose was administered, then 0.5, 0.75, 1, 1.5, 2, 4, and 8 hours after the start of 
the infusion. 
 
Blood samples were immediately refrigerated at 4°C and within 1 hour, centrifuged at 3000 rpm for 
10 minutes to separate plasma. Plasma samples were frozen at -80°C within 24 hours of collection. 
The frozen plasma samples were shipped on dry ice by a commercial courier company and were 
then assayed at the Burns, Trauma and Critical Care Research Centre (BTCCRC), The University of 
Queensland, Australia. 
 
Apart from blood collection, various demographic, anthropometric and clinical data were also 
collected prospectively. The severity of illness indices, which included the APACHE II score on 
admission [340] and the SOFA scores on each occasion of sampling [52], were recorded. CLCR was 
estimated on each occasion of sampling using the Cockcroft-Gault formula [341]. 
 
2.2.3.5     Doripenem assay 
Doripenem concentrations in plasma samples were measured, after protein precipitation, by a 
validated high-performance liquid chromatography (HPLC) method with ultraviolet detection on a 
Shimadzu Prominence (Shimadzu Corporation, Kyoto, Japan) instrument. Cefotaxime was used as 
the internal standard. Samples were assayed in batches, alongside calibration standards and quality 
control replicates at high, medium and low concentrations. All bioanalysis techniques were 
conducted in accordance with the US Food and Drug Administration’s guidance for industry on 
bioanalysis [342]. The assay limit for doripenem in plasma was 0.2 mg/L, with precision and 
accuracy determined at 5.7% and 4.4%, respectively. Linearity of the assay was demonstrated in the 
range of 0.2-100 mg/L. Inter-assay precision and accuracy, determined at three different 
concentrations over three separate days, were all within 7%. Observed concentrations of doripenem 
were corrected for protein binding by reducing the concentrations by 10% [343]. 
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2.2.3.6         Population pharmacokinetic analysis 
2.2.3.6.1      Software 
Plasma concentration-time data for doripenem were analysed using non-linear mixed-effect 
modelling approach in NONMEM® version 7.3 (Icon Development Solutions, Ellicott City, MD, 
USA) with an Intel® FORTRAN compiler and Perl-Speaks-NONMEM® (PsN) version 4.0 [344]. 
Throughout the model building process, typical population PK parameter estimates, between-
subject variability (BSV), between-occasion variability (BOV) and residual unexplained variability 
(RUV) were estimated using the first-order conditional estimation with interaction (FOCE-I) 
method. Data exploration and visualization, as well as model diagnostics were performed using PsN 
version 4.0 [345], Pirana version 2.7.1 [346], and Xpose version 4.0 (http://xpose.sourceforge.net) in 
R (http://www.r-project.org) [347]. 
  
2.2.3.6.2      Structural and stochastic model development    
Plasma concentration-time data for doripenem were fitted to one-, two- and three-compartment 
disposition models with first-order elimination using the ADVAN subroutines from the 
NONMEM® library. BSV and BOV were evaluated using an exponential variability model. BSV 
was evaluated on all PK parameter estimates and when significant, it was then included in the next 
model-building step. Covariance between values of BSV was estimated using a variance-covariance 
matrix. Additive, proportional and combined residual random error models were tested to describe 
RUV.   
 
Competing models were assessed on the basis of minimum objective function value (OFV), 
goodness-of-fit diagnostics and their physiological plausibility. A reduction in the OFV of >3.84 for 
one-degree of freedom was considered a statistically significant improvement (p <0.05) for a nested 
model. Observed versus population predicted concentration (PRED) or individual predicted 
concentration (IPRED) plots, individual weighted residual (IWRES) versus IPRED plots, and 
conditional weighted residual (CWRES) versus time after dose plots were used to evaluate the 
graphical goodness-of-fit of various models.   
 
2.2.3.6.3      Covariate screening and model development 
Potential covariates that were clinically plausible were screened for their influence on the PK of 
doripenem. Factors tested included patient total body weight, estimated CLCR and SOFA score on 
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the day of investigation. Covariate effects were identified via visual (scatter plots) and also 
numerical (stepwise, generalized additive models by Xpose version 4.0) methods. Allometric 
scaling was applied a priori and fixed to theory based values of ¾ for CL and 1 for Vd, all 
standardized to a bodyweight of 70 kg [348]. The covariate-parameter models that were evaluated 
were linear, piecewise-linear, exponential, power and sigmoidal models. During the covariate 
model-building process, stepwise forward inclusion and backward elimination approaches were 
employed. A reduction in the OFV of >3.84 (p <0.05) and >10.83 (p <0.01) was required for a 
covariate to be considered significant in the forward inclusion and backward elimination steps, 
respectively. 
 
2.2.3.6.4      Model evaluation and prediction 
A non-parametric bootstrap method (n = 2000) was used to assess the final model accuracy and 
stability. From the bootstrap empirical posterior distribution, 95% confidence interval for the 
bootstrap replicates were obtained and compared with parameter estimates from the final model. A 
visual predictive check (VPC) was also performed by simulating 5000 patients to evaluate the 
predictive performance of the final model. Visual checks were performed by overlaying the 
observed data points with the 95% confidence intervals of the simulated 5th, 50th and 95th percentile 
curves. 
 
2.2.3.6.5      Dosing simulations 
Different doripenem dosing regimens in subjects with various degrees of renal function were 
examined using Monte Carlo simulation in NONMEM®. Final PK model parameter estimates were 
used to generate concentration-time profiles based on 1000 simulations. Both a 1- and 4-hour 
infusion of 250 mg, 500 mg, 1000 mg and 2000 mg of doripenem every 8 hours was examined in 
subjects with a CLCR of 30 mL/min, 50 mL/min, 70 mL/min, 100 mL/min and 150 mL/min, 
respectively. The probability of target attainment (PTA) for a dosing regimen was calculated as the 
percentage of patients achieving an fT>MIC of 40% for a given MIC. These probabilities were then 
plotted against a range of MICs and optimal dosing was denoted by achieving at least 90% PTA. 
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2.2.4      Results 
2.2.4.1     Demographic and clinical data 
A total of 140 plasma samples across two sampling occasions were collected from 12 critically ill 
patients. Demographic and clinical characteristics of the recruited patients are presented in Table 2-
1. More than 65% of the cohort were males and ≥45 years of age. Median APACHE II and SOFA 
score on admission was 19 and 6, respectively. Median SOFA scores were similar on both sampling 
occasions. More than half of the patients had an estimated CLCR of ≥80 mL/min on ICU admission. 
The median CLCR on occasion 1 (88.0 mL/min) was higher than on occasion 2 (72.0 mL/min). The 
majority (66.7%) received doripenem for VAP and the most prevalent causative pathogen identified 
was A. baumannii. All patients required invasive mechanical ventilation and vasopressor support. 
Three patients died during their ICU stay and the deaths were more likely to be related to patients’ 
pre-existing comorbidities and progressive worsening of their clinical conditions. All three patients 
had a pre-ICU hospital stay of ≥2 months prior to study inclusion. 
 
2.2.4.2     Pharmacokinetic model-building 
The time course of doripenem in plasma was adequately described by a two-compartment linear 
model with combined residual error. BSV on CL (ΔOFV = -97.1), central volume of distribution 
(V1; ΔOFV = -46.6) and peripheral volume of distribution (V2; ΔOFV = -8.04) significantly 
improved the model fit. Introduction of BOV on CL (ΔOFV = -26.9) resulted in further model 
improvement. 
 
During covariate testing inclusion of an influence of CLCR (normalized to the population mean 
value of 82.5 mL/min) on CL improved the model fit (decreasing the OFV by 32.3 points and 
reducing BSV on CL from 56.7% to 10.4%). The influence of CLCR on CL of doripenem was best 
described in an exponential relationship as shown in Eq. 1:  
 
  (1) 
 
where CL is the estimated doripenem clearance in a given individual (in L/hr/70 kg), θCLpop is the 
typical value of doripenem clearance in the population; describes the influence of creatinine 
clearance on doripenem clearance and CLCR is the patient’s estimated creatinine clearance (in 
mL/min). Typical PK parameter estimates from the base and final model are summarized in Table 
2-2.     
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Table 2-1: Clinical and demographic details of the enrolled patients 
Subject Sex Age  
(in years) 
BMI 
(kg/m2) 
APACHE IIa SOFAb Admission diagnosis CLCR 
(mL/min)c 
Causative 
pathogen 
Clinical outcome 
1 M 68 23.4 22 10 Intra-abdominal sepsis 30 Nil Survived 
2 M 39 21.8 17 7 VAP 77 A. baumannii Died 
3 F 19 16.7 11 3 VAP 161 A. baumannii Survived 
4 M 74 29.7 18 5 Intra-abdominal sepsis 65 A. baumannii Died 
5 M 61 29.7 12 6 VAP 119 Nil  Survived 
6 M 49 23.2 19 6 VAP 116 Nil  Survived 
7 M 31 22.6 16 7 Intra-abdominal sepsis 92 Nil  Survived 
8 M 44 20.8 21 5 VAP 126 A. baumannii Died 
9 M 54 24.2 39 7 VAP 36 Nil  Survived 
10 M 58 24.7 20 5 VAP 44 A. baumannii Survived 
11 M 57 19.3 15 4 VAP 99 P. aeruginosa Survived 
12 F 31 22.2 23 5 Intra-abdominal sepsis 66 Nil  Survived 
Median  52 22.9 19 6  85   
IQR  33-60 21.1-24.6 15-22 5-7  49-118   
Abbreviation: APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; CLCR, estimated Cockcroft-Gault creatinine 
clearance; F, female; M, male; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia. 
Legend: 
aAPACHE II score on admission. 
bSOFA score on admission. 
cEstimated creatinine clearance on admission. 
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Table 2-2: Typical population parameter estimates for the base and final covariate model and 
the 2000 bootstrap runs 
 Base 
Model 
Final 
Model 
Bootstrap (n = 2000) 
Mean Median 95% CI 
  2.5% 97.5% 
Objective function value, 
OFV 
381.03 348.76     
Fixed effects       
   CL (L/hr/70kg) 11.5 10.1 9.9 9.9 8.9 10.9 
   V1 (L/70kg) 15.5 15.5 16.1 15.8 10.5 22.0 
   V2 (L/70kg)  17.9 17.7 18.6 18.1 12.2 26.6 
   Q (L/hr/70kg) 36.6 36.3 36.1 36.8 28.4 41.5 
    - 0.014 0.014 0.014 0.012 0.017 
Between-subject variability, 
BSV  
      
   CL (%) 56.7 10.4 14.8 14.3 4.8 21.5 
   V1 (%) 62.0 59.7 59.3 57.2 22.8 87.0 
   V2 (%) 73.3 73.8 68.4 64.7 40.0 94.0 
Between-occasion 
variability, BOV 
      
   CL (%) 33.9 22.2 16.2 8.7 4.11 28.3 
Random error       
   Proportional (% CV) 8.3 9.0 10.0 9.1 3.7 18.8 
   Additive (SD, mg/L) 1.31 1.25 0.97 1.17 0.17 1.64 
Abbreviation: CL, clearance; CV, coefficient of variation; Q, inter-compartmental clearance; V1, 
volume of distribution of central compartment; V2, volume of distribution of peripheral 
compartment;  , effect of estimated Cockcroft-Gault creatinine clearance on doripenem 
clearance.  
Final model: 
 
 
 
 
 
 
39 
 
Basic goodness-of-fit plots, including the CWRES versus time after dose plot, demonstrated that the 
final model adequately described the data with little model mis-specification (Figure 2-1). PRED 
and IPRED values were in good agreement with observed doripenem concentrations. CWRES 
values were generally homogeneously distributed over the sampling period. In a VPC plot 
associated with the final model the predicted median curve demonstrated a good fit to the observed 
data, albeit with a slight over-prediction of concentrations during the elimination phase (Figure 2-
2). Results from the non-parametric bootstrap further corroborated the robustness of the final 
model, demonstrating narrow 95% confidence interval with bootstrap median values close to typical 
population PK parameter estimates of the final model (Table 2-2). 
 
 
Figure 2-1: Goodness-of-fit plots associated with final population pharmacokinetic model for 
doripenem 
Legend: The solid black line represents the line of identity and the dashed grey line represents the 
smooth fitting for observations. Clinical observations are represented by the black solid circles. 
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Figure 2-2: Visual predictive check plot associated with the final population pharmacokinetic 
model for doripenem 
Legend: The solid black circles represent the observed data, the solid grey line represents the 50th 
percentile of the observed data, the solid black line represents the 50th percentile of the simulated 
data, the dashed grey lines represent the 5th and 95th percentiles of the observed data, the dashed 
black lines represent the 5th and 95th percentiles of the simulated data and the shaded areas represent 
the 95% confidence intervals of the 5th, 50th and 95th percentiles of the simulated plasma 
concentrations. 
 
2.2.4.3     Dosing simulations 
The PTA for 40% fT>MIC for various doripenem dosing regimens, with varying MIC and CLCR 
values, are presented in Figure 2-3. In patients with a CLCR of 70 mL/min, a standard doripenem of 
500 mg 8-hourly as a 1-hour infusion demonstrated optimal rates of PTA (>90%) against pathogens 
with an MIC of ≤2 mg/L. In other scenarios, alternative dosing strategies showed better rates of 
target attainment; with 1000 mg and 2000 mg 8-hourly as a 4-hour infusion demonstrating optimal 
rates of PTA against pathogens with an MIC of ≤8 and ≤16 mg/L, respectively. Increasing CLCR 
values were associated with lower rates of PTA for the same MIC. With increasing MIC values, the 
likelihood of obtaining optimal PTA diminishes whilst increasing the dose and prolonging the 
duration of infusion resulted in higher rates of PTA. 
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Figure 2-3: The probability of target attainment for various simulated doripenem dosing 
regimens to achieve 40% fT>MIC in patients with a creatinine clearance of (a) 30 mL/min; (b) 
50 mL/min; (c) 70 mL/min; (d) 100 mL/min; and (e) 150 mL/min 
Abbreviation: MIC, minimum inhibitory concentration. 
Legend: The dashed black lines denote optimal doripenem dosing, which was signified by 
achieving at least 90% of probability of target attainment. 
 
2.2.5 Discussion 
Despite profound PK and physiological differences to the non-critically ill population, critically ill 
patients are typically given conventional dosing regimens [27], potentially leading to sub-optimal 
antibiotic exposure and subsequently, therapeutic failures. Failure of emerging antibiotics in several 
recent clinical trials recruiting critically ill patients underscores the deficiencies associated with the 
licensed “one-dose-fits-all” dose in this unique population [336, 349]. Furthermore, the 
ramifications of this simplistic dosing approach may be more severe in some geographical regions, 
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particularly among the Southeast Asian countries, where local microbiology and antibiotic 
resistance patterns significantly vary from that of the Western countries. In our current study, we 
were able to demonstrate how bacterial susceptibility and physiological changes associated with 
critical illness substantially influence optimal doripenem exposure and importantly, how these 
alterations may be circumvented via alternative dosing strategies. 
 
In our cohort of critically ill patients, the PK of doripenem was best described using a two-
compartment model with zero-order input and first-order elimination. Such a disposition model is in 
agreement with other currently available literature in critically ill patients with conserved renal 
function [185-188]. Typical Vd (V1 + V2) of doripenem in our cohort was 0.47 L/kg (range: 0.14-
1.7 L/kg), which is generally consistent with other reports in critically ill patients with conserved 
renal function (0.30-0.54 L/kg) [185-188]. This estimate is considerably larger than that previously 
described in healthy volunteers (0.22-0.24 L/kg) [328, 329] and non-critically ill patients (0.18-0.24 
L/kg) [320, 321, 323, 327]. This is anticipated as the Vd of hydrophilic antibiotics, such as 
aminoglycosides [350, 351] and beta-lactams [56], are often reported to be two-fold greater in 
critically ill patients. This could be attributed to extreme fluid extravasation into the interstitium, a 
phenomenon commonly associated with increasing sickness severity [61]. Furthermore, medical 
interventions including aggressive fluid resuscitation [66] and mechanical ventilation [71], both of 
which were provided to all of our patients during their earlier course of therapy, have been 
associated with increased Vd.  
 
Typical CL of doripenem in this cohort was 0.14 L/kg/hr (range: 0.06-0.45 L/kg/hr), which is 
generally consistent with that reported in critically ill patients with conserved renal function (0.12-
0.25 L/kg/hr) [185-188]. However, this estimate is notably lower than that previously described in 
healthy volunteers (0.22-0.25 L/kg/hr) [328, 329] and non-critically ill patients (0.16-0.25 L/kg/hr) 
[320, 322, 323, 327]. The differences are expected as the non-critically ill population would 
presumably have better end-organ function than our patient cohort. Consistent with previous data 
[185, 313, 320, 327], estimated Cockcroft-Gault CLCR, a surrogate measure for renal function in our 
analysis albeit being less accurate as measured CLCR, was a key predictor of doripenem CL. This 
relationship is highly predictable since doripenem is extensively cleared via renal elimination; 
approximately 75% and in some reports, up to 90% of doripenem is cleared via the renal route 
[329]. Based on Eq. 1, a 30 mL/min increase in the estimated CLCR would increase doripenem CL 
by 52%.  
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Our model was also significantly improved with the incorporation of BOV on CL, denoting a 
certain degree of variability in doripenem CL between the first and second sampling occasion. 
Based on Eq. 1, doripenem CL on Day 1 (0.16 L/kg/hr) was approximately 30% higher than on Day 
2 (0.12 L/kg/hr). Essentially, this means that dosing requirements in this population may be 
dynamic and as such, regular dosing reviews and modifications may also be needed throughout 
antibiotic treatment. Given the variability in antibiotic exposures is being increasingly reported in 
critically ill patients, beta-lactam therapeutic drug monitoring (TDM) is highly warranted in this 
population and the approach would appear to be meritorious, not only to prevent underdosing which 
may increase the likelihood of antibiotic resistance, but also to minimize the risk of adverse effects 
during therapy.               
 
ARC [109] is highly prevalent in most ICU settings (17.9-41.1%) [352, 353], including Malaysian 
critically ill populations [354] and has been linked with sub-therapeutic concentrations of beta-
lactams and poor clinical outcomes [120, 121, 164]. In patients with an elevated CLCR (≥130 
ml/min), a conventional “one-dose-fits-all” approach to doripenem dosing appears to be grossly 
flawed. Our Monte Carlo simulations highlighted that while a standard dose of 500 mg 8-hourly as 
a 1-hour infusion in a patient with a CLCR of 70 mL/min would have 98.7% PTA against pathogens 
with an MIC of 2 mg/L, a patient with ARC manifesting a CLCR of 150 mL/min, would only have 
9.9% PTA. The repercussions of neglecting the phenomenon when dosing antibiotics in critically ill 
patients can be highlighted by the premature termination of a Phase III, prospective, multicentre, 
double-blind, RCT comparing a fixed 7-day course of doripenem (1000 mg 8-hourly as a 4-hour 
infusion) with a 10-day course of imipenem-cilastatin (1000 mg 8-hourly as a 1-hour infusion) in 
critically ill adult patients with VAP [336]. The trial was terminated when interim analyses revealed 
greater clinical failure and mortality rates in the doripenem treatment arm. Crucially, further 
analysis in the modified intention to treat group also showed that patients receiving doripenem with 
high CLCR (>150 mL/min) had clinical cure rates 27% worse than the comparator group (95% 
confidence interval 1.4% to 55.4%). Essentially, patients at high risk of ARC, such as young trauma 
patients without significant organ dysfunction [109], need to be identified early so that appropriate 
dose modifications can be implemented immediately.  
 
In Malaysia, particularly in our ICU, doripenem monotherapy is reserved for the management of 
complicated infections deemed to be caused by P. aeruginosa, and to some extent A. baumannii. In 
two large antibiotic susceptibility prevalence studies conducted in the Asia-Pacific region [332, 
333], the MIC90 for doripenem against P. aeruginosa was 8 mg/L. Our data suggest that for such an 
MIC, a dose of 1000 mg 8-hourly as a 4-hour infusion is optimal for patients with CLCR of 30-100 
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mL/min and a dose of 2000 mg every 8-hourly as a 4-hour infusion is best for patients manifesting a 
CLCR >100 mL/min. Such recommendations are consistent with several large PD simulation studies 
conducted in the Asia-Pacific region [331, 355] as well as other parts of the world [314, 356]. This 
study provides additional PK/PD data to support an alternative doripenem dosing approach in 
critically ill patients, particularly when pathogens with high MIC are involved. However, future 
clinical studies, preferably in the form of a multinational RCT, are required to ascertain the clinical 
efficacy and safety of the suggested doripenem dosing regimen in this patient group. For A. 
baumannii, which is commonly MDR, empirical combination antibiotic therapy is currently 
preferred than doripenem monotherapy in our ICU. Furthermore, the MIC90 for doripenem against 
A. baumannii in the Asia-Pacific region was reported as ≥32 mg/L [332, 333]. For such an MIC, 
even with a dose of 2000 mg 8-hourly as a 4-hour infusion, optimal exposure is only achieved for 
patients with reduced CLCR in our cohort (e.g., <70 mL/min).    
 
This study has several limitations. A relatively small number of critically ill patients (n = 12) with a 
narrow bodyweight- and CLCR-range were included and thus, our model may not fully characterize 
the PK of doripenem in all Malaysian ICU patients. A number of patients with conserved renal 
function were recruited to examine altered dosing approaches in this cohort. Dosing 
recommendations derived from our Monte Carlo simulations should not be extrapolated to other 
patient populations such as the obese or those on extra-corporeal renal support. We also 
acknowledge limitations with the Cockcroft-Gault formula in estimating renal function in this 
cohort, with measured CLCR more appropriate in the ICU setting. Neither free (unbound) doripenem 
concentrations nor drug concentration at the sites of infections (e.g., epithelial lining fluid 
concentrations) were measured in this study. Total doripenem concentration was measured and 
applied in the analysis with correction for protein binding. We believe that this approach is highly 
acceptable for drugs with low protein-binding properties, such as doripenem (approximately 10% 
protein bound) [99]. Although data on concomitant drugs were available, we did not evaluate the 
PK of those drugs and their potential influence on doripenem exposure in critically ill patients.  
 
2.2.6 Conclusions 
Critically ill patients frequently manifest extreme physiological changes, which may alter antibiotic 
PK and subsequently reduce effective drug exposure. Importantly, findings from this study further 
show that the licensed “one-dose-fits-all” dosing strategy for doripenem is likely to be flawed in the 
critically ill population. An alternative dosing approach such as the empirical use of a prolonged 4-
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hour infusion may be considered to account for PK and illness-severity differences in this unique 
patient population, particularly when MDR Gram-negative organisms are involved. 
 
2.2.7 Acknowledgments 
This project has received funding from the International Islamic University of Malaysia (IIUM) 
Research Endowment Grant. Mohd H. Abdul-Aziz and Azrin N. Abd Rahman would like to 
acknowledge the support of the Ministry of Education, Malaysia in the form of scholarship. Jason 
A. Roberts is funded by a Career Development Fellowship from the National Health and Medical 
Research Council of Australia (APP1048652). 
 
46 
 
2.3 Conclusion 
This chapter describes how critically ill patients are markedly different from those in general ward 
settings and demonstrates how these differences influence doripenem dosing requirements. The Vd 
and CL of doripenem in this patient cohort were observed to be substantially different than those 
usually described in healthy volunteers and non-critically ill patients. As current dosing 
recommendations were mostly derived from these two populations, findings from this study further 
emphasize that the licensed “one-dose-fits-all” dosing strategy for doripenem is likely to be flawed 
in critically ill patients. The findings of presented in this chapter also provides additional PK/PD 
data which supports alternative dosing approaches for doripenem in critically ill patients, 
particularly when less-susceptible pathogens are involved.      
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Chapter 3: Continuous beta-lactam infusion in critically ill patients: a 
structured review of published literatures 
3.1 Synopsis 
Mortality rates due to severe sepsis and septic shock in critically ill patients remain persistently high despite 
recent therapeutic advances. Beta-lactam antibiotics are commonly used and are regarded as first-line 
therapies around the world, particularly in the management of critically ill patients with severe sepsis. 
However, dosing modifications for these antibiotics are frequently needed in critically ill patients to prevent 
therapeutic failures due to significant pathophysiological perturbations in this patient population over time. 
Beta-lactam antibiotics display time-dependent bacterial kill characteristics, whereby fT>MIC best describes 
their antimicrobial properties. In terms of drug administration, CI administration of beta-lactam antibiotics, 
as opposed to conventional IB dosing, is more likely to achieve this PK/PD end-point. Despite this 
theoretical advantage, a global shift away from the traditional dosing method towards CI administration has 
been difficult to be instigated as comparative studies in humans mostly fail to demonstrate a significant 
difference in clinical outcomes between the two dosing approaches. However, comparisons between the two 
dosing approaches were mostly performed in heterogeneous non-critically ill patient population and thus, the 
question still remains whether there is any real benefit of administering beta-lactam antibiotics via CI dosing 
in critically ill patients. Therefore, this chapter aims to critically analyse the available literature, by 
comparing the PK/PD data and clinical outcomes associated with by CI and IB dosing, in order to establish 
any potential benefits supporting either of the two dosing approaches for critically ill patients. 
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3.2 Manuscript entitled “Continuous infusion vs. bolus dosing: implications 
for beta-lactam antibiotics” 
The manuscript entitled “Continuous infusion vs. bolus dosing: implications for beta-lactam 
antibiotics” has been accepted for publication in the Minerva Anestesiologica (2012; 78 (1): 94-
104). 
 
The co-authors contributed to the manuscript as follows: Conception and development of the study 
design was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. 
Jason A. Roberts and Prof. Jeffrey Lipman. Literature review was performed by the PhD candidate, 
Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. Jason A. Roberts. The PhD candidate took the 
leading role in manuscript preparation and all co-authors reviewed and contributed to the final draft 
of the manuscript. 
 
The accepted version of this manuscript is presented and incorporated in this chapter. However, 
some text, tables and figures may have been inserted at slightly different positions to fit the overall 
style of the thesis. Numbering of pages, tables and figures may also change to fit the thesis 
requirements. Manuscript references have been collated with all other references in the thesis. 
 
Permission has been granted by the publisher and copyright owner, Edizioni Minerva Medica, to 
reproduce the manuscript in this Thesis. 
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3.2.1 Abstract 
Beta-lactam antibiotics display time-dependant PD whereby constant antibiotic concentrations 
rather than high peak concentrations are most likely to result in effective treatment of infections 
caused by susceptible bacteria. CI administration has been suggested as an alternative strategy, to 
conventional IB dosing, to optimize beta-lactam PK/PD properties. With increasing data emerging, 
we elected to systematically investigate the published literature describing the comparative PK/PD 
and clinical outcomes of beta-lactam antibiotics administered by CI or IB. We found that the studies 
have been performed in various patient populations including critically ill, cancer and cystic fibrosis 
patients. Available in vitro PK/PD data conclusively support the administration of beta-lactams via 
CI for maximizing bacterial killing from consistent attainment of PD end-points. In addition, 
clinical outcome data supports equivalence of CI and IB, even with the use of a lower dose with CI. 
However, the present clinical data is limited with small sample sizes commonly associated with 
insufficient power to detect advantages in favour of either dosing strategy. With abundant positive 
pre-clinical data as well as document in vivo PK/PD advantages, large multicentre RCTs are needed 
to describe whether CI administration of beta-lactams is truly more effective than IB dosing.  
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3.2.2 Introduction 
The mortality rate due to severe sepsis and septic shock remains high despite recent therapeutic 
advances. Source control of the pathogen along with early and appropriate antibiotic administration 
remains the best strategy available to clinicians in the management of critically ill septic patients 
[330, 357]. However, appropriate antibiotic administration is not straightforward as critically ill 
patients may develop pathophysiological changes that alter the PK of the prescribed antibiotic [8, 
64]. Indeed dosing that does not account for these pathophysiological changes may lead to 
inadequate antibiotic concentrations and therapeutic failure. Therefore, different dosing approaches 
may be required to ensure that antibiotic concentrations meet PK/PD targets likely to enable clinical 
success.   
 
Beta-lactam antibiotics are still regarded as key antibiotics in severe infections due to their spectrum 
of antibacterial activity and overall tolerability. These antibiotics display time-dependent PD 
whereby fT>MIC best describes their bacterial kill characteristics (5). Based on this property, 
maximal beta-lactam activity is thought to be achieved by utilizing either smaller doses more 
frequently than standard IB dosing or utilizing EI or CI.  
 
The aim of this paper is to systematically review and critically analyse the published literature 
comparing the PK and clinical outcomes of administering beta-lactams by IB and CI in various 
patient populations. The review will address the question on which administration strategy most 
consistently achieves PK/PD targets and results in improvement of clinical endpoints.   
 
Data for this review were identified by incorporating PUBMED searches (1966 to February 2011) 
and references from relevant papers. Search terms were “continuous infusion” or “intermittent 
infusion”, “antibiotic” or “antibacterial” or “antimicrobial”, “beta-lactams” or “penicillins” or 
“cephalosporins” or “monobactams” or “carbapenems” and “pharmacokinetics” or 
“pharmacodynamics”. Relevant primary research papers comparing the administration of beta-
lactams by IB and CI were identified and evaluated. All relevant English original articles were 
systematically evaluated. To emphasize new developments in this area, we have given particular 
focus to the more recently published studies. Below, we discuss the published studies in terms of 
PK and clinical outcomes and then outline the results that have been obtained in specific patient 
populations.  
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3.2.3      The Pharmacodynamics of Beta-lactams 
Beta-lactam antibiotics include the penicillins, cephalosporins, carbapenems and monobactams. 
These antibiotics have slow bacterial kill characteristics which are almost exclusively dependent on 
the serum free drug concentration exceeding the MIC of the pathogen [12]. Maximal beta-lactam 
bacterial killing is achieved when the serum free drug concentration is maintained at 4-5 times the 
MIC [152]. The PD of beta-lactams have been extensively reviewed by Turnidge previously [358]. 
 
One of the main areas of contention for the PD of beta-lactams relates to the comparative target 
exposures required for CI and for IB. Mouton and den Hollander used an in vitro PK model that 
was able to replicate plasma ceftazidime concentrations administered by IB or by CI [152]. In this 
study, the authors found that maintaining a CI concentration near the MIC does not provide 
bacterial killing advantages over IB. However, when concentrations are maintained at 4 x MIC, CI 
is associated with significantly greater bacterial killing. In combination with other available PD 
data, this data suggests that therapeutic targets for CI therapy should be a steady-state concentration 
(Css) that is at least 4 x MIC. It follows, that comparative PK studies should be evaluating the 
relative ability of IB to achieve a Cmin greater than the MIC of the likely pathogen (this is likely to 
ensure 40-70% of the time that free (unbound) drug concentration remains four times above the 
MIC during a dosing interval [fT>4xMIC]) and for CI, a Css greater than 4 x MIC. 
 
Of particular importance, published PK/PD studies need to be interpreted in light of the new 
susceptibility breakpoints that have been classified by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST; available at: http://www.eucast.org/clinical_breakpoints) [359] 
and Clinical and Laboratory Standards Institute (CLSI; available at http://www.clsi.org/) [360, 361]. 
Specifically, the recent EUCAST susceptibility breakpoint recommendations are lower than those 
of CLSI, which may in turn influence clinicians’ view on the results from PK/PD studies. These 
new data may mean that the present dosing approaches are more, or less likely to achieve PK/PD 
targets. 
 
3.2.4      Comparative Studies between Intermittent and Continuous Administration 
3.2.4.1     Plasma Pharmacokinetics 
Before describing the published data, it is important to note that the PK advantages reported by 
studies comparing the Cmin from IB and Css from CI of beta-lactams are expected based on PK 
principles. Statistically significant differences favouring CI would be seen as the Css will always be 
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higher than Cmin from IB. This concept is described in Figure 3-1 which uses PK modelled data, 
adapted from a previous study with flucloxacillin [102], to describe the inevitability of achieving a 
higher Css from CI in critically ill patients. This limitation has also been discussed in a review article 
by Roberts et al., identifying the deficient reporting approach in some PK studies resulting 
disadvantages to IB [277]. The key comparison in the PK studies should be the achievement of the 
PD end-points, 100% fT>MIC for IB and 100% fT>4xMIC for CI. We would advocate a PD target of 
100% fT>MIC for IB as this is likely to result in a concentration 4 x MIC for 40-70% of the dosing 
interval as required for the different classes of beta-lactams. 
 
 
Figure 3-1: Comparative flucloxacillin concentration between continuous (CI) and 
intermittent administration (IB) assuming similar pharmacokinetic properties in ICU 
patients. The same daily dose for IB and CI was simulated from a previous population 
pharmacokinetic study whereby 2 g 6 hourly for IB and 8 g over 24 hours was simulated for 
CI 
Legend: 
Continuous infusion (dotted lines); intermittent bolus dosing (solid lines). 
 
Studies comparing the plasma PK of IB and CI administration of beta-lactams have generally 
shown that administration via CI maintains superior concentrations throughout a treatment period. 
Table 3-1 compares the published data of plasma pharmacokinetic exposures for each 
administration method.  
54 
 
Table 3-1: Comparison of respective plasma pharmacokinetic between continuous and intermittent administration of beta-lactams in critically ill or septic patients 
Antibiotic n Design MIC 
(mg/L) 
Dosage Regimen AUCa 
(mg/L*h) 
Cmaxa 
(mg/L) 
Cmina 
(mg/L) 
Cssa 
(mg/L) 
%fT>MIC 
(%) 
    CI IB CI IB IB IB CI CI IB 
Piperacillinb 
[85] 
13 RCT 
(critically ill septic) 
- 12 g/24 hrs 4 g q6/8hrs 464 803 152 
(90-275) 
2  
(2-8) 
17 
(11-24) 
- - 
Piperacillinb 
[253] 
7 Randomized crossover 
(critically ill septic) 
- 4 g LD then 8 g/24 hrs 4 g q8hrs 210±120 391±183 228 
(172-359) 
4.8 
(1-43) 
22 
(14-53) 
- - 
Piperacillin 
[362] 
52 RCT 
(complicated intra-abdominal infections) 
- 2 g LD then 12/24 hrs 3 g q6hrs - - 122±30 - 35±12 100 95 
Piperacillinb 
[173] 
24 RCT 
(severe infections) 
- 2 g LD then 8 g/24 hrs 4 g q8hrs 936 - - - 39 - - 
Meropenem 
[253] 
6 Randomized crossover 
(critically ill with CRRT) 
8 0.5 g LD then 2 g/24 hrs 1 g q12hrs 227 
(182-283) 
233 
(202-254) 
63 
(51-85) 
8 
(5-18) 
19 
(13-25) 
100 46 
Meropenemb 
[193] 
15 Randomized crossover 
(critically ill septic) 
- 2 g LD then 3 g/24 hrs 2 g q8hrs 118±13 194±21 110±7 9±1 12±5 - - 
Meropenem 
[86] 
10 RCT 
(critically ill septic) 
4 0.5 g LD then 3g/24 hrs 1.5 g LD then 1 g q8hrs 99c 97c 93 
(74-119) 
0 
(0-2) 
7d 
(5-16) 
100e 80e 
Ceftazidime 
[82] 
18 RCT 
(severe intra-abdominal infections) 
8 1 g LD then 4.5 g/24 hrs 1.5 g q8hrs 1131 
(505-2230) 
1064 
(505-1950) 
89 
(58-125) 
19 
(6-68) 
47 
(21-93) 
67f 69f 
Ceftazidime 
[254] 
30 RCT 
(critically ill, trauma, VAP) 
- 2 g LD then 60 mg/kg/24 
hrs 
2 g q8hrs - - 91±44 4±4 19±9 100 100g 
Ceftazidimeb 
[363] 
12 Randomized crossover 
(critically ill septic) 
P. aeruginosa 
isolate 
2 g LD then 3 g/24 hrs 2 g q8hrs 112±56 331±165 124±53 25±18 30±17 100 92 
Ceftazidimeb 
[364] 
56 Randomized crossover 
(Cystic fibrosis-chronic) 
- 100 mg/kg over 23.5 hrs 200 mg/kg divided thrice 
daily 
- - 159±44 9±5 32±12 - - 
Ceftazidime 
[365] 
49 Randomized crossover 
(Cystic fibrosis-acute exacerbation) 
- 60 mg/kg LD then 200 
mg/kg over 23 hrs 
200 mg/kg divided thrice 
daily 
- - 216±72 12±9 56±23 - - 
Ceftazidimeb 
[366] 
14 (Cystic fibrosis-chronic) - 100 mg/kg over 24 hrs 200 mg/kg divided thrice 
daily 
- - - 10±12h 30±10h - - 
Temocillin 
[247] 
13 RCT 
(critically ill septic) 
16 2 g LD then 4 g/24 hrs 2 g q12hrs 1759±188 1856±282 147±12 28±5 73±3 100 51 
Cefazolin 
[168] 
20 RCT 
(peri-operative-CPB) 
8 2 g LD then 3 g/18 hrs 2 g LD, 1 g after CPB, 1 g 
at 9 hrs &15 hrs after 2nd 
dose 
1700±205 1551±310 184±20 15±10.3i 53±19i 90j 30j 
Cefotaxime 
[79] 
15 RCT 
(peri-operative-liver transplant) 
4 1 g LD then 4 g/24 hrs 1 g q6hrs 53±23k 72±21k 43±13 2±2 18±5 100 60 
Abbreviation: AUC, area under the concentration-time curve; CI, continuous infusion; Cmax, peak concentrations; Cmin, trough concentrations; ; CPB, cardiopulmonary bypass; CRRT, continuous renal replacement therapy; Css, steady-state concentrations; IB, 
intermittent bolus; LD, loading dose;  MIC, minimum inhibitory concentration; RCT, randomized controlled trial; VAP, ventilator-associated pneumonia; % fT>MIC, percentage of time (dosing interval) where free (unbound) antibiotic concentration remains 
above MIC. 
Legend: 
aValues are described according to published results as mean (±SD) or median (range). 
bLower CI dose used. 
cDay 1 AUC0-8. 
dDay 1 Cmin. 
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e% of patients achieving 40% fT>MIC. 
 f4 x MIC. 
gAll patients achieved % fT>MIC of 100% except 1 who achieved 92%. 
hDay 3. 
iAverage concentration at 24 hours. 
j% of patients achieving 90% fT>MIC. 
kAUC0-8.
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Below, we will specifically discuss the previously published PK studies comparing the two study 
approaches in specific populations. The issues identified relating to different PK/PD targets are 
relevant to some of the studies depicted below. 
 
3.2.4.1.1      Critically ill 
Critically ill patients have been the focus of many studies (Table 3-1) as they are postulated to be 
likely to benefit most from the PK/PD advantages of CI [82, 85, 86, 173, 193, 247, 253, 254, 363, 
367]. These patients commonly develop an increased Vd and ARC thus producing low drug 
concentrations in the presence of standard dosing [357].   
 
Roberts et al., reported a superior PK/PD profile for piperacillin in an RCT where CI was compared 
to IB in 13 critically ill patients with sepsis [85]. Despite a 25% lower dose, the median Cmin on Day 
2 of therapy was 16.6 versus 4.9 mg/L for CI and IB respectively (p = 0.007).  Langgartner et al., 
observed higher median Css (18.6 mg/L) when meropenem was administered via CI compared to 
trough concentrations (8.2 mg/L) provided by IB in 6 critically ill patients who also received CRRT 
[253]. De Jongh et al., also reported significantly higher temocillin Css (73 mg/L) in CI compared to 
IB (trough concentrations; 28 mg/L) [247]. The authors also added that CI of temocillin achieved a 
plasma concentration that is 4 times the MIC of the least susceptible pathogens in the study. Other 
studies have described PK/PD advantages in critically ill patients [79, 82, 86, 172, 173, 193, 253, 
254, 362, 363].  
 
3.2.4.1.2      Peri-operative non-infected patients 
Several studies (Table 3-1) have sought to investigate the PK properties of CI of beta-lactams in 
preventing infections after surgical procedures [79, 168, 368]. The majority of these studies support 
the PK/PD superiority of CI compared to IB dosing. Adembri et al., described stable serum 
cefazolin concentrations with low interpatient variability using CI for antibiotic prophylaxis in 
cardiopulmonary bypass surgery [168]. 
 
3.2.4.1.3       Cystic fibrosis 
Several studies (Table 3-1) have shown PK/PD advantages supporting the use of CI of ceftazidime 
in cystic fibrosis patients [364-366, 369]. The idea of administering ceftazidime as CI was proposed 
due to the drug’s rapid renal elimination whereby 65% urinary recovery within 2 hours of 50 mg/kg 
ceftazidime bolus dose was reported in the sub-population [370].  Hubert et al., performed an RCT 
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to compare the PK properties of ceftazidime administered as either thrice-daily or 24-hour CI in 49 
cystic fibrosis patients with acute exacerbation of chronic pulmonary P. aeruginosa infection [365]. 
The authors found superior concentration-time profile benefits which favoured CI of ceftazidime 
whereby the mean Css was significantly higher compared to the Cmin of thrice-daily administration 
(CI; 56.2 mg/L versus IB; 12.1 mg/L, p <0.05). Some of the Cmin values were reported to be very 
low, even lower than the MIC of the offending pathogens whereas the Css remained constantly 
above the MIC throughout CI administration. However, it is unknown if these concentrations were 
indeed 4 x MIC to demonstrate maximal antibacterial activity. Riethmueller et al., found higher 
mean Css (32 mg/L) of CI compared to Cmin (8.5 mg/L) of thrice-daily administration of ceftazidime 
in 56 cystic fibrosis patients with chronic P. aeruginosa infection [364]. The authors described 
superior target ceftazidime concentration achievement by CI despite using a lower ceftazidime dose 
of 100 mg/kg/day compared to the conventional 200 mg/kg/day in three divided doses. Studies by 
Rappaz et al., and Vinks et al., also reported similar findings with a lower ceftazidime dose of 100 
mg/kg/day administered as continuous application [366, 371]. Each of the studies reported higher 
average steady-state beta-lactams concentrations in CI administration compared to trough 
concentrations of IB up to a factor of 4 which is theoretically likely to enable PK/PD superiority in 
favour of CI.       
 
3.2.4.1.4      Cancer patients 
Comparative studies on CI and IB dosing of beta-lactams in cancer patients are lacking. Most of the 
studies that are available have focused on the safety and efficacy of CI in cancer patients without the 
inclusion of an IB regimen for comparison [255, 372, 373]. Studies have also supported the notion 
of using CI administration in cancer patients based on the postulated superior PK/PD properties 
compared to IB dosing as neutropenic patients may develop increased Vd and higher drug CL [255, 
372, 373]. More prospective comparative studies are needed in to further describe the clinical 
applicability of CI in this sub-population.  
 
3.2.4.1.5      Paediatric population 
Studies (Table 3-1) comparing the PK properties of CI and IB in paediatric population are lacking 
[366, 372]. Robust prospective comparative studies are warranted in this specific patient group.  
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3.2.4.2     Tissue pharmacokinetics 
Antibiotic-bacteria interactions usually occur at the tissue level (e.g., interstitial fluid) thus, any 
administration method that could enhance antibiotic penetration into tissues is vital in predicting 
response. Significant antibiotic concentration is needed at the target site but most antibiotics are 
unevenly partitioned and serum concentration does not always reflect tissue concentrations. Table 
3-2 describes the penetration of beta-lactam antibiotics into various tissues when administered via 
CI or IB. 
 
Table 3-2: Penetration of beta-lactams into various tissues when administered as continuous or 
intermittent administration 
Antibiotic Population n Measurement site % Tissue penetration 
    CI IB 
Piperacillina 
[277] 
Critically ill 
septic patients 
13 Subcutaneous tissue 
(AUCtissue/AUCserum) 
21% 20% 
Piperacillin/tazobactam 
[211] 
Critically ill 
septic patients 
40 ELF 40-50% 57% 
Piperacillin/tazobactam 
[80] 
Critically ill 
septic patients 
10 ELF - 57% 
Meropenem 
[86] 
Critically ill 
septic patients 
10 Subcutaneous tissue 
(AUCtissue/AUCserum) 
89% 74% 
Cefotaxime 
[79] 
Peri-operative 
non-infected 
patients 
15 Bile 
(AUCbile/AUCserum) 
90%  80%  
Ceftazidime 
[82] 
Peri-operative 
infected 
patients 
18 Peritoneal exudate 
(AUCexudate/AUCserum) 
56% 35% 
Abbreviation: AUC, area under the concentration-time curve; CI, continuous infusion; ELF, 
epithelial lining fluid; IB, intermittent bolus. 
Legend: 
aLower CI dose used. 
 
Roberts et al., found similar plasma and tissue PK of piperacillin when administered by IB or CI 
[85]. However, the RCT also described higher PD targets attainment by CI despite utilizing 25% 
smaller dose compared to IB. The authors also added that the clinical significance of this difference 
is only important in pathogens with high MICs (2 or 4 mg/L). In a prospective comparative study, 
Boselli et al., sought to investigate plasma and alveolar PK of piperacillin/tazobactam administered 
via CI in critically ill patients with VAP and various degrees of renal impairment [211]. The authors 
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reported large variability in the drug’s concentrations with an alveolar percentage penetration of 40-
50% and 65-85% for piperacillin and tazobactam respectively. It is interesting to note that in 
patients with no/mild renal impairment, a CI daily dose of piperacillin/tazobactam 16/2 g achieved 
the alveolar target concentration which was not observed with 12/1.5 g per day. In this study, it was 
postulated that the latter dosing regimen in patients with no/mild renal impairment might produce 
inadequate antibiotic concentration in epithelial lining fluid (ELF) in patients with VAP caused by 
pathogens with high MICs. 
 
In one RCT involving 10 critically ill septic patients, Roberts et al., reported that CI of meropenem 
maintains higher median Cmin compared to IB, in both plasma (CI; 7 mg/L versus IB; 0 mg/L, p = 
0.02) and subcutaneous tissue (CI; 4 mg/L versus IB; 0 mg/L, p = 0.02) [86]. The authors also 
concluded that CI of meropenem achieves superior cumulative fraction of response (CFR) against 
less-susceptible microorganisms (P. aeruginosa and Acinetobacter spp.) in patients without renal 
impairment.       
 
3.2.4.3     Clinical outcomes 
Although the PK/PD data of beta-lactams support the use of CI, there is little data to confirm that 
this results in improved clinical outcomes. The published data on comparative clinical outcomes is 
scarce and insufficient to support a global practice change from conventional IB to CI. Lack of 
significance in the published results are likely to be due to the use of study designs that were not 
sufficient to explore the effect of both dosing approaches on clinical outcomes as well as the 
consistent, small sample sizes that resulted in insufficient power. Further to this, a single therapeutic 
intervention in a critically ill setting rarely influences mortality and clinical cure in the setting of a 
study [264]. 
 
Another possible contributor to a lack of clinical differences being measured between the methods 
of administration is that treatment of infections caused by highly susceptible pathogens will always 
result in similar outcomes for IB and CI.  This is because even a low Cmin achieved during IB is still 
likely to exceed the MIC for a sufficient period of each dosing interval.  If studies include many 
patients with highly susceptible pathogens, then the sample size required to show differences 
between the respective dosing methods increases dramatically. For less susceptible organisms, the 
likelihood of achieving target concentrations is less likely may risk therapeutic failure. 
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Below, we discuss the published clinical outcome data that have been reported in specific patient 
populations.  
 
3.2.4.3.1      Mortality 
Several studies, mostly in critically ill patients, have sought to evaluate the mortality outcome 
produced by beta-lactams administered via CI or IB (Table 5-3) [151, 172, 243, 248, 256, 274, 
298]. It is important to note that the number of RCTs in this area is limited and these trials described 
no significant mortality benefits achieved by either administration methods. The problem lies in the 
fact that many studies are underpowered and the mortality is often studied as a secondary end-point. 
A retrospective cohort study by Lorente et al., revealed similar mortality rate in 83 VAP patients 
receiving either IB or CI of piperacillin/tazobactam (IB; 30.5% versus CI; 21.6%, p = 0.46) [274]. 
Another non-randomized study that’s worth a mention is by Lodise et al., where they reported a 
significant lower 14-day mortality rate in patients with an APACHE II score ≥17 favouring EI 
compared to IB of piperacillin/tazobactam in critically ill patients infected with P. aeruginosa (IB; 
31.6% versus CI; 12.2%, p = 0.04) [298]. Intention-to-treat (ITT) analysis of an RCT by Roberts et 
al., found no significant difference in the mortality rate of 57 ICU patients (CI; 10% versus IB; 0%, 
p = 0.25) [243]. A recent systematic review of 14 randomized controlled trials performed by 
Roberts et al., reported that CI of beta-lactams were not associated with a significant improvement 
in mortality rate (odds ratio [OR]: 1.00, 95% confidence interval: 0.48-2.06, p = 1.00, I2 = 14.8%) 
[217].  
 
Hughes et al., compared 30-day mortality rate in patients receiving CI or IB of oxacillin for the 
treatment of infective endocarditis caused by Methicillin-susceptible Staphylococcus aureus 
(MSSA) [374]. The two groups were similar with respect to mortality rate (CI; 8% versus IB; 10%, 
p = 0.7) whether synergistic gentamicin (11%) was or not added (5%) into the studied regimen (p = 
0.2).      
 
3.2.4.3.2      Clinical cure 
Lorente et al., also compared the clinical cure rate in 83 VAP patients receiving either CI or IB of 
piperacillin/tazobactam [274]. CI was associated with greater clinical cure rate (CI; 89.2% versus 
IB; 56.5%, p = 0.001) and regression analysis further showed higher clinical cure of VAP by CI 
when the offending pathogen had a MIC of 8 mg/L or 16 mg/L. A priori analysis by Roberts et al., 
found significant advantage favouring CI of ceftriaxone compared to IB administration in critically 
ill septic patients receiving at least 4 days of therapy [243]. The authors also reported that low 
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APACHE II score was predictive of clinical cure. However, the systematic review by Roberts et al., 
found that the use of CI of a beta-lactam antibiotic was not associated with an improvement with 
clinical cure rate (OR: 1.04, 95% confidence interval: 0.74-1.46, p = 0.83, I2 = 0%) [217]. Again, 
the number of RCTs (Table 2-3) investigating this outcome is limited and most of them were 
underpowered [172, 243, 255-257, 266, 274, 375]. 
 
The clinical utility of CI and IB in cystic fibrosis have been compared in several studies [364-366]. 
These studies reported similar clinical outcomes. These studies have also compared patient 
improvements in pulmonary, inflammatory and nutritional parameters in both methods after 
antibiotic administration. However, these improvements were short-lived and patients frequently 
returned to pre-treatment values after cessation of therapy. 
 
Riethmueller et al., compared anti-infectious properties of CI and thrice-daily administration of 
ceftazidime in 56 cystic fibrosis patients in a randomized crossover study [364]. The authors found 
no significant difference between the two methods in terms of decrease in leukocyte counts, 
clinical, lung function and inflammatory parameters. Another randomized crossover study by 
Rappaz et al., had similar findings where CI of ceftazidime produced better pulmonary, 
inflammatory and nutritional improvements compared to IB [366]. However, the only significant 
improvement was in pre-albumin concentration. Hubert et al. reported similar improvements in 
forced expiratory volume in 1 second (FEV1) values between the two administration methods but 
the benefit of CI was seen in patients with resistant P. aeruginosa isolates (p <0.05) [365]. The 
interval between the next antibiotic administration was longer in CI compared to short infusion of 
ceftazidime in cystic fibrosis patients (p = 0.04). 
 
Van Zanten et al., reported similar clinical success rates in patients with acute exacerbations of 
COPD receiving either CI or thrice-daily administration of cefotaxime [257]. Clinical cure was 
achieved in 37/40 (93%) and 40/43 (93%) patients in the CI and IB dosing group respectively (p = 
0.93). Bodey et al., randomized cancer patients with febrile neutropenia to receive either CI or IB of 
cefamandole with carbenicillin [255]. Although no difference in clinical outcome was reported, a 
sub-analysis result revealed that CI administration in comparison to IB produced clinical benefits in 
patients with severe persistent neutropenia (CI; 65% versus IB; 21%, p = 0.03).   
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3.2.4.3.3      Severity of Illness 
The rate of resolution of infection as described by improvements in the level of severity of illness in 
critically ill patients has been used as a comparative index in some studies. In a study of 40 
critically ill septic patients by Rafati et al., reduction in APACHE II scores was faster in a CI 
compared to an IB group [248]. Significant difference in reduction of score was reported on Days 2, 
3 and 4 of treatment. 
 
3.2.4.3.4      Fever resolution/white blood cell normalization 
Most studies (Table 3-3) that have investigated fever resolution or WCC normalization between 
patients receiving CI or IB of beta-lactam antibiotics have found similar results [248, 254, 266, 364, 
374]. However, an RCT by Nicolau et al., reported shorter defervescence time with CI compared to 
IB of ceftazidime in 35 critically ill septic patients (CI; 3.1±2.1 days versus IB; 5.2±2.3 days, p = 
0.015) [266]. Hughes et al., reported similar defervescence time in 107 patients with infective 
endocarditis receiving either CI or IB dosing of oxacillin (CI; 3 days versus IB; 3 days, p = 0.8) 
[374]. However, it is interesting to note that defervescence time was significantly different when 
synergistic gentamicin was added, favouring the group without gentamicin addition. 
 
Riethmueller et al., found a decrease in WCC favouring CI of ceftazidime in cystic fibrosis patients 
[364]. However, the differences obtained in the randomized crossover study were insignificant 
when compared to IB (CI; -2216 versus IB; 2209, p = 0.98).    
 
3.2.4.3.5      Mechanical ventilation 
The duration of mechanical ventilation has been compared in several studies (Table 3-3), mostly in 
critically ill septic population but without significant differences favouring neither IB nor CI 
method [172, 243, 254, 274, 375]. Roberts et al., postulated that as the duration of mechanical 
ventilation is quite long, other confounding factors may influence the ventilation time in critically 
ill patients [264].   
 
3.2.4.3.6      Length of ICU/hospital stay 
To date, no significant difference has been reported in length of hospital [243, 254, 298, 374, 375] 
or ICU stay [172, 243, 254, 266, 274, 375] between patients receiving CI or IB of beta-lactam 
antibiotics (Table 3-3). Studies are often underpowered to detect any significant difference and the 
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studied outcome is usually confounded by several factors other than the intervention given [264]. 
Whilst the data that describes the effect of CI on length of stay, data from studies which examined 
the use of EI are worthy of noting. Among them is a retrospective cohort study by Lodise et al., who 
reported a significant shorter hospital stay favouring EI of piperacillin/tazobactam compared to IB 
in critically ill patients with P. aeruginosa infections (EI; 21 days versus IB; 38 days, p = 0.02) 
[298]. 
 
3.2.4.3.7       Adverse events 
Several studies (Table 3-3) have compared adverse events from CI and bolus administration of beta-
lactams, although no significant differences are evident [193, 256, 363-365, 375]. Interestingly, 
some studies have reported no adverse events [193, 363, 364] while others have made multiple 
identifications [256, 365, 375]. Hubert et al., reported 124 adverse events in a randomized crossover 
study comparing the safety and efficacy of the two antibiotic protocols in a cystic fibrosis 
population [365]. Fifty-six and 68 adverse events were reported during CI and IB respectively in the 
study. However, only 2 were considered as severe (one in CI and one in IB) and the majority of the 
adverse events were gastrointestinal related.    
 
3.2.4.4           Other considerations 
3.2.4.4.1        Stability Issues 
Increasing the % fT>MIC for beta-lactams has been associated with increased therapeutic efficacy 
and delaying the emergence of resistance and these benefits can be achieved with CI method. 
However, carbapenems such as meropenem may be unsuitable for administration via CI due to 
stability issues [284]. Meropenem is only stable for 8-12 hours at room temperature thus casting 
doubts on any potential benefit of continuous delivery. This is still an important issue in tropical 
countries where meropenem concentrations decreased by 4% and 12% when stored at room 
temperature for 3 and 8 hours respectively [376] although 24-hour stability can be maintained if 
meropenem’s temperature is kept below 4°C [369]. In tropical countries, EI (3-hour infusion) may 
be a useful alternative to CI as it is still likely to produce superior PK/PD end-points compared to 
IB dosing [376]. 
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Table 3-3: Clinical outcome data for patients receiving bolus or continuous infusion/extended-dosing of beta-lactam antibiotics 
Drug Population Study Clinical Outcome 
Measure 
CI IB Result 
Cefepime 
[172] 
Critically ill, Gram-negative 
infection  
(n = 50) 
RCT Mortality 12% 13% NS 
Clinical cure 85% 67% NS 
Duration of MV 24 ± 13 days 25.3 ± 10 days NS 
LOS ICU 34 ± 17 days 40 ± 15 days NS 
Ceftazidime 
[254] 
Trauma patients, NP  
(n = 35) 
RCT Duration of MV 22.9 ± 19.9 days 13.3 ± 6.1 days NS 
LOS Hospital 41.7 ± 30.5 days 28.7 ± 15.9 days NS 
LOS ICU 26.8 ± 20.1 days 15.5 ± 5.9 days NS 
Duration of leucocytosis 7.8 ± 7.3 days 11.3 ± 4.7 days NS 
Duration of pyrexia 7.9 ± 4.4 days 4.3 ± 4.7 days NS 
Meropenem 
[193] 
Severe infection  
(n = 15) 
Randomized, 
crossover 
Adverse events None None NS 
Ceftazidime 
[363] 
Critically ill, Gram-negative 
infections  
(n = 12) 
Randomized, 
crossover 
Adverse events None None NS 
Ceftazidime 
[364] 
Cystic fibrosis  
(n = 56) 
Randomized, 
crossover 
Decrease in WCC -2216 ± 2689 -2209 ± 3710 NS 
Adverse events None None NS 
Ceftazidime 
[365] 
Cystic fibrosis  
(n = 49) 
Randomized, 
crossover 
Change in FEV1 +7.6% +5.5% NS 
Adverse events 1 severe event 1 severe event NS 
Ceftazidime 
[366] 
Cystic fibrosis  
(n = 14) 
Randomized, 
crossover 
Pre-albumin 
improvement 
+0.11 +0.08 p =0.015 
Cefamandole 
[255] 
Malignant disease with neutropenia 
(n = 164) 
RCT Clinical cure 64.8% 56.5% NS 
Ceftriaxone Sepsis  RCT Mortality 10% 0% NS 
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[243] (n = 57) Duration of MV 4.3 ± 4.5 days 3.4 ± 4.1 days NS 
Clinical cure (a priori) 52% 20% p <0.04 
LOS Hospital 42 ± 6.9 days 24 ± 2.1 days NS 
LOS ICU 10.8 ± 23.2 days 5.6 ± 6.0 days NS 
Piperacillin 
[248] 
Critically ill patients, septicaemia  
(n = 40) 
RCT Mortality 30% 25% NS 
Decrease in illness 
severity 
  CI>IBa 
Duration of pyrexia 2.4 ± 1.5 days 1.7 ± 0.7 days NS 
WBC normalization 75% 83% NS 
Pip-Tazo 
[256] 
Intra-abdominal infections  
(n = 258) 
RCT Mortality 0.76% 2.6% NS 
Clinical cure 86.4% 88.4% NS 
Adverse events 89.2% 87.1% NS 
Ceftazidime 
[151] 
Septicaemic melioidosis  
(n = 21) 
RCT Mortality 20% 36.4% NS 
Pip-Tazo 
[274] 
VAP, Gram-negative bacilli  
(n = 83) 
Retrospective, 
cohort 
Clinical cure 89.2% 56.5% p = 0.001 
Mortality 21.6% 30.4% NS 
Duration of MV 18.0 ± 10.2 days 21.7 ± 18.1 days NS 
LOS ICU 21.8 ± 12.3 days 25.6 ± 19.8 days NS 
Pip-Tazo 
[298] 
P. aeruginosa, critically ill  
(n = 194) 
Retrospective, 
cohort 
Mortality 12.2% (EI) 31.6% p = 0.04 
LOS Hospital 21 days (EI) 38 days p = 0.02 
Oxacillin 
[374] 
Infective endocarditis  
(n = 107) 
Retrospective, 
cohort 
Mortality 8% 10% NS 
LOS Hospital 20 days 25 days NS 
Time to defervescence 3 days 3 days NS 
Ceftazidime 
[266] 
NP, critically ill  
(n = 35) 
RCT Clinical cure 41% 33% NS 
Duration of MV 7.9 ± 4.0 days 8.3 ± 4.3 days NS 
LOS ICU 8.5 ± 3.4 days 9.3 ± 4.0 days NS 
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Time to defervescence 3.1 ± 2.1 days 5.2 ± 2.3 days p = 0.015 
WBC normalization 7.3 ± 3.0 x 109/l 5.5 ± 4.2 x 109/l NS 
Ceftazidime 
[375] 
NP, critically ill  
(n = 35) 
RCT Clinical cure 41% 33% NS 
LOS 11.8 ± 6.3 days 15.3 ± 9.6 days NS 
Adverse events 9 13 NS 
Cefotaxime 
[257] 
COPD  
(n = 83) 
RCT Clinical cure 93% 
 
93% NS 
Abbreviation: CI, continuous infusion; COPD, chronic obstructive pulmonary disorder; EI, extended-infusion; IB, intermittent bolus; ICU, intensive 
care unit; LOS, length of stay; MV, mechanical ventilation; NP, nosocomial pneumonia; NS, non-significant; Pip-Tazo, piperacillin/tazobactam; 
RCT, randomized controlled trial; VAP, ventilator-associated pneumonia; WCC, white cell counts. 
Legend: 
Significant difference in APACHE II scores on Days 2, 3 and 4. 
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3.2.5 Conclusions 
Based on the data presented in this chapter, CI of beta-lactams may be meritorious. All of the 
present pre-clinical and PK/PD simulation data supports CI. The available clinical data suggests that 
CI and IB are associated with similar outcomes, even with the use of lower daily doses in CI. To 
date, no data has conclusively shown any superiority of CI in terms of clinical outcomes, although 
this is largely because existing studies were underpowered and unable to detect any significant 
difference between the two approaches. Similarly, no data has ever demonstrated inferiority of CI 
compared with IB. The available data in this chapter supports the undertaking of large scale 
prospective clinical outcome studies, particularly in critically ill or immunocompromised patients to 
confirm if these apparent advantages, do indeed translate into clinical superiority of CI. 
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3.3 Conclusion 
Based on the published literatures that were presented in this chapter, it can be deduced that CI 
administration of beta-lactam antibiotics will not be meritorious to all critically ill patients but may 
potentially be advantageous to specific subset of patients with severe infections. Although all of the 
present in vitro and PK/PD data supports CI administration, the current evidence also suggest 
neither superiority nor inferiority of the approach compared to IB administration in terms of clinical 
outcomes. Thus, the available data supports the undertaking of large-scale prospective clinical 
outcome studies, particularly in patients with severe infections to confirm if these compelling 
PK/PD advantages, do translate into clinical superiority favouring CI administration. 
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Chapter 4: Prolonged beta-lactam infusion in critically ill patients: a post 
hoc analysis on a large dataset of critically ill patients  
4.1 Synopsis 
Sepsis remains one of the major problems for patients in the ICU. Given the intrinsic relationship 
between infection and sepsis, optimizing antibiotic therapy has been suggested as one of the 
approaches by which clinical outcomes in critically ill patients can be improved. However, optimal 
antibiotic administration is not straightforward as critically ill patients may develop extreme PK 
derangements that alter the exposure of the prescribed antibiotic. It is highly likely that 
conventional antibiotic dosing does not account for these PK derangements and this may 
consequently lead to therapeutic failure. Aiming to improve antibiotic treatment in the ICU, the 
DALI study, a large multinational, PK point prevalence study, was undertaken to describe whether 
conventional dosing of beta-lactam antibiotics attains drug concentrations associated with 
therapeutic benefits in critically ill patients. The DALI study concluded that different dosing 
approaches are required in critically ill patients as compared to non-critically ill patients, to ensure 
optimal antibiotic exposures are achieved that can increase the opportunity for clinical success. 
However, this large dataset of critically ill patients were not specifically analysed to investigate the 
potential benefits of altered beta-lactam dosing in such patient population. Therefore, using the 
database of the DALI study, this chapter aims to compare the PK/PD target attainment and clinical 
outcomes between PI (i.e., CI and EI) and IB dosing of beta-lactam antibiotics in a large cohort of 
critically ill patients. Additionally, the patient sub-groups who are most likely to benefit from 
altered dosing approaches were also explored in this post hoc analysis.     
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4.2 Manuscript entitled “Is prolonged infusion of piperacillin/tazobactam and 
meropenem in critically ill patients associated with improved 
pharmacokinetic/pharmacodynamic and patient outcomes? An observation 
from the Defining Antibiotic Levels in Intensive care unit patients (DALI) 
cohort” 
The manuscript entitled “Is prolonged infusion of piperacillin/tazobactam and meropenem in 
critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient 
outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients 
(DALI) cohort” has been accepted for publication in the Journal of Antimicrobial Chemotherapy 
(2016; 71(1): 196-207). 
 
The co-authors contributed to the manuscript as follows: Conception and development of the study 
design was performed by Prof. Jason A. Roberts and Prof. Jeffrey Lipman. Literature review was 
performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. Jason A. 
Roberts, Prof. Jan J. De Waele and Prof. Jordi Rello. Data collection was performed by Dr. Murat 
Akova, Prof. Matteo Bassetti, Prof. Jan J. De Waele, Dr. George Dimopoulos, Dr. Kirsi-Maija 
Kaukonen, Dr. Despoina Koulenti, Prof. Claude Martin, Prof. Philippe Montravers, Prof. Jordi 
Rello, Prof. Andrew Rhodes and Therese Starr. Sample bioanalysis was performed by the PhD 
candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Dr. Steven C. Wallis. Data analysis was 
performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. Jason A. 
Roberts and Dr. Joel M. Dulhunty. The PhD candidate took the leading role in manuscript 
preparation and all co-authors reviewed and contributed to the final draft of the manuscript. 
 
The accepted version of this manuscript is presented and incorporated in this chapter. However, 
some text, tables and figures may have been inserted at slightly different positions to fit the overall 
style of the thesis. Numbering of pages, tables and figures may also change to fit the thesis 
requirements. Manuscript references have been collated with all other references in the thesis. 
 
Permission has been granted by the publisher and copyright owner, Oxford University Press 
(License no: 3886910071822), to reproduce the manuscript in this Thesis. 
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4.2.1      Abstract 
4.2.1.1     Objectives 
We utilized the database of the DALI study to statistically compare the PK/PD and clinical 
outcomes between PI and IB dosing of piperacillin/tazobactam and meropenem in critically ill 
patients using inclusion criteria similar to those used in previous prospective studies. 
 
4.2.1.2     Methods 
This was a post-hoc analysis of a prospective, multicentre PK point-prevalence study (DALI) which 
recruited a large cohort of critically ill patients from 68 ICUs across 10 countries.  
 
4.2.1.3     Results 
Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DALI study, 182 met 
inclusion criteria. Overall, 89.0% (162/182) of patients achieved the most conservative target of 
50% fT>MIC. Decreasing CLCR and the use of PI significantly increased the target attainment for 
most PK/PD targets. In the sub-group of patients who had respiratory infection, patients receiving 
beta-lactams via PI demonstrated significantly better 30-day survival when compared to IB patients 
(86.2% [25/29] versus 56.7% [17/30]; p = 0.012). Additionally, in patients with a SOFA score of 
≥9, administration by PI compared with IB dosing demonstrated significantly better clinical cure 
(73.3% [11/15] versus 35.0% [7/20]; p = 0.035) and survival rates (73.3% [11/15] versus 25.0% 
[5/20]; p = 0.025).  
  
4.2.1.4     Conclusions 
The analysis of this large dataset provides additional data of the niche benefits of administration of 
piperacillin/tazobactam and meropenem by PI in critically ill patients, particularly for patients with 
respiratory infections. 
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4.2.2 Introduction 
Beta-lactam antibiotics are routinely prescribed for severe infections in the ICU. As time-dependent 
antibiotics, the most important PK/PD index for its activity is fT>MIC [11]. IB dosing, the standard 
method of beta-lactam administration, commonly produces sub-optimal drug concentrations in 
critically ill patients with conserved renal function [86, 165, 169]. Such patients generally exhibit 
extreme physiological derangements which may alter the beta-lactam PK and consequently, reduce 
its exposure [6, 7]. Numerous PK/PD simulation studies suggest that optimal beta-lactam exposures 
are readily obtained via CI or an extended 2 to 4-hour infusion (i.e., EI) [86, 165, 169, 187]. CI and 
EI are jointly referred to as PI, with either approach considered to be potentially advantageous 
compared to traditional IB administration. 
 
Owing to persisting poor sepsis-related clinical outcomes in the ICU, there has been growing 
concerns that conventional antibiotic dosing in critically ill patients is sub-optimal. If this notion is 
true, global antibiotic prescribing practices may need to change accordingly. Aiming to improve 
antibiotic treatment in the ICU, the DALI study [213], a large multinational, PK point prevalence 
study, was undertaken to describe whether conventional dosing of beta-lactam antibiotics attains 
drug concentrations associated with therapeutic benefits in critically ill patients. The implications of 
the study are profound; 16% of the patients did not achieve the most conservative PK/PD target and 
these patients were 32% more likely to demonstrate negative clinical outcomes. Although these data 
concluded that different dosing strategies are needed in the ICU, they were not discretely analysed 
to ascertain the potential merits of altered beta-lactam infusion in critically ill patients. Of note, with 
the exception of piperacillin/tazobactam and meropenem, the other six beta-lactam antibiotics 
included in the DALI study were almost exclusively administered by IB dosing, which signifies its 
“authority” over PI dosing in current prescribing practices.    
 
Despite compelling pre-clinical and PK/PD data, clinical comparative trials have failed to 
demonstrate the perceived clinical advantage of PI over IB dosing [13]. Furthermore, most meta-
analyses of the clinical trials are still indecisive over the notion of PI clinical superiority over IB 
dosing [217, 239, 240, 267-271, 377]. There are currently four recent meta-analyses which report 
significant improvement in clinical cure [239, 268, 269] and survival [239, 268, 270] favouring PI 
administration. However, their findings should be interpreted with caution as these meta-analyses 
have included a considerable number of retrospective and non-randomized studies in their pooled 
analysis. Given the above uncertainty, we utilized the database of the DALI study with the primary 
aim of distinguishing the relative ability of PI and IB dosing of piperacillin/tazobactam and 
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meropenem to achieve specific PK/PD exposure targets in relation to the offending pathogens MIC 
during antibiotic therapy.  Secondary aims were to describe clinical response and 30-day survival 
for both administration approaches and which patient sub-groups were most likely to benefit from 
this intervention. 
 
4.2.3      Materials and methods 
4.2.3.1     Study design 
This is a post-hoc analysis of the DALI study which the detailed study protocol has been described 
elsewhere [213, 378]. Briefly, during a single dosing interval on the investigation day, each patient 
had two blood samples drawn for the beta-lactams they were receiving (mid-dose and a trough 
concentration). Various demographic, clinical and treatment-related variables were collected on the 
day of investigation. CLCR was estimated using the Cockcroft-Gault formula [341].  
 
Patients were included if they received either piperacillin/tazobactam or meropenem, which were 
administered by PI (either CI or EI) or IB dosing. We followed the inclusion criteria used in 
previous randomized clinical trials of this intervention [166, 242, 243], which meant that patients 
who received any form of extracorporeal renal support were excluded as patients with reduced drug 
clearances are less likely to benefit from altered administration approaches [211, 244, 245]. For 
clinical outcome assessment, only patients who received antibiotic for treatment of infection, as 
opposed to prophylaxis, were included. 
 
The lead site was The University of Queensland, Australia (ethical approval no. 201100283). 
 
4.2.3.2     Sample integrity and bioanalysis 
Blood samples were processed and stored per protocol prior to shipment to the BTCCRC, The 
University of Queensland, Australia, where they were assayed. The details concerning bioanalysis 
have been described in detailed elsewhere [379]. 
 
4.2.3.3     Pharmacokinetic/pharmacodynamic and clinical outcome measures 
The primary end-point, which was PK/PD target attainment, is described in detail in Table 4-1. 
Briefly, to assess the relative dosing adequacy of PI and IB administration, the observed unbound 
antibiotic concentrations were compared against the causative pathogens actual or “surrogate” MIC.  
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The secondary end-points, clinical response and 30-day survival, were assessed using definitions 
described in Table 4-1. Additionally, to investigate clinical differences between PI and IB dosing 
within the sub-group of patients with the highest illness severity, as described by Lodise et al., 
[298], we performed a Classification and Regression Tree (CART) analysis to further stratify 
patients based on SOFA score to identify the patients who were at the greatest risk for clinical 
failure and 30-day mortality. 
Table 4-1: Definitions used for pharmacokinetic/pharmacodynamic end-points and clinical 
outcome variables 
Primary PK/PD end-pointsa,b Definition 
      50% fT>MIC Free drug concentration maintained above the MIC of the 
pathogen for at least 50% of dosing interval. 
      50% fT>4 x MIC Free drug concentration maintained above a concentration four-
times the MIC of the pathogen for at least 50% of dosing 
interval.  
      100% fT>MIC Free drug concentration maintained above the MIC of the 
pathogen throughout the dosing interval. 
      100% fT>4 x MIC Free drug concentration maintained above a concentration four-
times the MIC of the pathogen throughout the dosing interval. 
  
Secondary endpoints Definition and description 
Clinical response  
      Clinical cure Completion of treatment course without change or addition of 
antibiotic therapy, and with no additional antibiotics 
commenced with 48 hours of cessation. 
      Clinical failure Any clinical outcome other than clinical cure. 
30-day survival Survival at Day 30 following entry to the study. 
Abbreviation: PK/PD, pharmacokinetic/pharmacodynamic; MIC, minimum inhibitory 
concentration. 
Legend: 
aThe PK/PD exposure targets have all been identified in clinical studies recruiting critically ill 
patients in which achieving these targets would increase the probability of clinical efficacy. 
bActual MIC values, provided by the local microbiology laboratory, were used when available. 
Where a pathogen was isolated but MIC was unavailable, the “surrogate” MIC was defined by the 
EUCAST MIC90 data. Where no pathogen was formally identified, the MIC breakpoints for P. 
aeruginosa (16 mg/L for piperacillin/tazobactam and 2 mg/L for meropenem) were inferred as the 
“surrogate” MIC, which reflects the least susceptible pathogen that could be encountered during 
beta-lactam therapy. 
77 
 
4.2.3.4     Statistical analysis 
Data are presented as median values with interquartile range (IQR) for continuous variables and 
number and percentage for categorical variables. A multivariate logistic regression model (manual 
entry and stepwise, backward elimination) was constructed to identify significant predictors 
associated with the primary and secondary end-points with OR and 95% confidence interval 
reported. Biologically-plausible variables with a p-value of ≤0.15 on univariate analysis were 
considered for model building. However, the administered beta-lactam and the method of 
administration were forced into the regression models regardless of the univariate analysis results. 
Goodness-of-fit was assessed by the Hosmer-Lemeshow statistic. A two-sided p-value of <0.05 was 
considered statistically significant in all analyses. Statistical analysis was performed using IBM 
SPSS statistic 22 (IBM Corporation, Armonk, New York). 
 
4.2.4 Results 
A total of 211 patients received either piperacillin/tazobactam or meropenem and were considered 
for study inclusion. Twenty-nine patients were further excluded as they received extracorporeal 
renal support during ICU stay. The patient inclusion and exclusion process is depicted in Figure 4-1 
and the baseline characteristics for the 182 included patients are presented in Table 4-2. For clinical 
outcome assessment, 37 patients who were only receiving antibiotic prophylaxis were further 
excluded. 
 
Of the 182 included patients, 110 (60.4%) received piperacillin/tazobactam. Additionally, 60.4% 
(110/182) of patients also received concomitant antibiotic therapy as part of their treatment. The 
most common administration method was IB where 63.2% (115/182) of the patients received beta-
lactams via this approach. Among the 67 PI patients, 23 (34.3%) and 44 (65.7%) were CI and EI 
patients, respectively. Figure 4-2 illustrates the preferred method of dosing by participating country. 
Although most countries favoured IB dosing, two countries, Belgium and France, had more than 
half of the patients receiving the beta-lactams by PI dosing. 
 
Of 182 patients who received beta-lactams, 70 (38.5%) were prescribed for either presumed or 
confirmed respiratory infection. Of the patients treated for infection (n = 145), 114 (78.6%) had at 
least one causative pathogen isolated with 40.4% (46/114) of them had actual MIC values for the 
causative pathogens identified. The number of patients with actual MIC data were similar between 
PI and IB treatment arms (37.5% [18/48] versus 42.4% [28/66], respectively; p = 0.769). The 
distribution of the isolated pathogens was similar between the treatment arms and most of the 
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isolates were Gram-negative bacteria (PI 79.2% [38/48] versus IB 80.3% [53/66]; p = 0.881). Of the 
114 isolated pathogens, the most prevalent Gram-negative and -positive pathogens were P. 
aeruginosa (24/91; 26.4%) and S. aureus (6/23; 26.1%), respectively. 
 
 
Figure 4-1: Study flowchart demonstrating the number of patients who were included and 
excluded in each stage of the planned analysis 
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Table 4-2: Baseline demographics and characteristics 
Characteristic All patients  
(n = 182) 
PI  
(n = 67) 
IB  
(n = 115) 
Significance p-
valuea,b 
Age (years) 61 (47-74) 56 (47-75) 64 (48-74) 0.417 
Male, n (%) 113 (62.1) 44 (65.7) 69 (60.0) 0.447 
Weight (kg) 73 (65-84) 73 (64-88) 74 (65-80) 0.646 
APACHE II 18 (13-25) 20 (13-26) 18 (14-24) 0.215 
SOFA 5 (3-8) 5 (3-8) 5 (3-8) 0.797 
Serum creatinine concentration (µmol/L) 71 (52-125) 64 (48-140) 73 (53-119) 0.726 
Cockcroft-Gault creatinine clearance (mL/min) 85 (46-131) 95 (42-141) 82 (48-130) 0.510 
Pre-ICU hospital stay (days) 2 (1-9) 1 (1-9) 2 (1-9) 0.260 
Duration of antibiotic therapy (days) 9 (4-14) 8 (4-13) 9 (4-14) 0.371 
Concomitant antibiotics usage, n (%) 110 (60.4) 39 (58.2) 71 (61.7) 0.733 
Surgery within 24 hours of antibiotic sampling, n (%) 33 (18.1) 14 (20.9) 19 (16.5) 0.460 
Organisms identified, n (%) 121 (66.5) 50 (74.6) 71 (61.7) 0.103 
Polymicrobial infection, n (%) 29 (15.9) 11 (16.4) 18 (15.7) 0.577 
Primary infection site, n (%)     
   Respiratory 70 (38.5) 33 (49.3) 37 (32.2) 0.041 
   Abdominal 50 (27.5) 16 (23.9) 34 (29.6) 0.593 
   Blood 23 (12.6) 6 (9.0) 17 (14.8) 0.664 
   Urinary 21 (11.5) 6 (9.0) 15 (13.0) 0.231 
   Central nervous system 8 (4.4) 4 (6.0) 4 (3.5) 0.639 
   Others 10 (5.5) 2 (3.0) 8 (7.0) 0.082 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; IB, intermittent bolus; PI, prolonged infusion; SOFA, Sequential Organ 
Failure Assessment. 
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*Data are presented as median (interquartile range) or number (percentage). 
Legend:  
aRepresents the p-value between prolonged infusion versus intermittent bolus dosing and values in bold indicate significant difference between the 
two dosing groups (p <0.05). 
bLinear variables were compared using Mann-Whitney U test as data were non-normally distributed as were indicated by Kolmogorov-Smirnov test. 
Dichotomous variables were compared using Pearson chi-square test or Fisher’s exact test as appropriate.  
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Figure 4-2: Method of piperacillin/tazobactam and meropenem administration according to 
participating countries 
Abbreviation: IB, intermittent bolus; PI, prolonged infusion. 
 
4.2.4.1     Pharmacokinetic/pharmacodynamic and clinical outcome measures 
Overall, 89.0% (162/182) of patients achieved the lower PK/PD target of 50% fT>MIC. For higher 
thresholds such as 100% fT>MIC and 100% fT>4xMIC, 63.2% (115/182) and 27.5% (50/182) of 
patients, respectively, achieved these PK/PD targets. Although PI patients generally demonstrated 
numerically higher target attainment rates as opposed to IB patients across all PK/PD indices, a 
statistically significant difference was only observed at 100% fT>MIC; 50% fT>MIC (PI 91.0% [61/67] 
versus IB 87.8% [101/115]; p = 0.532; 50% fT>4xMIC (PI 62.7% [42/67] versus IB 49.6% [57/115]; p 
= 0.106; 100% fT>MIC (PI 73.1% [49/67] versus IB 57.4% [66/115]; p = 0.045; and 100% fT>4xMIC 
(PI 31.3% [21/67] versus IB 25.2% [29/115]; p = 0.357. When only patients with actual MIC data 
were analysed, those who received beta-lactams via PI dosing also demonstrated numerically higher 
target attainment rates, albeit not statistically significant, compared to IB patients across all PK/PD 
indices.  
 
The clinical cure and 30-day survival rate of patients who received antibiotics for treatment of 
infection (n = 145) was 73.1% (106/145) and 73.1% (106/145), respectively. Table 4-3 presents the 
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differences in patient characteristics between those who demonstrated positive and negative clinical 
outcomes in this study. The clinical outcomes were mostly similar between PI and IB patients 
receiving antibiotics for treatment of infection (Figures 4-3 and 4-4). However, in sub-group of 
patients who had respiratory infection (n = 59), patients receiving beta-lactams via PI dosing 
demonstrated significantly better 30-day survival when compared to IB patients (86.2% [25/29] 
versus 56.7% [17/30], respectively; p = 0.012). 
  
Patients who had a SOFA score ≥9 were identified by CART analysis to have the greatest risk for 
clinical failure (clinical cure rates were 80.0% [88/110] in patients with a SOFA score <9 versus 
51.4% [18/35] in patients with a SOFA score ≥9; p = 0.004) and 30-day mortality (mortality rates 
were 18.2% [20/110] in patients with a SOFA score <9 versus 54.3% [19/35] in patients with a 
SOFA score ≥9; p = 0.001). In patients with a SOFA score ≥9 (n = 35), patients receiving beta-
lactams via PI dosing demonstrated significantly higher clinical cure (PI 73.3% [11/15] versus IB 
35.0% [7/20]; p = 0.035) and 30-day survival rates (PI 73.3% [11/15] versus IB 25.0% [5/20]; p = 
0.025). 
 
4.2.4.2     Outcome measures predictors  
Based on the most parsimonious model, decreasing CLCR values significantly increased the target 
attainment for all PK/PD targets; 50% fT>MIC (OR 0.97; 95% confidence interval 0.98-0.99; p = 
0.007); 50% fT>4xMIC (OR 0.97; 95% confidence interval 0.98-0.99; p = 0.014); 100% fT>MIC (OR 
0.97; 95% confidence interval 0.98-0.99; p <0.001); and 100% fT>4xMIC (OR 0.97; 95% confidence 
interval 0.96-0.98; p <0.001). The use of PI dosing, as opposed to IB dosing, significantly increased 
the PTA for 100% fT>MIC (OR 2.78; 95% confidence interval 1.24-6.24; p = 0.013).  
 
The results of all multivariate logistic regression models for clinical cure and 30-day survival are 
available in Table 4-4. Based on the most parsimonious logistic regression model, SOFA score (OR 
0.89; 95% confidence interval 0.80-0.99; p = 0.029) and concomitant antibiotic use (OR 0.31; 95% 
confidence interval 0.10-0.96; p = 0.043) were identified as significant factors associated with 
clinical cure whilst only SOFA score (OR 0.82; 95% confidence interval 0.73-0.92; p = 0.001) was 
identified as the factor associated with 30-day survival. 
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Table 4-3: Differences in patient characteristics and treatment-related variables between those who demonstrated positive and negative 
clinical outcome 
Variable Clinical cure Significance 
p-valuea,b 
30-day survival Significance 
p-valuea,b Yes 
(n = 106) 
No 
(n = 39) 
Alive 
(n = 106) 
Deceased 
(n = 39) 
Age (years) 65 (50-75) 64 (51-79) 0.297 59 (47-74) 65 (56-77) 0.048c 
Male, n (%) 67 (63.2) 24 (61.5) 0.929 66 (62.3) 25 (64.1) 0.890 
Weight (kg) 73 (63-86) 75 (65-81) 0.927 75 (65-88) 71 (60-76) 0.074c 
APACHE II score 19 (15-25) 18 (15-24) 0.643 18 (14-25) 21 (16-24) 0.499 
SOFA score 5 (2-7) 7 (4-9) 0.029c 4 (2-7) 7 (4-10) 0.001c 
Serum creatinine (µmol/L) 65 (51-144) 87 (53-130) 0.457 64 (48-130) 92 (64-143) 0.101 
Cockcroft-Gault CLCR (mL/min) 86 (41-130) 78 (39-131) 0.445 93 (45-147) 59 (36-93) 0.014
c 
Duration of treatment (days) 9 (5-13) 7 (4-10) 0.030c 10 (5-14) 8 (4-12) 0.217 
Pre-ICU hospital stay (days) 2 (1-8) 6 (2-12) 0.005c 2 (1-9) 3 (1-12) 0.046c 
Surgery within 24 hours, n (%) 12 (11.3) 6 (15.4) 0.420 14 (13.2) 4 (10.3) 1.000 
Culture positive, n (%) 83 (78.3) 31 (79.5) 0.759 85 (80.2) 29 (74.4) 0.387 
Gram-negative pathogen, n (%) 61 (73.5) 30 (96.8) 0.036c 64 (75.3) 27 (93.1) 0.039c 
Polymicrobial infection, n (%) 16 (19.3) 7 (22.6) 0.536 20 (23.5) 7 (24.1) 0.824 
Primary infection site, n (%)       
         Respiratory 40 (37.7) 19 (48.7) 0.303 42 (39.6) 17 (43.6) 0.591 
         Abdominal 30 (28.3) 12 (30.8) 0.695 31 (29.2) 11 (28.2) 0.639 
         Blood 14 (13.2) 5 (12.8) 1.000 13 (12.3) 6 (15.4) 0.542 
         Urinary 14 (13.2) 0 (0.0) 0.035 11 (10.4) 3 (7.7) 0.515 
         Central nervous system 4 (3.8) 1 (2.6) 1.000 4 (3.8) 1 (2.6) 1.000 
         Others 4 (3.8) 2 (5.1) 1.000 5 (4.7) 1 (2.6) 1.000 
Beta-lactam antibiotics, n (%)       
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Piperacillin 60 (56.6) 26 (66.7) 0.295c 62 (58.5) 24 (61.5) 0.787 
Meropenem 46 (43.4) 13 (33.3)  44 (41.5) 15 (38.5)  
Concomitant antibiotics, n (%) 58 (54.7) 32 (82.1) 0.020c 60 (56.6) 30 (76.9) 0.023c 
Dosing method, n (%)       
Prolonged infusion 44 (41.5) 14 (35.9) 0.641c 47 (44.3) 12 (30.8) 0.156c 
Intermittent bolus 62 (58.5) 25 (64.1)  59 (55.7) 27 (69.2)  
PK/PD ratiod       
50% fT>MIC 7.1 (2.2-13.0) 3.5 (2.1-10.0) 0.097
c 5.3 (1.9-11.7) 8.1 (2.9-15.0) 0.383 
100% fT>MIC 2.2 (0.6-7.1) 1.7 (0.5-3.1) 0.280 1.7 (0.5-5.3) 3.2 (1.1-7.2) 0.060
c 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; CLCR = creatinine clearance; ICU, intensive care unit; MIC, minimum 
inhibitory concentration; PK/PD, pharmacokinetic/pharmacodynamic; SOFA, Sequential Organ Failure Assessment. 
Legend: 
 aLinear variables were compared using Mann-Whitney U test as data were non-normally distributed as were indicated by Kolmogorov-Smirnov test. 
Dichotomous variables were compared using Pearson chi-square test or Fisher’s exact test as appropriate. 
bBold values indicate statistical significance (p <0.05). 
cRepresents variable that was included in the multivariate logistic regression model. 
dThe pharmacokinetic/pharmacodynamic (PK/PD) ratios observed at 50% and 100% of the dosing interval. These indices were defined as the ratio 
between the unbound plasma concentration (either piperacillin/tazobactam or meropenem) at 50% or 100% of the dosing interval and the causative 
pathogens MIC. Actual MIC values were used when available. Where MIC was unavailable or no pathogen was formally identified, “surrogate” MIC 
values were assumed. 
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Figure 4-3: Clinical cure rates comparison between prolonged infusion and intermittent bolus 
dosing for patients who received antibiotics for treatment of infections, stratified according to 
sub-groups 
Abbreviation: IB, intermittent bolus; n, number; PI, prolonged infusion; SOFA, Sequential Organ 
Failure Assessment. 
Legend: 
An asterisk indicates significant difference between prolonged infusion versus intermittent bolus 
dosing (p <0.05). 
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Figure 4-4: Comparison of 30-day survival between prolonged infusion and intermittent bolus 
dosing for patients who received antibiotics for treatment of infections, stratified according to 
sub-groups. 
Abbreviation: IB, intermittent bolus; n, number; PI, prolonged infusion; SOFA, Sequential Organ 
Failure Assessment. 
Legend: 
An asterisk indicates significant difference between prolonged infusion versus intermittent bolus 
dosing (p <0.05). 
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Table 4-4: Factors predicting clinical cure and 30-day survival for all patients who received antibiotics for treatment of infections (n =145) 
Variable All factors included in the model Final model 
 Odds ratio  
(95% CI) 
Significance 
(p-value) 
Odds ratio 
(95% CI) 
Significance  
(p-value) 
Factors predicting clinical cure     
SOFA score (per 1-point increase) 0.90 (0.80-1.01) 0.071 0.89 (0.80-0.99) 0.029 
Concomitant antibiotic therapya 0.24 (0.07-0.84) 0.025 0.31 (0.10-0.96) 0.043 
Duration of antibiotic therapy (per 1-day increase) 1.08 (0.98-1.18) 0.115 - - 
Gram-negative pathogenb 0.35 (0.06-1.87) 0.218 - - 
50% fT>MIC
c (per 1-point increase) 1.02 (0.97-1.08) 0.405 - - 
Piperacillind 0.84 (0.28-2.46) 0.746 - - 
Prolonged infusione 0.86 (0.31-2.43) 0.782 - - 
Pre-ICU hospital stay (per 1-day increase)  1.00 (0.97-1.03) 0.966 - - 
Goodness-of-fit     
Hosmer-Lemeshow test X2 = 6.00, df = 8 0.647 X2 = 8.41, df = 8 0.394 
     
Factors predicting 30-day survival     
SOFA score (per 1-point increase) 0.83 (0.73-0.96) 0.009 0.82 (0.73-0.92) 0.001 
Concomitant antibiotic therapya 0.24 (0.05-1.04) 0.056 - - 
Piperacillind 2.70 (0.86-8.49) 0.090 - - 
Age (per 1-year increase) 0.96 (0.92-1.01) 0.099 - - 
Weight (per 1-kg increase) 1.03 (0.99-1.07) 0.119 - - 
Gram-negative pathogenb 0.32 (0.05-2.05) 0.228 - - 
Pre-ICU hospital stay (per 1-day increase)  0.98 (0.95-1.01) 0.232 - - 
Estimated Cockcroft-Gault CLCR (per mL/min) 1.00 (0.99-1.01) 0.675 - - 
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Prolonged infusione 1.10 (0.33-3.67) 0.878 - - 
100% fT>MIC
f (per 1-point increase) 1.00 (0.92-1.08) 0.960 - - 
Goodness-of-fit     
Hosmer-Lemeshow test X2 = 6.57, df = 8 0.584 X2 = 5.05, df = 8 0.751 
Abbreviation: CI, confidence interval; CLCR, creatinine clearance; df, degree of freedom; MIC, minimum inhibitory concentration; SOFA, Sequential 
Organ Failure Assessment; X2 = chi-square.  
*When available, actual MIC values were used. 
**Dashes indicate there was no variable output in the model. 
Legend: 
aOdds ratio compares concomitant antibiotic therapy relative to antibiotic monotherapy.   
bOdds ratio compares Gram-negative relative to Gram-positive pathogens. 
cThe ratio between the unbound plasma concentration (either piperacillin or meropenem) at 50% of the dosing interval and the causative pathogens 
MIC (actual or assumed values). 
dOdds ratio compares piperacillin relative to meropenem. 
eOdds ratio compares prolonged infusion relative to intermittent bolus dosing. 
fThe ratio between the unbound plasma concentration (either piperacillin or meropenem) at 100% of the dosing interval and the causative pathogens 
MIC (actual or assumed values). 
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4.2.5 Discussion 
Altered beta-lactam PK is widely reported among ICU patients, potentially leading to suboptimal 
antibiotic exposures when “standard” beta-lactam dosing is applied in the cohort [6, 7, 56]. In this 
study, the majority of patients achieved a lower PK/PD target of 50% fT>MIC and the attainment 
rates were similarly high across the two administration methods and antibiotics. However, clinical 
data from critically ill patients have suggested that such exposure should be regarded as the 
minimum, with larger exposures associated with improved outcomes [5, 20, 21, 28]. A more 
prudent target of 100% fT>MIC should be considered and this was not achieved by one-third of the 
study patients. Nonetheless, the patients in this cohort were three-times more likely to achieve 
100% fT>MIC when receiving beta-lactams via PI dosing (OR 2.78; 95% confidence interval 1.24-
6.24; p = 0.013). Although such an observation was anticipated, our current work remains unique 
given that the data were derived from a broad range of ICU environment across 10 countries and the 
strength of association was established and supported by multivariate regression analyses.  
 
As the beta-lactams are predominantly cleared by the kidney, elevated renal function as observed in 
ARC may likely lead to suboptimal PK/PD target attainment [117, 120, 121]. In our cohort, 
increasing values of the estimated CLCR significantly reduced the probability of target attainment 
for all PK/PD indices. Moreover, the observed relationship between CLCR and sub-optimal PK/PD 
exposure was relatively strong in both univariate and multivariate analysis for all PK/PD indices. 
The probability of attaining 100% fT>MIC would be reduced by 3% with every 1 mL/min increase in 
the estimated CLCR (OR 0.97; 95% confidence interval 0.98-0.99; p <0.001). The median CLCR of 
patients who did not attain 100% fT>MIC was 132 mL/min and only 28.2% (11/39) of those with a 
CLCR ≥132 mL/min achieved the target. Such patients who are at-risk, usually in those with 
apparently “normal” renal function, need to be identified early so that appropriate dose modification 
can occur. Young trauma patients (<60 years), without significant organ dysfunction (SOFA ≤4) 
[109, 353], were more likely to develop ARC and these factors were also evident in our patients 
who manifested elevated CLCR; median age was 45 (IQR: 35-57) and median SOFA was 4 (IQR: 2-
7). 
  
The significance of illness severity for clinical outcome is also highlighted in this study. In this 
context, higher SOFA scores were independently associated with greater likelihood of developing 
clinical failure and death at 30-days post antibiotic sampling. An increase in SOFA score by 1-point 
reduced the probability of clinical cure and survival by 11.0% and 18.0%, respectively (Table 4-4). 
Accordingly, we also observed that patients with a SOFA score ≥9 were more likely to demonstrate 
90 
 
negative clinical outcomes and when only these patients were tested, those receiving beta-lactams 
via PI dosing demonstrated significantly better outcomes as opposed to IB dosing (Figures 4-3 and 
4-4). Higher survival rates favouring PI dosing were also seen in sub-group of patients with 
respiratory infection and our finding further substantiate similar claims of earlier studies which 
suggested potential benefits of PI administration in severely-ill patients with pneumonia [274, 275, 
290]. As inappropriate antibiotic treatment has been associated with reduced survival in patients 
with severe pneumonia [20, 21, 31, 380], prompt antibiotic administration, with an optimal dosing 
schedule, is therefore an essential intervention in this population. In this respect, the application of 
PI dosing could be meritorious by enhancing beta-lactam penetration into the interstitial fluid of the 
infected lung tissues [85, 141, 211], where the antibiotic-bacteria interactions occur [77]. 
Furthermore, optimal antibiotic dosing is crucial in this population as it may be directly linked with 
patient outcomes [381, 382], whilst for other infection sites such as intra-abdominal and surgical-
site infections, effective source control and the role of the surgeons are probably more crucial in 
predicting positive outcomes.     
 
However, it is also important to mention that the sample size of patients in these two sub-groups 
was relatively small compared to the clinically evaluable patients (<60 versus 145, respectively) 
and thus, the observed statistical significance could have been the result of random chance, although 
they do agree with previous published data [298]. Furthermore, due to the relatively small number 
of patients in the two sub-groups, logistic regression analyses could not be performed and therefore, 
the clinical benefits of PI were concluded based on unadjusted analyses which does not consider the 
influence of potential confounders. Hence, it is important to highlight the median pre-ICU days for 
PI patients in the two sub-groups were significantly shorter compared to IB patients (PI 2; IQR: 1-8 
versus IB 7; IQR: 2-12; p = 0.039), and the large difference might skew the results in favour of PI. 
Indeed, our clinical findings provide further evidence that PI dosing of beta-lactam antibiotics may 
not be beneficial for all but rather a specific subset of critically ill patients with severe infections. 
Interestingly, no sub-group has worse outcomes with PI dosing, suggesting that widespread use of 
such an intervention is not likely to have an inferior effect compared with the current standard 
practice. We believe that this study generates an interesting “therapeutic” signal, signifying 
potential clinical superiority of PI dosing in patients with higher SOFA scores and in patients with 
respiratory infections. Accordingly, future clinical studies should focus and test the hypotheses 
specifically in these patient groups. As what has been demonstrated by a recent RCT, Dulhunty et 
al., [166] showed that CI demonstrated better PK/PD and clinical outcomes when compared to IB 
dosing and these findings may stem from the strategic approach of only recruiting patients with a 
higher acuity of illness and in patients not receiving RRT. 
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In this study, concomitant antibiotic therapy also reduced the probability of clinical cure by 69.0% 
(Table 4-4). Although the reasons were unclear, we hypothesize that the more severely-ill the 
patient was, the more likely for the patient to receive multiple antibiotics in an attempt to “reverse” 
the impending poor prognosis associated with such patients. Our notion was corroborated by the 
higher median SOFA score observed in patients who received concomitant antibiotics compared to 
those who did not (6; IQR: 3-9 versus 4; IQR: 1-7, respectively; p = 0.048). Whilst data on 
concomitant antibiotics were available, we did not specifically evaluate their duration of therapy 
and also assess the PK/PD of those antibiotics, all of which could have confounded the findings in 
this study. 
 
This study has several limitations we would like to declare. It is imperative to clarify that in 60% of 
the patients, “surrogate” MIC values were assumed from population estimates and such approach 
could markedly inflate, or even deflate, the magnitudes of PK/PD target non-attainment observed in 
this study. In addition, this approach would adversely affect the target attainment rates of IB 
patients more than the PI patients if the “surrogate” MIC values were indeed higher than the actual 
MIC values. However, when we employed actual MIC data in our analysis, the findings were 
consistent with our main approach where PI patients demonstrated numerically higher target 
attainment rates, albeit not statistically significant, compared to IB patients across all PK/PD 
indices. Actual MIC values would have been preferable although we believe that our present 
approach closely “mimics” the real-life clinical approach where the MIC of a pathogen is rarely 
available upon antibiotic treatment initiation. We also acknowledge the limitation of Cockcroft-
Gault formula in estimating the measures of renal function in this cohort and measured CLCR would 
be more appropriate, particularly in patients with ARC. The post hoc nature of this analysis also 
limits our ability to establish a causal relationship between the methods of beta-lactam 
administration and clinical outcomes. As the antibiotic dosing regimen and all subsequent patient 
management was at the discretion of the treating physician, this might have introduced potential 
bias towards a better patient management among PI patients in this study.  
 
4.2.6 Conclusion       
This study provides additional PK/PD and clinical outcome data to support the practice of 
administration of piperacillin/tazobactam and meropenem by PI in critically ill patients, particularly 
for patients with respiratory infections. However, future clinical studies should focus and test the 
potential clinical superiority of the altered beta-lactam dosing approaches in a specific subset of 
critically ill patients with severe infections and that are not receiving RRT. 
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4.3 Conclusion 
This chapter supports the notion that altered beta-lactam dosing strategies may not be meritorious to 
all critically ill patients but rather in a specific subset of patients with severe infections. Similar to 
other previous small-scale studies, data from this chapter suggest that the critically ill patients who 
are most likely to benefit from altered dosing strategies are those with severe pneumonia and not 
receiving RRT. The information on patient groups which are more likely to benefit from altered 
dosing approaches is vital to determine if PI is truly more advantageous than IB dosing. With this 
data, future clinical studies should focus and test the potential clinical superiority of PI 
administration in this specific subset of critically ill patients.    
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Chapter 5: The ideal characteristics of a clinical trial investigating 
continuous infusion versus intermittent bolus dosing of beta-lactam 
antibiotics 
5.1 Synopsis 
Superior bacterial killing of beta-lactam antibiotics via CI compared with traditional IB dosing has 
been demonstrated in pre-clinical studies. Superior PK/PD profiles favouring CI administration 
have also been reported in studies involving critically ill septic patients. Despite all the theoretical 
advantages, to date, no study has conclusively shown any superiority of CI compared to IB dosing 
in terms of patient clinical outcomes. Furthermore, recent meta-analyses of published literature 
found no significant difference between CI and IB dosing with regards to clinical cure or patient 
survival. However, a particularly noteworthy feature in these studies has been the inclusion of non-
critically ill patients, which may mask any potential benefits of either dosing approaches in 
critically ill patients with severe sepsis. This chapter describes the methodological shortcomings 
that are associated with current clinical studies in the comparison of CI and IB administration of 
beta-lactam antibiotics. Several intriguing issues and problems surrounding the interpretation of 
results obtained from these clinical studies are also discussed in the chapter. Based on these 
discussions, a description of a methodologically robust, definitive clinical trial is proposed. 
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5.2 Manuscript entitled “Continuous beta-lactam infusion in critically ill 
patients: the clinical evidence” 
The manuscript entitled “Continuous beta-lactam infusion in critically ill patients: the clinical 
evidence” has been accepted for publication in the Annals of Intensive Care (2012; 16(2): 37). 
 
The co-authors contributed to the manuscript as follows: Conception and development of the study 
design was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. 
Jason A. Roberts and Prof. Jeffrey Lipman. Literature review was performed by the PhD candidate, 
Mohd-Hafiz Abdul-Aziz, under the guidance and supervision of Prof. Jason A. Roberts and Prof. 
Rinaldo Bellomo. The PhD candidate, Mohd-Hafiz Abdul-Aziz took the leading role in manuscript 
preparation and writing with the supervision and guidance of Prof. Jason A. Roberts, Prof. Jeffrey 
Lipman, Prof. Rinaldo Bellomo and Dr. Joel M. Dulhunty. All co-authors reviewed and contributed 
to the final draft of the manuscript. 
 
The accepted version of this manuscript is presented and incorporated in this chapter. However, 
some text, tables and figures may have been inserted at slightly different positions to fit the overall 
style of the thesis. Numbering of pages, tables and figures may also change to fit the thesis 
requirements. Manuscript references have been collated with all other references in the thesis. 
 
Permission has been granted by the publisher and copyright owner, BioMed Central Ltd., to 
reproduce the manuscript in this Thesis. 
 
 
103 
 
CONTINUOUS BETA-LACTAM INFUSION IN CRITICALLY ILL PATIENTS: THE 
CLINICAL EVIDENCE 
 
Mohd H. Abdul-Aziz (1), Joel M. Dulhunty (1, 2), Rinaldo Bellomo (3), Jeffrey Lipman (1, 2), 
Jason A. Roberts (1, 2, 4) 
  
Affiliation: 
(1) Burns, Trauma & Critical Care Research Centre, University of Queensland, Brisbane, Australia. 
(2) Department of Intensive Care Medicine, Royal Brisbane and Woman’s Hospital, Brisbane, 
Australia. 
(3) Department of Intensive Care, Austin Hospital, Melbourne. 
(4) Pharmacy Department, Royal Brisbane and Woman’s Hospital, Brisbane, Australia. 
 
Keywords: 
Beta-lactam antibiotic; continuous infusion; critically ill; pharmacokinetic; pharmacodynamic; 
treatment outcome.  
 
Address for correspondence: 
Dr. Joel Dulhunty, 
Department of Intensive Care Medicine, 
Royal Brisbane and Women’s Hospital, 
Herston, QLD 4029, Australia. 
Ph: +6 1 7 3636 8111    Fax: +6 1 7 3636 3542 
104 
 
5.2.1 Abstract 
Beta-lactam antibiotics display time-dependant PD whereby constant antibiotic concentrations 
rather than high peak concentrations are most likely to result in effective treatment of infections 
caused by susceptible bacteria. CI has been suggested as an alternative strategy, to conventional IB 
dosing, to optimize beta-lactam PK/PD properties. With the availability of emerging data, we 
elected to systematically investigate the published literature describing the comparative PK/PD and 
clinical outcomes of beta-lactam antibiotics administered by CI or IB dosing. We found that the 
studies have been performed in various patient populations including critically ill, cancer and cystic 
fibrosis patients. Available in vitro PK/PD data conclusively support the administration of beta-
lactams via CI administration for maximizing bacterial killing from consistent attainment of PD 
end-points. In addition, clinical outcome data supports equivalence, even with the use of a lower 
dose by CI. However, the present clinical data is limited with small sample sizes common with 
insufficient power to detect advantages in favour of either dosing strategy. With abundant positive 
pre-clinical data as well as document in vivo PK/PD advantages, large multicentre RCTs are needed 
to describe whether CI administration of beta-lactams is truly more effective than IB dosing. 
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5.2.2 Introduction        
The mortality rate of severe sepsis and septic shock in critically ill patients remains high despite 
recent therapeutic advances. Swift and judicious antibiotic use in these patients is vital and any 
delays are associated with increases in mortality [4, 357]. Beta-lactam antibiotics are used 
commonly and are regarded as a cornerstone in the management of critically ill patients with severe 
sepsis in ICUs around the world [357, 383, 384]. However, the occurrence of severe 
pathophysiological changes, namely the fluid shift phenomenon [64] and ARC [385], in critically ill 
patients may alter the PK of the antibiotics. Thus, appropriate dosing modifications should be 
applied to prevent inadequate antibiotic concentrations and therapeutic failure [8, 56, 64]. 
 
Antibiotic PD is the discipline that attempts to relate PK parameters to the ability of an antibiotic to 
kill or inhibit the growth of bacterial pathogens [11]. Antibiotics can be classified based on these 
PD characteristics. Generally, antibiotics are classified into three categories based on their mode of 
bacterial killing: (a) concentration-dependent; (b) time-dependent; or (c) both (Figure 5-1). The first 
category includes antibiotics, such as aminoglycosides, where the best predictor of efficacy is 
Cmax/MIC [386, 387]. Some antibiotics, such as fluoroquinolones and glycopeptides, are more 
complex and exhibit both a concentration and time-dependent kill characteristics where the best 
predictor of efficacy is AUC0-24/MIC. Therefore, increasing the dose or/and concentration for these 
antibiotics can be logically expected to enhance the rate and extent of bacterial killing [388, 389]. In 
contrast, higher beta-lactam concentrations do not significantly influence their efficacy. Based on 
numerous in-vitro and in-vivo experimental data, it is the duration of effective antibiotic exposure 
that is more important for these time-dependent antibiotics [12, 24, 390, 391]. 
 
The debate persists about whether traditional IB dosing or CI administration is clinically preferable 
for administration of beta-lactam antibiotics. This is despite the fact that beta-lactam PD data 
suggest advantages for CI compared with IB [79, 85, 247, 253, 330, 362, 363], showing time-
dependent activity and demonstrating that the fT>MIC best describes its bacterial kill characteristics 
[12] (Figure 5-1). Thus, administration via CI should be advantageous, because it inevitably 
produces higher and sustained antibiotic concentrations above the MIC. It also is noteworthy that IB 
yields unnecessary high peak and low trough concentrations below MIC for much of the dosing 
interval [67, 174, 175, 250] (Figure 5-2 and Figure 5-3). The constant and sustainable antibiotic 
concentrations provided by CI are particularly important for pathogens with high MIC values. Such 
pathogens are relatively common in the ICU [14, 86, 264].  
 
106 
 
 
Figure 5-1: Study flowchart demonstrating the number of patients who were included and 
excluded in each stage of the planned analysis 
Abbreviation: AUC0-24, area under the concentration-time curve during a 24-hour time period; Cmax, 
maximum plasma antibiotic concentration; T>MIC, time that a drug’s plasma concentration remains 
above the minimum inhibitory concentration (MIC) for a dosing period. 
 
 
Figure 5-2: The simulated concentration-time profile of a beta-lactam when administered by 
intermittent bolus dosing or continuous infusion (Vd = 0.22 L/kg; T½ = 2.45 hr) 
Legend: Continuous infusion (dotted lines); intermittent bolus dosing (solid lines). 
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Figure 5-3: Observed steady state plasma and tissue concentrations for meropenem 
administered to critically ill patients with sepsis by intermittent bolus dosing and continuous 
infusion (adapted from Roberts et al., 2009, J Antimicrob Chemother) 
Abbreviation: CI, continuous infusion; ISF, interstitial fluid. 
Legend: 
Continuous infusion (CI) meropenem plasma concentration (solid dark lines); IB meropenem 
plasma concentration (dotted grey lines); IB meropenem interstitial fluid (ISF) concentration (solid 
grey lines); CI meropenem ISF concentration (dotted dark lines). 
 
Despite these theoretical advantages, a global practice shift towards CI of beta-lactam antibiotics 
has not taken place. Although CI has been shown to be superior to IB dosing during in in vitro [152, 
219] and in vivo [231, 233, 235, 392] experimental studies, comparative clinical studies have so far 
failed to demonstrate significant differences in patient outcome. Furthermore, three recent meta-
analyses of these clinical trials have found similar outcomes between CI and IB, in heterogeneous 
hospitalized patient populations [217, 267, 377]. This dissociation between pre-clinical data and 
clinical reports raises uncertainty for the treating clinician. Additionally, most trials have important 
methodological flaws and have used inconsistent methods and therapeutic end-points [14]. There 
also is a lack of general consensus about which patient groups should be investigated and the 
appropriate methodology that should be employed to identify whether clinical outcome differences 
between these two dosing approaches exist in all hospitalized patients. The possible advantages and 
disadvantages from the two dosing methods are further summarized in Table 5-1. 
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Table 5-1: Possible advantages and disadvantages of employing continuous or intermittent 
administration of beta-lactam antibiotics 
Administration method Advantages Disadvantages 
Continuous infusion More predictable antibiotic 
pharmacokinetic profiles 
Relatively new antibiotic 
administration method thus 
requiring intensive educational 
effort to update clinical staff on 
the administration method prior to 
implementation 
Lower antibiotic daily dose 
may be appropriate with 
continuous infusion 
May increase the cost of treatment 
Reduced drug acquisition 
costs when lower antibiotic 
doses are used 
Some beta-lactams  
(e.g., meropenem) are not stable 
under prolonged exposure at room 
temperature and may produce and 
enhance degradation products that 
cause hypersensitivity reactions 
Effective resource 
consumption  
(e.g., reduce the time 
required for pharmacists or 
nurses to prepare and 
administer antibiotic) 
Risk of drug wastage is high with 
this approach (e.g., when 
treatment ceased before infusion 
bag completed) 
Intermittent bolus Simple. Pharmacokinetic and 
pharmacodynamic targets may not 
be achieved (especially in 
critically ill patients) 
Does not require dedicated 
line access for drug 
administration 
(incompatibility issues 
unlikely) 
Neurological adverse effects are 
theoretically more possible with 
high Cmax 
Less likely to have 
unexpected device failures 
and dosing delivery rate 
errors 
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The purpose of this review is to describe the published clinical trials and their associated 
methodological shortcomings in their comparison of CI and IB administration in hospitalized 
patients. Several intriguing issues or problems involved in the interpretation of results obtained 
from the available studies also will be highlighted. Finally, based on these discussions, description 
of a methodologically robust, definitive clinical trial will be proposed. 
 
5.2.3      PK/PD considerations 
The % fT>MIC during a dosing interval is regarded as the optimal PD index for beta-lactam 
antibiotics and as such, maintaining effective drug concentration above the MIC should be the 
priority when this antibiotic class is used. Specifically, the % fT>MIC needed for bacteriostasis and 
bactericidal is 35-40% and 60-70% for cephalosporins, 30% and 50% for penicillins, 20% and 40% 
for carbapenems, respectively [10, 11, 152, 393]. However, it is imperative to note that these 
indices should be regarded as the minimum PD end-points and that they may not be adequate to 
treat severe infections and to prevent the development of antibiotic resistance [394]. Furthermore, 
emerging retrospective clinical data for critically ill patients suggest patients’ benefits with higher 
and longer antibiotic exposures than those described for the in vitro and in vivo experimental studies 
[28, 298]. Thus, it has been suggested that maintaining concentrations above the MIC for 90-100% 
of the dosing interval is a rational PD end-point to ensure that the above minimum targets are 
achieved [153]. Combining the above data, beta-lactams should be more effective when delivered 
continuously to achieve a concentration above the MIC throughout treatment.  
 
Alternatively, prolonging the infusion time via EI dosing, also has been suggested to maximize the 
fT>MIC for this antibiotic class without some of the CI-associated drawbacks outlined in Table 5-1 
[190, 242]. Both CI and EI may be particularly advantageous in the treatment of severe infections. 
 
5.2.3.1     Inconsistent PD end-points for comparison 
Different PD end-points have been used in published studies which make comparison between CI 
and IB difficult. However, several reviews have suggested that prolonged antibiotic exposures will 
achieve better PD profile [56, 395, 396]. Apparent benefits with regards to maximum bacterial 
killing also were reported in several studies when antibiotic concentrations were maintained above 
the MIC for extended periods, ideally four- to five-times the MIC especially when less susceptible 
microorganisms were involved [25, 28, 82, 152, 221, 397]. In combination with other PK/PD data, 
it is suggested that therapeutic targets for CI therapy should be a Css that is at least 4 x MIC [152]. 
Thus, future comparative PK/PD studies should evaluate the relative ability of IB to achieve a Cmin 
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greater than the 4 x MIC of the offending pathogen for 40-70% of a dosing interval and for CI, a Css 
greater than 4 x MIC to prevent biased comparisons. It follows that the real challenge for IB is to 
obtain a Cmin greater than 4 x MIC in a severely ill patient who is infected with a pathogen with 
high MIC. 
 
5.2.3.2     The role of post-antibiotic effect 
Another consideration for optimizing antibiotic pharmacokinetic exposure is the PAE i.e., the 
suppression of bacterial growth even with antibiotic concentrations below the MIC [12, 154, 157, 
158]. Although all antibiotics demonstrate PAE against susceptible Gram-positive pathogens (i.e., 
staphylococci and streptococci), only some antibiotics, such as the aminoglycosides and 
fluoroquinolones produce prolonged PAE for Gram-negative pathogens [12]. In contrast, beta-
lactams except for the carbapenems, produce minimal or no PAE against Gram-negative pathogens. 
It follows that the reduced % fT>MIC required for carbapenems bacteriostatic (20%) and bactericidal 
(40%) activity may relate to the antibiotics PAE [154, 158, 160-162, 398]. Therefore, the need for 
frequent dosing and continuous administration is deemed supplemental when antibiotics such as 
carbapenems display significant PAE. 
 
5.2.3.3     Revision in antibiotic breakpoints 
The recent revision in antibiotic breakpoints to indicate if an organism is susceptible or resistant to 
different antibiotics, as classified by EUCAST and CLSI, have had an impact on how clinicians 
view and manage infections worldwide [14]. These new rules also are applicable for interpretation 
of antibiotic PK/PD studies. Due to these changes, future studies need to be interpreted in light of 
the new susceptibility breakpoints [361]. These new rules may mean that the present dosing 
approaches are more, or less likely to achieve PK/PD targets. 
 
5.2.3.4     The role of optimal PK/PD targets in the prevention of antibiotic resistance   
Antibiotic resistance patterns have significantly changed during the past 15 years with increasing 
resistance currently regarded as a major health crisis [399, 400]. Furthermore, the rate at which the 
pathogens are currently developing antibiotic resistance is likely to far outpace the rate of 
development of new antibiotics. Thus, optimizing the use of new or existing antibiotics via PK/PD 
principles may prolong their life span in clinical practice [10, 398]. Although numerous studies 
have been performed to determine the optimal PK/PD targets for clinical and bacteriological 
success, very little data exist that describe their roles in the prevention of bacterial resistance. 
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However, extensive research in this area has been conducted with fluoroquinolones and more 
importantly, the corresponding optimal PD targets (i.e., AUC/MIC breakpoints) for resistance 
prevention has been described for this antibiotic class [349, 401, 402]. The success with 
fluoroquinolones further emphasizes that PK/PD principles are not only relevant in bacterial 
eradication but also should be considered to minimize the development of bacterial resistance. For 
the beta-lactams, however, limited data are currently available, with the exception of several in vitro 
[365, 403] and in vivo experimental studies [404], which suggest the optimal PD targets for the 
prevention of resistance. Thus, appropriate targets are initially needed for this antibiotic class before 
a dosing regimen that minimizes resistance development can be recommended. Until convincing 
evidence becomes available, antibiotic dosing that targets concentrations greater than 4-6 x MIC for 
an extended interval should be aimed at to prevent resistance [149, 152, 405]. It also follows that 
once the targets are defined, it will then be possible to evaluate the relative ability of CI versus IB in 
reducing the emergence of resistance associated with the use of beta-lactam antibiotics. However, 
several reviews have suggested that the currently proposed PK/PD target is probably best achieved 
by using CI or EI [14, 153].  
   
5.2.4      Controversies surrounding data interpretation    
Since the initial availability of antibiotics, methods to optimize antibiotic dosing have been explored 
[391, 406]. Numerous trials have been conducted with beta-lactams testing various dosing strategies 
in various patient populations [82, 151, 171-173, 243, 248, 254-258, 261, 262, 266, 305, 407]. The 
characteristics and findings of these relevant clinical trials are described in Tables 5-2 and 5-3, 
respectively. However, these studies have not defined whether altered dosing approaches are 
advantageous and which patient groups may benefit. Most of these trials were conducted in North 
America and Europe between 1979 and 2008 with all but two studies published after the year 2000 
[255, 262]. A number of articles also have discussed the potential advantages and disadvantages of 
CI [14, 15, 17, 153, 264]. Yet, the limitations of the existing studies have not been analysed in 
detail and require further elaboration. Figure 5-4 briefly summarizes the current limitations 
associated with the available clinical trials. 
112 
 
Table 5-2: Characteristics of previously published studies of continuous versus bolus dosing of beta-lactam antibiotics 
Study Setting 
(Country) 
Antibiotic Critically ill Population Sample 
size 
Agea Allocation 
sequence 
generator 
Allocation 
concealment 
Masking Concomitant 
antibiotic CI IB 
Angus et al., 
[151] 
Not specified 
(Thailand) 
Ceftazidime Yes Septicaemic 
melioidosis 
21 48 
(29-58) 
43 
(27-73) 
Not specified Not specified Not specified Various 
Bodey et al., 
[255] 
Non-ICU  
(USA) 
Cefamandole No Malignant diseases 
with neutropenia 
204 Not specified Adequate Adequate Not specified Carbenicillin 
Buck et al., 
[173] 
Non-ICU 
(Germany) 
Piperacillin/tazobactam No Hospitalized 
infections 
24 60-88b 32-76b Not specified Adequate No Nil stated 
Georges et al., 
[172] 
ICU  
(France) 
Cefepime Yes Critically ill with 
Gram-negative 
infections 
50 50±17 46±24 Not specified Not specified No Amikacin 
Hanes et al., 
[254] 
ICU  
(USA) 
Ceftazidime Yes Critically ill trauma 32 33.5±12.5 36.1±12.8 Not specified Not specified No Nil stated 
Lagast et al., 
[262] 
Not specified 
(Belgium) 
Cefoperazone No Gram-negative 
septicaemia 
45 37-77b Not specified Not specified No Nil stated 
Lau et al., 
[256] 
ICU  
(USA) 
Piperacillin/tazobactam No Complicated intra-
abdominal infections 
262 50.4±16.6 49.3±17.8 Not specified Not specified No Nil stated 
Lubasch et al., 
[258] 
Not specified 
(Germany) 
Ceftazidime No Hospitalized patients 
with COPD 
exacerbation 
81 65.3±10.1 Not specified Not specified No Nil stated 
Nicolau et al., 
[266] 
ICU  
(USA) 
Ceftazidime Yes Critically ill patients 
with sepsis 
41 46±16 56±20 Adequate Not specified No Tobramycin 
Pedeboscq et al., 
[261] 
ICU  
(France) 
Piperacillin/tazobactam Yes Severe sepsis 7 58±12 Not specified Not specified No Ofloxacin 
Rafati et al., 
[248] 
ICU  
(Iran) 
Piperacillin Yes Critically ill patients 
with sepsis 
40 50.1±22.2 48.0±20.7 Not specified Not specified No Amikacin 
Roberts et al., 
[243] 
ICU  
(Australia) 
Ceftriaxone Yes Critically ill patients 
with sepsis 
57 43±19 52±16 Adequate Adequate Adequatec Multiple 
depending on 
indication 
Sakka et al., 
[171] 
ICU  
(Germany) 
Imipenem/cilastatin Yes Critically ill patients 
with sepsis 
20 62±16 59±16 Not specified Adequate No Nil stated 
Van Zanten et al., 
[257] 
 
Not specified 
(Netherlands) 
Cefotaxime No Hospitalized patients 
with COPD 
exacerbation 
93 65.3±8.4 68.6±5.3 Not specified Not specified No Nil stated 
Abbreviation: CAP, community-acquired pneumonia; CI, continuous infusion; COPD, chronic obstructive pulmonary disease; CVVH, continuous venovenous haemofiltration; IB, intermittent bolus; ICU, intensive care unit. 
Legend: 
aValues are reported according to published results as mean (±SD) or median (interquartile range). 
bValues are reported as range. 
cOnly outcome assessment was blinded. 
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Table 5-3: Antibiotics dosage and outcome data of previously published studies for CI versus IB dosing of beta-lactam antibiotics 
Study Types of infection Number of patients 
(APACHE II scorea) 
Antibiotic dosage regimen Concurrent 
PK/PD analysis 
Clinical outcome 
measures 
CI IB p-valueb 
CI IB CI IB 
Angus et al., 
[151] 
Septicaemic 
melioidosis 
10 (15) 11 (21) 12 mg/kg LD, then 4 
mg/kg every 1 hr 
40 mg/kg every 8 hrs Yes Mortality 20% 36.4% 0.89 
Bodey et al., 
[255] 
Pneumonia, UTI & 
neutropenic fever 
167 (ND) 162 (ND) 3 g LD, then 12 g/24 
hrs 
3 g every 6 hrs No Clinical cure 64% 57% ND 
Buck et al., 
[173] 
Pneumonia, IAI & fever 
of unknown origin 
12 (ND) 12 (ND) 2 g LD, then 8 g/24 hrs 4 g every 8 hrs Yes Clinical response 67% 67% ND 
Georges et al., 
[172] 
Pneumonia & blood 
stream infection 
24 (45)c 23 (44)c 2 g/12 hrs twice daily 2 g every 12 hrs No Clinical cure 85% 67% ND 
Mortality 12% 13% ND 
Duration of MV 24 days 25 days ND 
ICU LOS 34 days 40 days ND 
Hanes et al., 
[254] 
Pneumonia 17 (13) 14 (11) 2 g LD, then 60 mg/kg 
every 24 hrs 
2 g every 8 hrs Yes Duration of leukocytosis 8 days 11 days 0.35 
Duration of pyrexia 8 days 4 days 0.06 
Duration of MV 23 days 12 days 0.16 
ICU LOS 27 days 16 days 0.11 
Hospital LOS 41 days 29 days 0.37 
Lagast et al., 
[262] 
Blood stream infection 20 (ND) 25 (ND) Day 1: 1 g LD, then 3 
g/24 hrs 
Day 2 +: 4 g/24 hrs 
2 g every 12 hrs No Clinical cure 25% 16% ND 
ICU mortality 70% 80% ND 
Lau et al., 
[256] 
IAI 81 (8) 86 (8) 2 g LD, then 12 g /24 
hrsg 
3 g every 6 hrsg No Clinical cure 86% 88% 0.817 
Bacteriological cure 77% 88% 0.628 
Lubasch et al., 
[258] 
Pneumonia 41 (ND) 40 (ND) 2 g LD, then 2 g/7 hrs 
twice daily 
2 g every 8 hrs Yes Clinical cure 90% 90% ND 
Bacteriological cure 90% 88% ND 
Nicolau et al., 
[266] 
Pneumonia 17 (14) 18 (16) 1 g LD, then 3 g/24 hrsh 2 g every 8 hrsh No Clinical cure 41% 33% 0.592 
Duration of MV 8 days 8 days 0.97 
Days to defervescence 3 days 5 days 0.015 
Days to WCC 
normalization 
7 days 6 days 0.259 
LOS ICU 9 days 9 days 0.691 
Pedeboscq et al., 
[261] 
IAI 3 (ND) 4 (ND) 12 g/24 hrs 4 g every 8 hrs Yes Mortality 0% 0% ND 
Rafati et al., 
[248] 
Pneumonia, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
20 (16) 20 (14) 2 g LD, then 8 g/24 hrs 3 g every 6 hrs Yes Mortality 30% 25% 0.72 
Decrease in illness 
severity 
  CI>ITd 
Duration of pyrexia 2 days 1 day 0.08 
WCC normalization 75% 83% ND 
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Roberts et al., 
[243] 
Pneumonia, IAI, UTI, 
CNS infection, SSTI & 
blood stream infection 
29 (19) 28 (16) 0.5 g LD, then 2 g/24 
hrs 
Day 1: 2.5 g/24 hrs 
Day 2: 2 g/24 hrs 
No Clinical curee 52% 20% 0.04 
Mortality 10% 0% 0.25 
Duration of MV 4 days 3 days 0.33 
ICU LOS 11 days 6 days 0.29 
Hospital LOS 42 days 24 days 0.34 
Sakka et al., 
[171] 
Pneumonia 10 (26) 10 (28) 1 g LD, then 2 g /24 hrs 1 g every 8 hrs Yes Mortality 10% 20% ND 
Van Zanten et al., 
[257] 
 
COPD exacerbation 40 (ND) 43 (ND) 1 g LD, then 2 g/24 hrs 1 g every 8 hrs Yes Clinical cure 93% 93% 0.93 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; CI, continuous infusion; CNS, central nervous system; CRP, C-reactive protein; IAI, intra-abdominal infection; IB, intermittent bolus; ICU, 
intensive care unit; LD, loading dose; LOS, length of stay; MV, mechanical ventilation; ND, not described; PK/PD, pharmacokinetic/pharmacodynamic; SOFA, Sequential Organ Failure Assessment; SSTI, skin and skin-
structure infection; UTI, urinary tract infection; WCC, white cell counts. 
Legend: 
aValues are reported as mean or median. 
bBold values indicate statistical significance at p <0.05. 
cValues are SAPS scores. 
dStatistically significant difference in APACHE II scores on Days 2, 3 and 4. 
eA priori analysis. 
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Figure 5-4: The summary of the current limitations and flaws associated with the available 
clinical trial 
 
5.2.4.1     Heterogeneous patient populations 
Most of the relevant trials recruited hospitalized patients from different populations, especially the 
non-critically ill patient groups (Table 5-2). The diverse range of patient groups include critically ill 
patients with sepsis [151, 172, 243, 248, 261, 262, 266], trauma patients (86), patients with 
abdominal infections [256, 407], COPD patients [257, 258], cancer [255] and non-specific 
hospitalized infections [173]. Thus, meta-analyses have evaluated heterogeneous patient groups and 
any potential benefits of CI or IB that may exist in a particular patient group were not assessed. This 
issue was previously discussed by Roberts et al., in their meta-analysis, where large CI were 
observed suggesting clinical differences may exist between CI and IB administration if more 
stringent and rigorous inclusion criteria were used in clinical studies [217].  
 
5.2.4.2     Inclusion of patients with a low level of illness severity 
Detecting significant difference between CI and IB is difficult because the potential benefits may be 
masked by the inclusion of low-risk patients who have much lower mortality rates than reported in 
epidemiological studies. This selection bias was further described in two recent meta-analyses [217, 
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377]. For example, two of the nine ICU studies that were meta-analysed by Roberts et al., reported 
a mortality rate ≤10% when the mortality rate for severe sepsis is usually reported between 40% and 
50% [33, 408, 409] (Table 6-3). Other studies also recruited patients with low illness severity 
whereby more than 70% of the cohort presented with an APACHE II score of only 10 [256]. This is 
a problem because any differences between CI and IB are more likely emerge in more severely ill 
patients [151, 298]. Critically ill patients with severe sepsis are more likely to benefit from CI, 
because they commonly develop severe pathophysiological changes which may reduce effective 
antibiotic exposure [129]. Furthermore, these patients are usually infected with pathogens that are 
less susceptible to antibiotic therapy. Thus, in combination, the two important factors may reduce 
PK/PD target attainment in severely ill patients. In contrast, it has been shown that IB dosing of 
beta-lactam antibiotics achieves adequate PK/PD target for bacterial eradication in patients with low 
level of illness severity.   
 
5.2.4.3     Inconsistent antibiotic dosing regimen 
Most of the studies included in the three meta-analyses utilized higher IB doses than the CI 
treatment arm, potentially favouring the former [151, 171, 173, 248, 254, 256, 257, 266] (Table 5-
3). This treatment bias might have skewed the results of these meta-analyses towards the null 
hypothesis. Another logical conclusion is that a lower dose in the CI group was able to achieve 
equivalent outcomes to a higher dose in the IB group. A significant difference in clinical outcomes 
might emerge if the two approaches utilized the same daily dose. This notion has been supported by 
a meta-analysis, whereby clinical failures were less frequent in the CI group, when separate 
analyses were performed in trials which used the same total daily dose in the two treatment arms 
[267]. Furthermore, dosing inconsistency with regards to initial bolus administration of antibiotic 
was reported in several studies [172, 261, 407] (Table 5-3). An initial loading dose was not 
provided to the CI protocol in these studies. This approach delays attainment of target antibiotic 
concentrations compared with the IB group. To make the two dosing protocols comparable, an 
initial and equal loading dose of beta-lactam antibiotic should be provided to both groups. 
 
5.2.4.4     Pathogens with low MIC values 
The offending pathogens isolated in most of the clinical trials have MIC values that make them 
highly susceptible. Simulation data suggests that there will be little difference in the achievement of 
PK/PD targets for IB and CI if the pathogens involved are in the susceptible range. When less 
susceptible pathogens are present, the true potential benefits of CI may be seen because treatment 
failures are more likely with IB [28, 151, 174, 398]. This limitation has been highlighted in the two 
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most recent meta-analyses and has been proposed as one of the contributing reasons why clinical 
differences between CI and IB of beta-lactams have not been found. This notion is supported by one 
RCT [151] and two retrospective, observational studies [274, 298] which were conducted in 
critically ill patients infected with Gram-negative organisms. These studies reported clinical cure 
and mortality benefits favouring CI for pathogens with high MIC values. 
 
5.2.4.5     Concomitant administration of other antibiotics 
Another noteworthy limitation is that patients included in the available clinical trials were 
frequently prescribed concomitant antibiotics that, unrelated to the method of beta-lactam 
administration, may influence clinical outcome [267, 377]. Such additional antibiotics 
(aminoglycosides and fluoroquinolones) provide adequate antimicrobial coverage for most Gram-
negative pathogens. Therefore, the exclusive contribution of beta-lactam antibiotics to patient 
outcomes will be poorly defined in these trials. However, in reality, beta-lactam antibiotics are 
usually administered in conjunction with an aminoglycosides especially when treating patients with 
severe infections. It follows that regardless of the beta-lactam administration method, the 
aminoglycosides or fluoroquinolones may be “protecting” patients from Gram-negative pathogens 
during periods of inadequate beta-lactams concentration. A plausible explanation could be that the 
method of administering beta-lactams is not that important when additional Gram-negative 
coverage (i.e., aminoglycosides or fluoroquinolones) is used.       
 
5.2.4.6     Insufficient sample sizes 
The lack of significance in the published results also may be attributed to the consistently small 
sample sizes that have been used to explore the effect of CI versus IB. The typical study cohort size 
has varied from 10 to 531 patients but the majority of these trials studied less than 60 patients [82, 
171-173, 243, 248, 254, 262, 266, 407] (Table 5-2). The small sample sizes and heterogeneous 
patient background in the clinical studies contribute to insufficient power to investigate the value of 
both dosing methods. Further to this, if the population of interest is critically ill patients, a single 
intervention in this setting is unlikely to influence mortality and clinical cure [264] and, as a 
consequence, a much larger sample size is needed to show significance [172, 267, 330]. For 
instance, Roberts et al., calculated that a sample size of 560 patients in each dosing protocol would 
be needed to detect difference in bacteriological outcomes [243]. Considering the difficulties in 
achieving these numbers in critically ill patients, perhaps it is time for clinicians to fully 
acknowledge the importance of surrogate end-points in the setting of a study. Clinical cure and 
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ICU-free days are suitable surrogate end-points and may be used as primary outcomes in a phase II 
study of this intervention. 
 
5.2.5      Other relevant concerns 
Apart from the discussion above, there are several other plausible reasons why clinical differences 
have not been established between CI and IB in previous trials. It is important to note that some 
patients, especially in the ICU, may have some degree of renal impairment on admission or during 
their hospital stay [136, 410, 411]. Whereas a commonly prescribed beta-lactam dose may not be 
sufficient in patients with mild or no renal impairment, target antibiotic concentrations are more 
easily achieved in patients with moderate to advanced renal impairment [211]. Similarly, beta-
lactam exposure will still be adequate in patients with significant renal impairment as antibiotic CL 
is reduced, regardless of the drug administration method [253]. Finally, one of the strongest bodies 
of evidence suggesting the superiority of CI has been derived from animal studies. However, the 
metabolic pathways and tissue distribution patterns of an antibiotic in animals may differ from 
humans. In addition, more often than not, these animal models fail to mimic human sepsis [412, 
413].  
 
Based on the discussion above, clearer insights regarding CI and IB administration in patients 
receiving beta-lactam antibiotics are emerging. Importantly, the results from previous clinical 
studies suggest that CI of beta-lactam antibiotics is unlikely to be advantageous for all hospitalized 
patients but may be important in specific patient cohorts. Thus, in an attempt to elucidate the true 
benefits, we contend that the patient population most likely to adequately test the putative benefits 
of CI of beta-lactam antibiotics must involve: (a) critically ill patients; (b) patients with higher level 
of illness severity (i.e., APACHE II score ≥15); (c) patients infected with less susceptible 
microorganisms; and (d) patients with Gram-negative infections. 
 
5.2.6      Methodology concerns and the proposed characteristics of an “ideal” trial 
Several reviews have suggested the importance of designing and conducting a methodologically 
sound clinical trial in the investigation of CI versus IB antibiotic administration benefits in critically 
ill patients [14, 217, 267, 377]. These recommendations cannot be overemphasized due to frequent 
reports of low methodological quality clinical studies. It also is noteworthy that a previous study, 
which utilized the most rigorous and stringent methods was the only study to demonstrate a clinical 
cure advantage in favour of CI administration of beta-lactams [243]. The characteristics of an 
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“ideal,” randomized, clinical trial to compare CI versus IB administration of beta-lactam antibiotics 
in critically ill patients are described in Table 5-4. 
Table 5-4: Description of a randomized clinical trial that should be performed to investigate 
CI versus IB of beta-lactam antibiotics 
Criteria Comments 
Population Should only include patients with sepsis or severe sepsis 
Intervention Antibiotic dosing regimen should be similar between CI and IB group 
a. A loading dose should be given to continuous infusion group to 
ensure rapid attainment of target antibiotic concentration 
b. An equal daily antibiotic dose should be given to continuous and 
bolus administration group 
c.  Antibiotic doses should be specified according to the patient’s body 
weight 
d. Concomitant administration of other non-beta-lactam antibiotics 
should be allowed 
PK/PD analysis Concurrent PK/PD analysis should be performed to support any findings 
a. Measurements of antibiotic concentrations should be performed as 
long as contributing sites have necessary infrastructure to ensure apt 
sampling 
b. PK/PD analysis should evaluate the relative ability of IB to achieve a 
Cmin greater than 4 x MIC of the offending pathogen for 40-70% of 
the dosing interval while for CI, a Css greater than 4 x MIC 
Methods Design 
Preferably multicenter in nature and recruits participants from different 
regions to improve generalizability of results 
Patients 
Define eligibility criteria for participants to be included into trial 
a. Definition of sepsis and severe sepsis should be described in detail 
b. Inclusion and exclusion criteria used should be explained 
Randomization 
Detailed explanation on allocation sequence generation development 
Detailed allocation concealment mechanism 
Blinding/masking 
Outcome evaluators for the trial should be blinded to treatment allocation 
End-points 
a. End-points selection should include primary (clinical outcome) and 
secondary (PK/PD; adverse event) end-points 
b. Data collection on the observed bacterial resistance in the two 
treatment arms should occur 
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 Most studies did not address the methods for allocation sequence generation and concealment 
further increasing the chance for selection bias [172, 173, 248, 254, 256-258, 261, 262, 266, 305, 
407] (Table 5-2). In many studies, masking or blinded assessment of the study end-points were not 
adequately addressed causing detection bias [151, 171-173, 248, 254-258, 262, 266, 305, 407] 
(Table 5-2). In addition, most of the available studies have failed to have blinded clinicians to assess 
the clinical and bacteriological outcomes. Each of these issues increases the possibility of 
systematic errors in these studies. 
 
Ideally, the antibiotic dosing regimen in each treatment arm (i.e., CI and IB) should be comparable 
in terms of the provision of an initial loading dose with an equal daily antibiotic dose. Alternatively, 
a suitable surrogate end-point, such as a cost-effective analysis, may be used to compare these two 
dosing approaches when unequal antibiotic doses are used between them. Concomitant 
administration of other non-beta-lactam antibiotics, such as the aminoglycosides or 
fluoroquinolones, in the setting of a study is appropriate considering that a single empirical therapy 
is unlikely to occur during antibiotic initiation in ICU patients [357, 384]. Furthermore, the 
concomitant administration of other antibiotics should be regarded as a limitation rather than a 
major flaw in future trials, because it reflects real clinical practice. However, the number of 
concomitant antibiotics that are used and their administration sequences in relation to the main 
study antibiotic should at least be described in the trials.   
 
Only a number of studies measured antibiotic concentrations and included a concurrent PK/PD 
evaluation to confirm whether the dosing approaches were actually meeting their respective PK/PD 
end-points (Table 5-3) [82, 171, 248, 254, 256, 257]. Hence, it is difficult to relate clinical 
outcomes to the respective antibiotic exposure obtained via the two approaches. It is imperative to 
note the difference in PK/PD end-points with regards to CI and IB. In a comparison that reflects 
current practice, CI has to achieve a Css greater than 4 x MIC to be microbiologically more effective 
than IB. On the other hand, IB has to achieve an antibiotic Cmin greater than 4 x MIC during the 
typical 40-70% of the dosing interval [14, 151, 152, 358]. Therefore, concentration measurement 
and concurrent PK/PD analysis needs to be done in light of this information or the extent of 
antibiotic exposure may not occur as predicted and therefore the influence on clinical cure and 
mortality will remain unclear. Concurrent analysis should be considered “compelling” in future 
trials as long as contributing clinical sites have the necessary infrastructure to ensure appropriate PK 
sampling. 
  
121 
 
Considering the rampant development of bacterial resistance, the exact role of altered dosing 
approaches to reduce the problem should be addressed. To date, studies investigating the impact of 
various beta-lactams dosing approaches and their associated risk of bacterial resistance are scarce 
[149]. However, it is interesting to note the findings of a recent prospective, multicenter, 
randomized study that compared the clinical benefits of EI doripenem versus IB imipenem patients 
with VAP [305]. The authors reported that only 18% of patients treated with EI developed 
resistance of P. aeruginosa compared with 50% who received the conventional imipenem dosing. 
This is one of the few recent studies to evaluate the relative ability of the two dosing approaches in 
the prevention of resistance; similar studies, particularly involving critically ill patients, should 
ensue. Although there are not enough prior clinical data to power a study in the ICU and describe 
the appropriate methodology, data collection on the observed resistance should be performed in 
future clinical trials investigating the two dosing approaches.                
 
Previously published studies have mostly been single-center in design. To our knowledge, only 
three studies were conducted as a multicenter study, and only two of the three studies were able to 
include more than 200 patients [256, 258, 305]. The need for more multicenter studies should be 
emphasized, because these studies will provide a stronger basis for subsequent generalization of any 
findings. Participation from different regions and countries in such studies also should be 
encouraged to facilitate generalization even more to an extent of a possible global practice change. 
 
Because of the cost of large-scale trials, a step-wise approach to consider potential problems and 
feasibility is desirable. An initial pilot study before proceeding with a larger multicenter trial is 
beneficial. In this regard, the BLING I feasibility study has now led to the design of large clinical 
outcome study, BLING II. BLING I was a prospective, multicenter, double-blind, double dummy, 
pilot RCT enrolling 60 critically ill patients from 5 ICUs across Australia and Hong Kong [166]. 
The primary end-point of the study was to establish the PK separation between CI and IB in terms 
of achieving plasma antibiotic concentrations above the MIC of causative pathogens. The PK 
findings in BLING I demonstrated significant differences in plasma antibiotic concentrations above 
MIC favouring the CI group (CI; 81.8 % versus IB; 28.6 %, p = 0.001) thus supporting the notion of 
PK/PD superiority associated with CI administration. Clinical cure also was superior in the CI 
group (CI; 70.0 % versus IB; 43.3 %, p = 0.037). Other relevant findings include the feasibility of 
the proposed randomization and blinding process used by the BLING I investigators and the 
suggestion of appropriate surrogate end-points for survival to be utilized in a multicenter study. 
Thus, based on the findings from BLING I, BLING II was designed with rigorous and stringent 
methods to answer the ultimate question of whether administration of beta-lactam antibiotics by CI 
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will result in improved outcomes for patients with severe sepsis. BLING II is a phase II, 
multicenter, double-blinded, RCT that will recruit critically ill patients with severe sepsis in several 
ICUs in New Zealand as well as Australia and Hong Kong. The Australian National Health and 
Medical Research Council (NHMRC)-funded clinical trial aims to compare the effects of two 
approaches to the administration of beta-lactam antibiotics (i.e., CI versus IB) on ICU-free days up 
to day 28. 
 
5.2.7 Conclusion 
Although numerous PK/PD data from various in vitro and in vivo experimental studies favour the 
use of CI dosing, the current clinical data are less convincing and insufficient to instigate a global 
shift from conventional bolus dosing. However, this lack of convincing data may be due to several 
methodological flaws and inconsistencies among the available studies, thus contributing towards 
insufficient power to detect any significant differences between CI and IB, if they exist. Based on 
the published literature, it can be concluded that CI of beta-lactams will not be beneficial to all 
patients, but may potentially be beneficial in specific subsets of patients. If any patient group is 
likely to benefit from CI, it may be critically ill patients with severe infections. If benefits from CI 
do exist in critically ill patients, a large-scale, prospective, multinational trial with a robust design is 
required. A step-wise approach to conduct such clinical trials has begun and already shows promise. 
A phase II study involving 420 patients is about to start and will provide high quality information to 
confirm or refute the need for a pivotal phase III double-blinded RCT of CI versus IB dosing of 
beta-lactam antibiotics in critically ill patients with sepsis. 
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5.3 Conclusion  
This chapter describes numerous limitations associated with previous studies in this area, which has 
reduced the quality of any findings related to whether CI or IB administration of beta-lactam 
antibiotics should be preferred in critically ill patients with severe sepsis. The data presented in this 
chapter also highlighted that previous studies lacked a design that was sufficient to explore the 
effect of both dosing approaches with regards to clinical outcomes, and some involved small patient 
numbers. Other methodological flaws associated with previously published studies include an 
absence of allocation sequence generation and allocation concealment, possibly leading to selection 
bias. Masking or blinding of health care providers was also not adequately addressed making 
detection bias a possibility in most of these studies. Thus, it is critical for future clinical studies to 
address these limitations in order to conduct a methodologically sound and robust RCT. In addition 
to these methodological flaws, most previous studies recruited participants with low burden of 
disease and with highly susceptible microorganisms. Such subject selection may mask the potential 
advantages of CI of beta-lactams in critically ill patients with severe sepsis where PK alterations 
will be more pronounced. There are no apparent benefits of one approach over the other in the 
management of highly susceptible pathogens. If many patients with highly susceptible pathogens 
are included in a study, the sample size required to show a clinical difference between CI and IB 
dosing will rise dramatically. Hence, future studies should focus on recruiting critically ill patients 
with severe sepsis that are at risk of infection by less-susceptible pathogens to determine if true 
differences exist between the two dosing approaches. 
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Chapter 6: Continuous beta-lactam infusion in critically ill patients with 
severe sepsis: A prospective, two-centre, open-labelled, randomized 
controlled trial 
6.1 Synopsis 
Although CI has been suggested as one of the methods to optimize beta-lactams dosing in critically 
ill patients, most clinical outcome studies have failed to demonstrate a clinical advantage over 
conventional IB dosing in terms of clinical cure and patient survival. Meta-analyses of these 
outcome studies have also not found any significant clinical benefits favouring CI over IB dosing. 
However, the efficacy of CI administration in critically ill patients has not been investigated in 
high-quality RCTs. Most of the available studies recruited heterogeneous patient groups and have 
important methodological inconsistencies that may mask any possible merits of CI dosing, if they 
exists in critically ill patients. However, three recent RCTs which utilized a more rigorous and 
stringent methodology have reported some clinical outcome advantages favouring CI administration 
of beta-lactam antibiotics. Hence, this chapter aims to address all the methodological limitations of 
previous studies by performing a methodologically sound and robust prospective RCT to 
investigate the clinical and PK/PD outcomes associated with CI and IB dosing of beta-lactam 
antibiotics in a cohort of critically ill patients with severe sepsis. 
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6.2 Manuscript entitled “BLISS: Beta-Lactam Infusion in Severe Sepsis: a 
prospective, two-centre, open-labelled, randomized controlled trial of 
continuous versus intermittent beta-lactam infusion in critically ill patients with 
sepsis” 
The manuscript entitled “BLISS: Beta-Lactam Infusion in Severe Sepsis: a prospective, two-centre, 
open-labelled, randomized controlled trial of continuous versus intermittent beta-lactam infusion in 
critically ill patients with sepsis” has been accepted for publication in the Intensive Care Medicine 
(2016). 
 
The co-authors contributed to the manuscript as follows: Conception and development of the study 
design was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, Dr. Helmi Sulaiman, Dr. 
Mohd-Basri Mat-Nor, under the guidance of Prof. Jason A. Roberts. Literature review was 
performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. Jason A. 
Roberts. Data collection was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, Dr. Helmi 
Sulaiman, Dr. Vineya Rai, Dr. Kang K. Wong, Dr. Mohd. S. Hasan and Azrin N. Abd Rahman. 
Sample bioanalysis was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, and Janattul-
Ain Jamal, under the supervision of Dr. Steven C. Wallis. Data analysis was performed by the PhD 
candidate, Mohd-Hafiz Abdul-Aziz, under the supervision of Prof. Jason A. Roberts. The PhD 
candidate took the leading role in manuscript preparation and all co-authors reviewed and 
contributed to the final draft of the manuscript. 
 
The accepted version of this manuscript is presented and incorporated in this chapter. However, 
some text, tables and figures may have been inserted at slightly different positions to fit the overall 
style of the thesis. Numbering of pages, tables and figures may also change to fit the thesis 
requirements. Manuscript references have been collated with all other references in the thesis. 
 
Permission has been granted by the publisher and copyright owner, Springer Science + Business 
Media (License no: 3886900914112), to reproduce the manuscript in this Thesis. 
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6.2.1      Abstract 
6.2.1.1     Purpose 
This study aims to determine if CI is associated with better clinical and PK/PD outcomes compared 
to IB dosing in critically ill patients with severe sepsis. 
 
6.2.1.2     Methods 
This was a two-centre, RCT of CI versus IB dosing of beta-lactam antibiotics, which enrolled 
critically ill participants with severe sepsis who were not on RRT. The primary outcome was 
clinical cure at 14 days after antibiotic cessation. Secondary outcomes were PK/PD target 
attainment, ICU-free days and ventilator-free days at day 28 post-randomization, 14- and 30-day 
survival, and time to WCC normalization. 
    
6.2.1.3     Results 
One-hundred and forty (140) participants were enrolled with 70 participants each allocated to CI 
and IB dosing. CI participants had higher clinical cure rates (56% versus 34%, p = 0.011) and 
higher median ventilator-free days (22 days versus 14 days, p <0.043) than IB participants. PK/PD 
target attainment rates were higher in the CI arm at 100% fT>MIC than the IB arm on Day 1 (97% 
versus 70%, p <0.001) and Day 3 (97% versus 68%, p <0.001) post-randomization. There was no 
difference in 14-day or 30-day survival between the treatment arms. 
  
6.2.1.4     Conclusions 
In critically ill patients with severe sepsis not receiving RRT, CI demonstrated higher clinical cure 
rates and had better PK/PD target attainment compared to IB dosing of beta-lactam antibiotics. 
Continuous beta-lactam infusion may be mostly advantageous for critically ill patients with high 
levels of illness severity and not receiving RRT. 
 
Malaysian National Medical Research Register ID: NMRR-12-1013-14017.  
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6.2.2 Introduction 
Mortality due to severe infections remains persistently high worldwide, ranging from 30-50% in 
patients with severe sepsis and 40-80% in those with septic shock [1]. Optimized antibiotic therapy 
is an intervention likely to improve treatment outcomes in severe sepsis [7]. 
 
Beta-lactam antibiotics display time-dependent activity where bacterial killing and treatment 
efficacy correlates with fT>MIC [12]. Based on this characteristic, maximal beta-lactam effects are 
considered more likely with CI rather than traditional IB dosing. IB dosing may produce beta-
lactam concentrations below the MIC for much of the dosing interval [13], particularly in the ICU 
where pathogens with higher MIC values are relatively common [5]. 
 
Although CI has been shown to be superior to IB dosing in numerous pre-clinical and PK/PD 
simulation studies [13], most clinical comparative trials have failed to demonstrate a clinical 
advantage of CI dosing in terms of clinical cure and/or patient survival [151, 172, 248, 254, 256-
258, 266]. Meta-analyses of prospective studies have also not found any significant clinical benefits 
favouring CI over IB dosing [217, 240, 267]. However, most of the studies recruited heterogeneous 
patient groups and have important methodological flaws, potentially masking any possible benefits 
of CI dosing in critically ill patients [217, 240]. Three recent RCTs have demonstrated some clinical 
outcome advantages favouring CI administration of beta-lactam antibiotics when only critically ill 
patients were recruited [166, 242, 243]. As most of the current evidence was derived from Western 
countries, the wider applicability of CI dosing remains largely unexplored in some regions which 
are plagued by more resistant pathogens and patients with higher levels of sickness severity [332]. 
Data from such areas, particularly from the South East Asian countries, are vital in order to support 
a global practice change if subsequent studies identify CI benefits in critically ill patients. The 
primary aim of the Beta-Lactam Infusion in Severe Sepsis (BLISS) study was to determine if CI of 
beta-lactam antibiotics is associated with improved clinical outcomes compared to IB dosing in a 
large cohort of critically ill patients with severe sepsis in a Malaysian ICU setting. 
 
Findings of the BLISS study were presented, in part, at the 55th Interscience Conference on 
Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, September 18-21, 2015 [414]. 
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6.2.3      Methods 
6.2.3.1     Study design 
The BLISS study was a prospective, two-centre, open-labelled, RCT of CI versus IB dosing of beta-
lactam antibiotics in critically ill patients with severe sepsis from the two following Malaysian 
ICUs: (1) Tengku Ampuan Afzan Hospital (HTAA), Kuantan; and (2) University Malaya Medical 
Centre (UMMC), Kuala Lumpur. Institutional ethics approval was obtained at each participating 
site. Written informed consent to participate in the study was obtained from each participant or their 
legally-authorized representative prior to study enrolment. The study was registered with the 
Malaysian National Medical Research Register (ID: NMRR-12-1013-14017). 
 
6.2.3.2     Participants and randomization 
ICU patients were eligible for inclusion if they met all of the following criteria: (a) adult (≥18 
years); (b) developed severe sepsis (defined as presumed or confirmed infection with new organ 
dysfunction) [24] in the previous 48 hours; (c) indication for cefepime, meropenem or 
piperacillin/tazobactam with <24 hours therapy at time of assessment; (d) and expected ICU stay 
greater than 48 hours. Patients were excluded if they: (a) were receiving RRT; (b) had impaired 
hepatic function (defined as total bilirubin >100 µmol/mL); (c) were receiving palliative treatment; 
(d) had inadequate central venous catheter access; (e) or death was deemed imminent.  
 
Participants currently receiving, or about to receive, cefepime, meropenem or 
piperacillin/tazobactam were randomly allocated to either a CI (intervention arm) or IB (control 
arm) treatment arm. Randomization was performed using a computer program 
(http://www.randomization.com) based on blocks of four with an allocation ratio of 1:1 stratified by 
participating sites. Following study enrolment, an unblinded pharmacist on-duty who was 
responsible for preparing medications, determined treatment allocation by opening sequentially-
numbered opaque, sealed and stapled envelopes. The tamper-evident envelopes were prepared by an 
unblinded investigator and were provided to each participating site. 
 
6.2.3.3     Intervention 
Each antibiotic dose was prepared by an unblinded ICU pharmacist on-duty in accordance with 
standard pharmacy practice. The dosing regimen was determined by the treating intensivist, with 
guidance from a local dosing protocol (Table 6-1). To ensure early achievement of therapeutic beta-
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lactam exposures in the intervention arm, a single loading dose infused over 30 minutes was given 
at initiation of antibiotic therapy meaning that the CI group received a larger antibiotic dose on Day 
1 post-randomization compared to those in the IB arm (Table 6-1). The study antibiotic was 
administered until, (a) the treating intensivist decided to cease the drug; (b) the participant withdrew 
from the study; (c) ICU discharge; or (d) ICU death. All subsequent patient management including 
addition of other antibiotics and non-study drugs was at the treating intensivist’s discretion. 
 
Table 6-1: Antibiotic dosing protocol according to treatment arm in the BLISS study 
Antibiotic and treatment arm Dosing regimen 
Cefepime  
   Intervention arm  
   (continuous infusion) 
 Day 1: 2 g IV loading dose (infused over 30 minutes) 
followed by 2 g IV (infused over 480 minutes) every 8 
hours  
 Day 2 onwards: 2 g IV (infused over 480 minutes) 
every 8 hours  
 
   Control arm  
   (intermittent bolus dosing) 
 2 g IV (infused over 30 minutes) every 8 hours  
  
Meropenem  
   Intervention arm  
   (continuous infusion)  
 Day 1: 1 g IV loading dose (infused over 30 minutes) 
followed by 1 g IV (infused over 480 minutes) every 8 
hours  
 Day 2 onwards: 1 g IV (infused over 480 minutes) 
every 8 hours  
 
   Control arm  
   (intermittent bolus dosing) 
 1 g IV (infused over 30 minutes) every 8 hours  
  
Piperacillin/tazobactam  
   Intervention arm  
   (continuous infusion) 
 Day 1: 4 g/0.5 g IV loading dose (infused over 30 
minutes) followed by 4 g/0.5 g IV (infused over 360 
minutes) every 6 hours 
 Day 2 onwards: 4 g/0.5 g IV (infused over 360 minutes) 
every 6 hours  
 
   Control arm  
   (intermittent bolus dosing) 
 4 g/0.5 g IV (infused over 30 minutes) every 6 hours 
Abbreviation: IV, intravenous. 
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6.2.3.4     Outcomes and measurements 
The primary end-point investigated in this study was clinical cure at 14 days after antibiotic 
cessation. Clinical cure was rated as either: (a) Resolution: complete disappearance of all signs and 
symptoms related to infection; (b) Improvement: a marked or moderate reduction in disease severity 
and/or number of signs and symptoms related to infection; or (c) Failure: insufficient lessening of 
the signs and symptoms of infection to qualify as improvement, death or indeterminate for any 
reason. Clinical cure was scored as a “Yes” for resolution and a “No” for all other findings (i.e., 
sum of 2 and 3 above). Secondary end-points investigated in this study include: (a) PK/PD target 
attainment; (b) ICU-free days at day 28; (c) ventilator-free days at day 28; (d) survival at day 14; (e) 
survival at day 30; and (f) time to WCC normalization. The definitions used to assess these end-
points are described in Table 6-2. 
 
Table 6-2: Definitions used for primary and secondary clinical end-points 
Primary end-pointa Definition and description 
Clinical cure Clinical cure was evaluated at 14 days after cessation of study 
antibiotic and was rated as: 
1. Resolution: complete disappearance of all signs and 
symptoms related to infection. 
2. Improvement: a marked or moderate reduction in 
disease severity and/or number of signs and symptoms 
related to infection. 
3. Failure: insufficient lessening of the signs and 
symptoms of infection to qualify as improvement, 
including death or indeterminate (i.e. no evaluation 
possible, for any reason). 
Clinical cure was scored as a “Yes” for resolution and a “No” 
for all other findings (i.e., sum of 2 and 3 above). 
  
Secondary end-pointsb,c,d Definition and description 
PK/PD – 50% fT>MIC Free (unbound) drug concentration maintained above the MIC 
of the causative pathogen for at least 50% of dosing interval 
(i.e., mid-interval drug concentration). For CI participants, this 
was the first sample taken over a 24-hour interval.   
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PK/PD – 100% fT>MIC Free (unbound) drug concentration maintained above the MIC 
of the causative pathogen for at least 100% of dosing interval 
(i.e., trough drug concentration or steady-state drug 
concentration). For CI participants, this was the second sample 
taken over a 24-hour interval.  
ICU-free days at day 28 The number of days the participant was ICU-free after 
successful transfer to a general ward in the first 28 days post-
randomization. ICU-free days were 0 if a patient died or stayed 
in the ICU for ≥28 days. 
Ventilator-free days at day 28 The number of days the participant was ventilator-free (for at 
least 48 consecutive hours) in the first 28 days post-
randomization. Ventilator-free days were 0 if a patient died or 
required mechanical ventilation for ≥28 days. 
14-day survival Survival at day 14 post-randomization. 
30-day survival Survival at day 30 post-randomization 
Time to WCC normalization The number of days from randomization to the first identified 
date when WCC was ≥4.0x109/L and ≤10.0x109/L (for at least 
48 consecutive hours) in participants who had values outside 
this range. 
Abbreviation: CI, continuous infusion; ICU, intensive care unit; MIC, minimum inhibitory 
concentration; PK/PD, pharmacokinetic/pharmacodynamic; WCC, white cell count. 
Legend:  
aClinical cure was evaluated by a blinded clinician if the participant was still in the ICU or by 
blinded review of the medical records if the participant was discharged from the ICU.   
bPharmacokinetic/pharmacodynamic (PK/PD) analysis only included participants with complete 
pharmacokinetic data (i.e., those who had both trough and mid-interval concentrations collected on 
both sampling days). 
cPK/PD analysis was performed on Days 1 and 3 post-randomization. 
dWhere a pathogen was isolated, the “surrogate MIC” was defined by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) MIC90 data. Where no pathogen was formally 
identified, the MIC breakpoints for P. aeruginosa (8 mg/L for cefepime, 2 mg/L for meropenem 
and 16 mg/L for piperacillin/tazobactam) were inferred as the “surrogate MIC”. Participants who 
were infected with beta-lactam resistant pathogens were excluded from PK/PD analysis. 
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For the secondary end-point of PK/PD target attainment, assessment was made by comparing the 
unbound (free) beta-lactam concentrations against the “surrogate MIC” of the pathogen. This MIC 
was inferred from EUCAST database. PK/PD target attainment was evaluated as a dichotomous 
variable and scored as a “Yes” if measured drug concentration exceeded pathogens “surrogate 
MIC”. Only participants with complete PK data were included in the analysis (i.e., those who had 
both trough and mid-interval drug concentrations collected on Days 1 and 3 post-randomization). 
Participants who were infected with beta-lactam resistant pathogens were excluded from the PK/PD 
analysis. 
 
Independent investigators who were blinded to treatment allocation, patient care and management 
assessed the end-points of interest. These investigators were not working in the participating ICUs 
during this study. 
 
Demographic, clinical and treatment-related variables were collected. Microbiological cultures were 
collected from the most likely infection site immediately before or during antibiotic treatment. CLCR 
was estimated using the Cockcroft-Gault formula [341]. APACHE II [340] and SOFA [52] scores 
were calculated and recorded within 24 hours of ICU admission. Comorbidity was scored using the 
Charlson comorbidity index [415].  Adverse events during the study period were recorded and 
evaluated as “almost certainly”, “probably”, “possibly”, or “unlikely” to be caused by study 
antibiotics [416]. Data were collected until participants were discharged from hospital or death. 
 
6.2.3.5     Pharmacokinetic sampling and bioanalysis 
PK sampling was coordinated by unblinded investigators and was performed on Days 1 and 3 post-
randomization. Blood (5 mL) was collected into lithium-heparinised tubes. For participants in the 
IB arm, mid-dosing interval and trough concentrations were collected. For participants in the CI 
arm, two blood samples were taken at least 12 hours apart. All blood samples were immediately 
refrigerated at 4°C and within 1 hour, centrifuged at 3000 rpm for 10 minutes to separate plasma. 
Plasma samples were frozen at -80°C within 24 hours of collection. Frozen plasma samples were 
shipped on dry ice by a commercial courier and assayed at the BTCCRC, the University of 
Queensland, Australia. 
 
Beta-lactam concentration in plasma was measured, after protein precipitation, by a validated HPLC 
method with ultraviolet detection [417], on a Shimadzu Prominence (Shimadzu Corporation, Kyoto, 
Japan) instrument. Samples were assayed in batches, alongside calibration standards and quality 
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control replicates at high, medium and low concentrations. All bioanalysis techniques were 
conducted in accordance with regulatory standards [342]. Observed concentrations were corrected 
for protein binding using published protein binding values (20% for cefepime, 2% for meropenem 
and 30% for piperacillin) [99]. 
 
6.2.3.6     Sample size calculations 
A sample size of 120 participants (60 in each treatment arm) was estimated to demonstrate a 
statistical significant difference in the primary end-point (power 0.8, alpha 0.05). For clinical cure, 
75% of patients in the intervention arm versus 45% in the control arm were estimated to achieve 
clinical cure [166]. The final study sample size was increased to 140 participants (70 in each arm) 
factoring in a 15-20% drop-out rate.   
 
6.2.3.7     Statistical analysis 
Statistical analyses were primarily performed on the ITT population. A mITT analysis was also 
performed in all participants who received at least one dose of study antibiotic. A per-protocol (PP) 
analysis was performed in all participants who received study antibiotic for ≥4 days. 
 
Data are presented as median values with IQR for continuous variables and number and percentage 
for categorical variables. Differences in free plasma antibiotic concentration and free plasma 
antibiotic concentration to MIC ratio in the ITT population were analysed using a Mann-Whitney U 
test and are graphically presented as box (median and IQR) and whisker (10-99 percentile) plots. 
Primary and secondary end-points were compared between the two treatment arms using a 
Pearson’s chi-square test or a Mann-Whitney U test as appropriate. For the primary end-point, sub-
group analyses (determined a priori) were performed according to the study beta-lactams used, 
concomitant antibiotic treatment, infection sites and A. baumannii or P. aeruginosa infection. For 
ICU-free days and ventilator-free days, results are presented for ICU survivors. A Kaplan-Meier 
survival curve was constructed to compare survival trends at Day 14 and Day 30 in the ITT 
population. Comparison of survival between the two treatment arms was performed using a log-
rank test with the hazard ratio (HR) and 95% confidence interval reported. A multivariate logistic 
regression was constructed to identify significant predictors associated with cure, with OR and 95% 
confidence interval reported. Biologically-plausible variables with a p-value ≤0.15 on univariate 
analysis were considered for model building. A two-sided p-value of <0.05 was considered 
statistically significant in all analyses. Statistical analysis was performed using IBM SPSS Statistics 
22 (IBM Corporation, Armonk, New York). 
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6.2.4      Results 
6.2.4.1     Baseline demographics and clinical characteristics 
Participants were recruited from April, 2013 to July, 2014. The sites enrolled 55 and 85 
participants, respectively. Two hundred and twenty patients were assessed for eligibility of whom 
140 were randomized and 134 received at least one dose of the study antibiotic. One hundred and 
twenty-six participants received ≥4 days of randomized treatment. The BLISS study CONSORT 
flow diagram is presented in Figure 6-1 and details that the most common reason for patient 
exclusion was presence of RRT on assessment (n = 32). The baseline characteristics of the ITT 
population are presented in Table 6-3. 
 
 
Figure 6-1: The BLISS study CONSORT flow diagram 
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Table 6-3: Baseline demographic and clinical characteristics of the intention-to-treat 
population 
Characteristic Intervention 
(n = 70) 
Control 
(n = 70) 
Age (years) 54 (42-63) 56 (41-68) 
Male, n (%) 46 (66) 50 (71) 
Body weight (kg) 70 (59-80) 65 (59-75) 
Body mass index (kg/m2) 27 (23-30) 24 (22-29) 
APACHE II 21 (17-26) 21 (15-26) 
SOFA 8 (6-10) 7 (5-9) 
Charlson comorbidity index 3 (1-5) 4 (2-6) 
Serum creatinine concentration (µmol/L) 111 (73-118) 92 (59-158) 
Cockcroft-Gault creatinine clearance (mL/min) 64 (43-98) 72 (41-122) 
Pre-randomization ICU stay (days) 2 (2-5) 3 (2-6) 
Pre-randomization antibiotic therapy, n (%) 52 (74) 56 (80) 
Pre-randomization appropriate antibiotic therapy, n (%)a 38 (79) 41 (73) 
Post-randomization ICU stay (days) 8 (5-10) 6 (4-13) 
Duration of randomized treatment (days) 7 (5-9) 7 (5-9) 
Mechanically-ventilated, n (%) 66 (52) 61 (48) 
Post-randomization renal replacement therapy, n (%) 15 (21) 12 (17) 
White cell count (x 109/L) 17 (13-25) 15 (13-20) 
Study antibiotic, n (%)   
   Piperacillin/tazobactam 38 (54) 47 (67) 
   Meropenem 21 (30) 21 (30) 
   Cefepime 11 (16) 2 (3.0) 
Pharmacokinetic sampling, n (%)b   
   Piperacillin/tazobactam 35 (92) 37 (79) 
   Meropenem 19 (91) 17 (81) 
   Cefepime 9 (82) 2 (100) 
Concomitant antibiotic, n (%) 33 (47) 33 (47) 
   Azithromycin 13 (19) 12 (17) 
   Vancomycin 6 (9) 12 (17) 
   Metronidazole 6 (9) 10 (6) 
   Clindamycin 2 (3) 4 (6) 
   Aminoglycosides 3 (4) 3 (4) 
   Colistin 1 (1) 1 (1) 
   Otherc 7 (10) 5 (7) 
Primary infection site, n (%)   
   Lung 46 (66) 36 (51) 
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   Intra-abdominal 11 (16) 15 (21) 
   Blood 4 (6) 6 (9) 
   Urinary tract 2 (3) 3 (4) 
   Skin or skin structure 6 (9) 7 (10) 
   Central nervous system 1 (1) 3 (4) 
Organ dysfunction, n (%)   
   Respiratory 46 (66) 44 (63) 
   Cardiovascular 40 (57) 37 (53) 
   Hematologic 18 (26) 12 (17) 
   Renal 17 (24) 10 (14) 
   Metabolic acidosis 4 (6) 3 (4) 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care 
unit; SOFA, Sequential Organ Failure Assessment. 
*Data are presented as median (interquartile range) or number (percentage). 
Legend: 
aAppropriate antibiotic therapy was assumed if a participant received at least one antibiotic (24 
hours before study inclusion) which was effective against the isolated pathogen(s). Only 
participants who had at least one organism identified was assessed (n = 104; intervention = 48, 
control = 56).    
bParticipants who had complete pharmacokinetic data i.e., those who had mid-dose and trough 
concentrations on both sampling occasions. 
cIncludes cloxacillin (n = 7), doxycycline (n = 2), co-trimoxazole (n = 2) and ciprofloxacin (n = 1). 
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The allocation of beta-lactam antibiotics was comparable between the treatment arms except for 
cefepime where 11 participants were allocated to the intervention arm and only 2 to the control arm. 
The median 24-hour antibiotic dose was not different between the intervention and control arms: 
cefepime 6 g (IQR: 6-6) versus 6 g (2 participants), meropenem 3 g (IQR: 3-3) versus 3 g (IQR: 3-
3) and piperacillin/tazobactam 18 g (IQR: 18-18) versus 18 g (IQR: 9-18), respectively. The median 
antibiotic treatment course was 7 days (IQR: 5-9) in both treatment arms. Thirty-three participants 
(47%) in both treatment arms received concomitant antibiotic therapy as part of their treatment. The 
median ICU stay was 8 days (IQR: 5-10) for participants in the intervention arm and 6 days (IQR: 
4-13) in the control arm (p = 0.544). The median ventilator days were 6 (IQR: 3-7) and 5 (IQR: 3-
11) for participants in the intervention and control arms (p = 0.662), respectively. There was no 
difference between the groups of proportion of patients with appropriate initial therapy. 
 
Microbiological characteristics of the ITT population are shown in Table 6-4.  Forty-eight 
participants (69%) in the CI arm and 56 participants (80%) in the IB arm had at least one causative 
pathogen identified before or during the course of treatment. Eighteen participants (34%) in the CI 
arm and 26 participants (46%) in the IB arm had polymicrobial infections during the course of 
treatment. The most prevalent Gram-negative pathogens in the intervention arm were P. aeruginosa 
(37%) and A. baumannii (25%) and for the control arm, A. baumannii (31%) and Klebsiella 
pneumoniae (23%). There were 9 participants (6%) who had a non-susceptible pathogen identified 
as the primary causative organism: intervention arm 6 participants (9%) versus control arm 3 
participants (4%). The median “surrogate MIC” values were similar in both treatment arms: 8 mg/L 
(IQR: 4-8) for cefepime, 2 mg/L (IQR: 2-2) for meropenem, and 16 mg/L (IQR: 8-16) for 
piperacillin/tazobactam. 
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Table 6-4: Microbiological characteristics of the intention-to-treat population 
Characteristic Intervention 
(n = 70) 
Control 
(n = 70) 
Participants who had organisms identified, n (%) 48 (69) 56 (80) 
Gram-positive, n (%) 12 (20) 25 (33) 
   Staphylococcus aureus 5 (42) 11 (44) 
   Staphylococcus epidermidis 4 (33) 6 (24) 
   Enterococcus faecalis 0 (0) 3 (12) 
   Streptococcus intermedius 1 (8) 2 (8) 
   Streptococcus pneumoniae 2 (17) 1 (4) 
   Mycoplasma pneumoniae 0 (0) 2 (8) 
   Enterococcus faecium 0 (0) 1 (4) 
   Streptococcus anginosus 0 (0) 1 (4) 
   Streptococcus constellatus 0 (0) 1 (4) 
Gram-negative, n (%) 49 (80) 52 (68) 
   Acinetobacter baumannii 12 (25)a 16 (31)b 
   Pseudomonas aeruginosa 18 (37) 10 (19) 
   Klebsiella pneumoniae 9 (18)c 12 (23) 
   Escherichia coli 5 (10)d 5 (10) 
   Proteus mirabilis 2 (4) 2 (4) 
   Bulkholderia cepacia 1 (2) 1 (2) 
   Chlamydophila pneumoniae 0 (0) 2 (4) 
   Stenotrophomonas maltophilia 1 (2) 1 (2) 
   Bulkholderia pseudomallei 1 (2) 0 (0) 
   Enterobacter aerogenes 0 (0) 1 (2) 
   Morganella morganii 0 (0) 1 (2) 
   Serratia marcescens 0 (0) 1 (2) 
Polymicrobial infection, n (%) 18 (38) 26 (46) 
Legend: 
aFour isolates were multi-drug resistant A. baumannii. 
bThree isolates were multi-drug resistant A. baumannii. 
cOne isolate was extended-spectrum beta-lactamase (ESBL) K. pneumoniae. 
 
6.2.4.2     Outcome measures 
Primary and secondary end-points in the ITT population and the clinical outcome for the sub-groups 
of interest are presented in Table 6-5. Participants in the intervention arm had higher clinical cure 
rates and shorter median time to WCC normalization. The number needed to treat with CI to 
improve the likelihood of clinical cure is three patients. Additionally, CI administration 
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demonstrated higher clinical cure rates than IB dosing in participants who had respiratory infection, 
participants who received piperacillin/tazobactam and in those without concomitant antibiotic 
treatment (Table 6-5). Differences in PK/PD target attainment rates were significantly higher in the 
intervention group at 100% fT>MIC on Day 1 and Day 3 post-randomization. At 28 days, there was 
no difference in median ICU-free days but median ventilator-free days were significantly higher in 
the participants of the intervention arm. There was no difference in survival at 14 days or 30 days 
between the treatment arms (Figure 6-2). 
 
Findings in the mITT and PP population were similar to those reported in the ITT population and 
the primary and secondary end-points for these groups are presented in Tables 6-6 and 6-7. 
 
6.2.4.3     Outcome measures predictors 
Significant predictors associated with clinical cure in the ITT population are presented in Tables 6-8 
and 6-9. Based on the most parsimonious logistic regression model, CI administration of beta-
lactam antibiotics (OR 3.21, 95% confidence interval 1.48-6.94; p = 0.003), pre-randomization 
antibiotic therapy (OR 2.85, 95% confidence interval 1.12-7.23; p  = 0.028), non-bacteraemia 
related infection (OR 11.73, 95% confidence interval 1.30-105.94; p = 0.028), lower APACHE II 
score (OR 0.95, 95% confidence interval 0.90-0.99; p = 0.036), and meropenem (OR 6.54, 95% 
confidence interval 1.48-28.90; p = 0.013) or piperacillin/tazobactam administration (OR 4.21, 95% 
confidence interval 1.06-16.64; p = 0.041) (as opposed to cefepime administration) were all 
statistically significant predictors for clinical cure. 
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Table 6-5: Primary and secondary end-points by treatment arm in the intention-to-treat population and the sub-groups of interest  
Primary end-point Intervention  
(n = 70) 
Control  
(n = 70) 
Absolute difference 
(95% CI) 
Significance  
(p-value)a,b 
Clinical cure for ITT population, n (%) 39 (56) 24 (34) 22 (-0.4 to -0.1) 0.011 
   Clinical cure by antibiotic, n (%)c     
             Piperacillin/tazobactam 22 (58) 15 (32) 26 (-0.4 to -0.1) 0.016 
             Meropenem 14 (67) 8 (38) 29 (-0.5 to 0.1) 0.064 
             Cefepime 3 (27) 1 (50) 23 (-0.3 to 0.7) 1.000 
   Clinical cure by concomitant antibiotic treatment, n (%)d     
             Yes 14 (42) 13 (39) 3 (-0.3 to 0.2) 0.802 
             No 25 (68) 11 (30) 38 (-0.6 to -0.2) 0.001 
   Clinical cure by site of infection, n (%)e     
             Lung 27 (59) 12 (33) 25 (-0.4 to -0.1) 0.022 
   Clinical cure by A. baumannii or P. aeruginosa infection, n 
(%)f 
    
             Yes 13 (52) 6 (25) 27 (-0.5 to 0.1) 0.052 
             No 10 (44) 12 (38) 6 (-0.3 to 0.2) 0.655 
     
Secondary end-points Intervention  
(n = 70) 
Control  
(n = 70) 
Absolute difference 
(95% CI) 
Significance  
(p-value)a,b 
PK/PD target attainment, n (%)g     
   50% fT>MIC on day 1 56 (98) 49 (93) 5 (-0.2 to 0.1) 0.194 
   100% fT>MIC on day 1 55 (97) 37 (70) 27 (-0.4 to -0.1) <0.001 
   50% fT>MIC on day 3 56 (98) 49 (93) 5 (-0.2 to 0.1) 0.194 
   100% fT>MIC on day 3 55 (97) 36 (68) 29 (-0.4 to -0.1) <0.001 
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   ICU-free days 20 (12-23) 17 (0-24) 3 (-4 to 1) 0.378 
      ICU survivorsh 21 (19-23) 21 (14-24) (-2 to 2) 0.824 
   Ventilator-free days 22 (0-24) 14 (0-24) 8 (-7 to 0) 0.043 
      ICU survivorsi 23 (21-25) 21 (0-25) 2 (-6 to 0) 0.076 
   14-day survival, n (%) 56 (80) 50 (71) 9 (-0.2 to 0.1) 0.237 
   30-day survival, n (%) 52 (74) 44 (63) 11 (-0.3 to 0.1) 0.145 
   WCC normalization days 3 (2-7) 8 (4-15) 5 (1 to 5) <0.001 
Abbreviation: CI, confidence interval; ICU, intensive care unit; ITT, intention-to-treat; PK/PD, pharmacokinetic/pharmacodynamic; WCC, white cell 
count; 50% fT>MIC, unbound (free) plasma concentration at 50% of the dosing interval (mid-interval concentration) was above the causative pathogens 
MIC; 100% fT>MIC, unbound (free) plasma concentration at 100% of the dosing interval (trough concentration) was above the causative pathogens 
MIC. 
Legend:  
aRepresents the p-value between the intervention arm versus the control arm and values in bold indicate significant difference between the two 
treatment arms (p <0.05). 
bContinuous variables were compared using Mann-Whitney U test as data were non-normally distributed as indicated by Kolmogorov-Smirnov test. 
Dichotomous variables were compared using Pearson chi-square test or Fisher’s exact test as appropriate. 
cNumber of participants analysed: (1) piperacillin/tazobactam (n = 85; intervention = 38, control = 47), (2) meropenem ( n = 42; intervention = 21, 
control = 21), and (3) cefepime (n = 13; intervention = 11, control = 2). 
dNumber of participants analysed: (1) patients who received concomitant antibiotics ( n = 66; intervention = 33, control = 33) and (2) patients who did 
not receive concomitant antibiotics (n = 74; intervention = 37, control = 37). 
eNumber of participants analysed: lung (n = 82; intervention = 46, control = 36). 
fNumber of participants analysed: (1) A. baumannii or P. aeruginosa infection (n = 49; intervention = 25, control = 24) and (2) other infections (n = 
55; intervention =23, control = 32).  
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gOnly participants with complete pharmacokinetic data (n = 119; intervention = 63, control = 56) and those who were infected with beta-lactam 
susceptible pathogens (n = 110; intervention = 57, control = 53) were included in the analysis. 
hOnly participants who survived at ICU discharge was included in this sub-analysis (57 and 53 participants in the intervention and control arm, 
respectively). 
iOnly mechanically-ventilated participants who survived at ICU discharge was included in this sub-analysis (53 and 46 participants in the intervention 
and control arm, respectively). 
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Table 6-6: Primary and secondary end-points by treatment arm in the modified intention-to-treat population 
Primary end-point Intervention  
(n = 68) 
Control  
(n = 66) 
Absolute difference 
(95% CI) 
Significance  
(p-value)a,b 
Clinical cure for mITT population, n (%)     
   Clinical cure, n (%) 39 (57.4) 23 (34.8) 22.5 (-0.4 to -0.1) 0.009 
     
Secondary end-points Intervention  
(n = 68) 
Control  
(n = 66) 
Absolute difference 
(95% CI) 
Significance 
(p-value)a,b 
PK/PD target attainment, n (%)c     
   50% fT>MIC on day 1 54 (98.2) 48 (94.1) 4.1 (-0.1 to 0.1) 0.350 
   100% fT>MIC on day 1 53 (96.4) 37 (72.5) 23.9 (-0.4 to -0.1) 0.001 
   50% fT>MIC on day 3 54 (98.2) 48 (94.1) 4.1 (-0.1 to 0.1) 0.350 
   100% fT>MIC on day 3 53 (96.4) 36 (70.6) 25.8 (-0.4 to -0.1) <0.001 
     
   ICU-free days 20 (11-23) 16 (0-23) 4 (-4 to 0) 0.287 
      ICU survivorsd 21 (19-23) 21 (12-24) 0 (-3 to 1) 0.565 
   Ventilator-free days 22 (0-24) 14 (0-24) 8 (-7 to 1) 0.045 
      ICU survivorse 23 (21-25) 20 (0-25) 3 (-6 to 0) 0.050 
   14-day survival, n (%) 54 (79.4) 47 (71.2) 8.2 (-0.2 to 0.1) 0.271 
   30-day survival, n (%) 50 (73.5) 42 (63.6) 9.9 (-0.2 to 0.1) 0.217 
   WCC normalization days 3 (2-7) 8 (4-15) 5 (1-5) <0.001 
Abbreviation: CI, confidence interval; ICU, intensive care unit; mITT, modified intention-to-treat population; PK/PD, 
pharmacokinetic/pharmacodynamic; WCC, white cell count; 50% fT>MIC, unbound (free) plasma concentration at 50% of the dosing interval (mid-
interval concentration) was above the causative pathogens MIC; 100% fT>MIC, unbound (free) plasma concentration at 100% of the dosing interval 
(trough concentration) was above the causative pathogens MIC. 
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Legend: 
aRepresents the p-value between the intervention arm versus the control arm and values in bold indicate significant difference between the two 
treatment arms (p <0.05). 
bContinuous variables were compared using Mann-Whitney U test as data were non-normally distributed as indicated by Kolmogorov-Smirnov test. 
Dichotomous variables were compared using Pearson chi-square test or Fisher’s exact test as appropriate. 
cOnly participants with complete pharmacokinetic data (n = 115; intervention = 61, control = 54) and those who were infected with beta-lactam 
susceptible pathogens (n = 106; intervention = 55, control = 51) were included in the analysis. 
dOnly participants who survived at ICU discharge was included in this sub-analysis (55 and 50 participants in the intervention and control arm, 
respectively). 
eOnly mechanically-ventilated participants who survived at ICU discharge was included in this sub-analysis (52 and 43 participants in the intervention 
and control arm, respectively). 
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Table 6-7: Primary and secondary end-points by treatment arm in the per-protocol population 
Primary end-point Intervention  
(n = 66) 
Control  
(n = 60) 
Absolute difference 
(95% CI) 
Significance  
(p-value)a,b 
Clinical cure for PP population, n (%)     
   Clinical cure, n (%) 39 (59.1) 20 (33.3) 25.8 (-0.4 to -0.1) 0.004 
     
Secondary end-points Intervention  
(n = 66) 
Control  
(n = 60) 
Absolute difference 
(95% CI) 
Significance 
(p-value)a,b 
PK/PD target attainment, n (%)     
   50% fT>MIC on day 1 54 (98.2) 42 (93.6) 4.6 (-0.2 to 0.1) 0.332 
   100% fT>MIC on day 1 53 (96.4) 34 (72.3) 24.1 (-0.4 to -0.1) 0.001 
   50% fT>MIC on day 3 54 (98.2) 42 (93.6) 4.6 (-0.2 to 0.1) 0.332 
   100% fT>MIC on day 3 53 (96.4) 34 (72.3) 24.1 (-0.4 to -0.1) 0.001 
     
   ICU-free days 20 (12-23) 17 (0-23) 3 (-4 to 0) 0.276 
      ICU survivorsd 21 (19-23) 21 (14-24) 0 (-3 to 1) 0.662 
   Ventilator-free days 22 (0-24) 14 (0-24) 8 (-7 to 0) 0.025 
      ICU survivorse 23 (21-25) 19 (1-25) 4 (-7 to 0) 0.027 
   14-day survival, n (%) 53 (80.3) 42 (70.0) 10.3 (-0.3 to 0.1) 0.180 
   30-day survival, n (%) 49 (74.2) 38 (63.3) 10.9 (-0.3 to 0.1) 0.186 
   WCC normalization days 3 (2-6) 8 (5-15) 5 (2 to 5) <0.001 
Abbreviation: CI, confidence interval; ICU, intensive care unit; PK/PD, pharmacokinetic/pharmacodynamic; PP, per-protocol; WCC, white cell 
count; 50% fT>MIC, unbound (free) plasma concentration at 50% of the dosing interval (mid-interval concentration) was above the causative pathogens 
MIC; 100% fT>MIC, unbound (free) plasma concentration at 100% of the dosing interval (trough concentration) was above the causative pathogens 
MIC. 
148 
 
aRepresents the p-value between the intervention arm versus the control arm and values in bold indicate significant difference between the two 
treatment arms (p <0.05). 
bContinuous variables were compared using Mann-Whitney U test as data were non-normally distributed as indicated by Kolmogorov-Smirnov test. 
Dichotomous variables were compared using Pearson chi-square test or Fisher’s exact test as appropriate. 
cOnly participants with complete pharmacokinetic data (n = 110; intervention = 60, control = 50) and those who were infected with beta-lactam 
susceptible pathogens (n = 102; intervention = 55, control = 47) were included in the analysis. 
dOnly participants who survived at ICU discharge was included in this sub-analysis (54 and 45 participants in the intervention and control arm, 
respectively). 
eOnly mechanically-ventilated participants who survived at ICU discharge was included in this sub-analysis (51 and 40 participants in the intervention 
and control arm, respectively). 
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Table 6-8: Differences in clinical characteristics and treatment-related variables between participants who demonstrated clinical cure 
and clinical failure in the ITT population 
Variable Cure (n = 63) Failure (n = 77) p-valuea,b 
Age (years) 55 (45-63) 53 (40-68) 0.774 
Male, n (%) 46 (73.0) 50 (64.9) 0.306 
Body weight (kg) 70 (56-80) 68 (60-75) 0.875 
Body mass index (kg/m2) 25 (22-30) 25 (22-29) 0.793 
APACHE II 19 (16-22) 23 (17-28) 0.009* 
SOFA 7 (6-9) 8 (5-10) 0.695 
Charlson comorbidity index 3 (2-5) 4 (2-6) 0.126* 
Serum albumin (g/dL) 26 (21-30) 22 (17-28) 0.037* 
Serum creatinine concentration (µmol/L) 94 (63-176) 120 (66-165) 0.697 
Cockcroft-Gault creatinine clearance (mL/min) 68 (50-115) 59 (38-97) 0.268 
Pre-randomization ICU stay (days) 2 (2-5) 3 (2-6) 0.580 
Pre-randomization antibiotic therapy, n (%) 24 (28.1) 34 (44.2) 0.469 
Pre-randomization appropriate antibiotic therapy, n (%) 34 (82.9) 45 (71.4) 0.180 
Duration of randomized treatment (days) 7 (6-9) 6 (4-8) 0.040* 
Mechanically-ventilated, n (%) 57 (90.5) 70 (90.9) 0.930 
Post-randomization renal replacement therapy, n (%) 7 (11.1) 20 (26.0) 0.027* 
Surgery within 24 hours of study inclusion, n (%)  24 (38.1) 34 (44.2) 0.469 
White cell count (x 109/L) 16 (13-21) 16 (14-21) 0.769 
Pre-randomization antibiotic therapy, n (%) 44 (69.8) 64 (83.1) 0.063* 
Study antibiotic, n (%)    
   Piperacillin/tazobactam 37 (58.7) 48 (62.3) 0.357 
   Meropenem 22 (34.9) 20 (26.0)  
   Cefepime 4 (6.3) 9 (11.7)  
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Concomitant antibiotic use, n (%) 27 (42.9) 39 (50.6) 0.358 
    
Treatment    
   Continuous infusion 39 (61.9) 31 (40.3) 0.011* 
   Intermittent bolus 24 (38.1) 46 (59.7)  
    
Primary infection site, n (%)    
   Lung 39 (61.9) 43 (55.8) 0.469 
   Intra-abdominal 13 (20.6) 13 (16.9) 0.570 
   Blood 1 (1.6) 9 (11.7) 0.023* 
   Urinary tract 3 (4.8) 2 (2.6) 0.657 
   Skin or skin structure 6 (9.5) 7 (9.1) 0.930 
   Central nervous system 1 (1.6) 3 (3.9) 0.627 
    
Organ dysfunction, n (%)    
   Respiratory 40 (63.5) 50 (64.9) 0.859 
   Cardiovascular 37 (58.7) 40 (51.9) 0.422 
   Hematologic 13 (20.6) 17 (22.1) 0.836 
   Renal 13 (20.6) 14 (18.2) 0.714 
   Metabolic acidosis 4 (6.3) 3 (3.9) 0.701 
    
Participants who had organisms identified, n (%) 41 (65.1) 63 (81.8) 0.024* 
Gram-negative infections, n (%) 35 (85.4) 45 (71.4) 0.099* 
PK/PD ratio    
   Concentration at 50% of the dosing interval to MIC D1 5.8 (3.4-15.0) 6.5 (3.6-16) 0.547 
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   Concentration at 100% of the dosing interval to MIC D1 4.5 (2.1-12.4) 4.7 (2.1-10.1) 0.823 
   Concentration at 50% of the dosing interval to MIC D3 7.9 (3.8-17.0) 6.9 (13.2-16.1) 0.583 
   Concentration at 100% of the dosing interval to MIC D3 6.3 (2.2-13.8) 4.2 (1.7-12.8) 0.282 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; MIC, minimum inhibitory concentration; 
PK/PD, pharmacokinetic/pharmacodynamic; SOFA, Sequential Organ Failure Assessment. 
*Data are presented as median (interquartile range) or number (percentage). 
Legend: 
aBold values indicate statistical significance (p <0.05). 
bRepresents variable that was included in the multivariate logistic regression model. 
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Table 6-9: Factors predicting clinical cure in the ITT population 
Variable All factors included in the model Final model 
 Odds ratio  
(95% CI) 
Significance  
(p-value) 
Odds ratio  
(95% CI) 
Significance  
(p-value) 
Factors predicting clinical cure     
   Continuous infusiona 3.08 (1.38-6.94) 0.007 3.21 (1.48-6.94) 0.003 
   Bacteremiab 0.10 (0.01-0.92) 0.042 0.09 (0.09-0.770) 0.028 
   Pre-randomization antibiotic therapyc  2.74 (1.02-7.32) 0.045 2.85 (1.12-7.23) 0.028 
   APACHE II score (per 1-point increase) 0.95 (0.90-1.00) 0.060 0.95 (0.90-0.99) 0.036 
   Study drugd  0.075  0.047 
      Piperacillin/tazobactam 4.15 (1.01-17.01) 0.049 4.21 (1.06-16.64) 0.041 
      Meropenem 6.04 (1.28-28.47) 0.023 6.54 (1.48-28.90) 0.013 
      Cefepime 1.0 - 1.0 - 
   Causative organism identifiede 0.54 (0.22-1.33) 0.180 - - 
   Duration of randomized treatment (per 1-day increase) 1.04 (0.98-1.09) 0.208 - - 
   Albumin (per 1 g/dL increase) 1.02 (0.96-1.08) 0.597 - - 
   Charlson comorbidity index (per 1-point increase) 0.98 (0.85-1.13) 0.781 - - 
Goodness-of-fit     
Hosmer-Lemeshow test X2 = 6.96, df = 8 0.541 X2 = 3.843, df = 8 0.871 
Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; df, degree of freedom; X2, chi-square. 
*Bold values indicate statistical significance (p <0.05). 
Legend:  
aOR compares continuous infusion relative to IB dosing of beta-lactam antibiotics. 
bOR compares bacteraemia relative to other sites of infections. 
cOR compares those who received pre-randomization antibiotic therapy relative to those who did not. 
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dOR compares piperacillin/tazobactam and meropenem relative to cefepime. 
eOR compares those who had at least one causative organism identified relative to those who did not. 
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6.2.4.4     Pharmacokinetic/pharmacodynamic data 
The data describing free (unbound) plasma antibiotic concentration and free (unbound) plasma 
antibiotic concentration to MIC ratio are presented in Figures 6-2 and 6-3, respectively. Plasma 
antibiotic concentrations measured at 50% and 100% of the dosing interval were relatively higher in 
the intervention group on Day 1 and Day 3 post-randomization (Figure 6-2). The ratio of plasma 
antibiotic concentration to MIC was also relatively higher in the intervention group on both 
sampling days for all study antibiotics (Figure 6-3). 
 
 
Figure 6-2: Free plasma antibiotic concentration by beta-lactam antibiotics and treatment 
groups measured at (a) 50% of the dosing interval on Day 1 (b) 100% of the dosing interval 
on Day 1 (c) 50% of the dosing interval on Day 3 and (d) 100% of the dosing interval on Day 3 
Abbreviation: CI, continuous infusion; IB, intermittent bolus.  
*Median, interquartile range and range are presented. 
**An asterisk indicates a significant difference between continuous infusion and intermittent bolus 
dosing (p <0.05). 
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Figure 6-3: Free plasma antibiotic concentration to minimum inhibitory concentration (MIC) 
ratio by beta-lactam antibiotics and treatment groups measured at (a) 50% of the dosing 
interval on Day 1 (b) 100% of the dosing interval on Day 1 (c) 50% of the dosing interval on 
Day 3 and (d) 100% of the dosing interval on Day 3 
Abbreviation: CI, continuous infusion; IB, intermittent bolus. 
*Median, interquartile range and range are presented. 
**An asterisk indicates a significant difference between continuous infusion and intermittent bolus 
dosing. 
***PK/PD ratio is defined as the ratio between the measured plasma antibiotic concentration at 
50% or 100% of the dosing interval and the causative pathogen’s “surrogate MIC” (i.e., not actual 
MIC values), as defined in Table 6-2. Note that a ratio of 1 at 100% of the dosing interval is 
generally considered to be a minimum PK/PD target during beta-lactam therapy. 
 
6.2.4.5     Adverse events 
No adverse events occurred during study participation. A total of 18 deaths occurred during receipt 
of the study drug: CI arm 7 participants versus IB arm 11 participants. 
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6.2.5 Discussion 
In this RCT, we found that continuous beta-lactam infusion demonstrated higher clinical cure rates 
and better PK/PD target attainment compared to IB dosing in critically ill patients with severe 
sepsis. Other significant benefits for CI participants in two other surrogate clinical end-points were 
increased ventilator-free days and a reduced time to WCC normalization. Given that these results 
were derived from a population of ICU patients with severe sepsis, who were not on extra-corporeal 
renal support, our findings provide further evidence that CI of beta-lactam antibiotics are likely to 
be beneficial for patients with a high level of illness severity not receiving RRT. Although three 
recent RCTs have also reported similar findings [166, 242, 243], our current work remains unique 
considering that we recruited patients from a different geographical region, one which is rarely 
investigated but commonly associated with higher illness severity, than those commonly reported.  
 
Clinical evidence supporting improved patient outcome with CI of beta-lactams has been mixed, 
varying from no significant effect [151, 172, 241, 256-258] to significant patient benefits [166, 242, 
243, 248, 254, 266]. We would note that there is yet to be a report suggesting inferior patient 
outcomes when CI is used. Meta-analyses of the above prospective clinical studies have failed to 
comprehensively demonstrate the superiority of CI over IB dosing in terms of clinical cure and 
patient survival [217, 240, 267]. However, a particularly noteworthy feature in most of these studies 
has been the inclusion of non-critically ill patients, whereas the patients who may be most likely to 
benefit from CI dosing are critically ill patients with high illness severity [166, 242]. Critically ill 
patients, particularly those with severe sepsis, commonly develop extreme physiological 
derangements, which may severely reduce antibiotic exposure, particularly when IB dosing is 
employed [7, 291]. Patients that received beta-lactams via CI dosing in our study were ten-times 
more likely to achieve 100% fT>MIC on Day 1 (p <0.001) and nine-times more likely to achieve 
100% fT>MIC on Day 3 (p <0.001). As maintaining 100% fT>MIC in critically ill patients is associated 
with improved patient outcomes [28], we believe that the observed clinical cure difference in the 
ITT analysis (absolute difference of 22%) favouring CI dosing may be partly explained by the 
relative ability of CI dosing to achieve the target PK/PD exposure more consistently than IB dosing 
in patients with severe sepsis [164, 291]. Importantly, CI participants in this study were three-times 
more likely to achieve clinical cure when compared with IB participants, even after controlling for 
confounding variables (OR 3.21, 95% confidence interval 1.48-6.94; p = 0.003). 
 
Significant advantages of CI over IB for beta-lactam antibiotics were also observed in two recent 
RCTs of critically ill patients with severe sepsis. In a prospective, multicentre, double-blind, RCT 
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(BLING I; n = 60), Dulhunty et al., [166] showed that participants in the CI treatment arm 
demonstrated greater fT>MIC (82% versus 29%; p = 0.001) and higher clinical cure rates (77% 
versus 50%; p = 0.032) compared to the IB arm. In a single-centre RCT which recruited 240 
critically ill Czech participants, Chytra et al., [242] reported higher microbiological cure rates in the 
CI treatment arm as opposed to the IB arm (91% versus 78%; p = 0.020). Neither study 
demonstrated significant mortality advantages. 
 
Despite these results, disease severity is only one of the many variables which can influence the 
outcome of CI versus IB dosing in critically ill patients. This was recently highlighted in a 
multicentre, double-blind, RCT (BLING II; n = 420) [241]. Despite recruiting only patients with 
severe sepsis, Dulhunty et al., found no significant difference between participants in both treatment 
arms, in all five clinical end-points evaluated. In their study, the absolute difference in clinical cure 
between CI and IB participants was 3% in favour of CI dosing compared with the 22% in the 
present BLISS study. In contrast to BLISS, the BLING II trial included patients receiving RRT 
(~25% of participants) and this inclusion criterion may reduce PK/PD exposure differences between 
CI and IB dosing because patients with reduced drug clearances are less likely to manifest sub-
therapeutic antibiotic exposures [244, 245] and consequently, are less likely to benefit from altered 
dosing approaches such as CI administration. Interestingly, all five clinical studies which 
demonstrated patient benefits with CI dosing only recruited critically ill patients with conserved 
renal function [166, 242, 243, 248, 254]. 
 
Other than recruiting participants with a low burden of disease, most clinical studies have also 
isolated pathogens which are highly susceptible to the study antibiotics [166, 172, 241-243, 248, 
254, 256-258, 266]. PK/PD principles states that IB dosing will be just as likely as CI to achieve 
target exposures when MICs are low [13] with treatment failures more likely with IB dosing when 
less susceptible pathogens are present [151, 290, 293]. In the present study, although actual MIC 
values were not available, 41% of the causative pathogens were either A. baumannii or P. 
aeruginosa which mostly have higher MICs to the study antibiotics [418], thereby reducing the 
likelihood of achieving therapeutic concentrations with IB dosing. However, it should also be 
highlighted that benefits of CI may not be apparent in some geographical regions with different 
microbiology and antibiotic resistance patterns. Importantly, use of combination therapy to treat 
infections caused by Gram-negative pathogens was infrequent in this study, which may differ from 
practices in other centres.    
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This study has several limitations. Participants were only recruited from two centres in one country 
which may limit the generalizability of the findings to other treatment settings. Despite the baseline 
characteristics of the treatment arms being relatively well balanced, CI participants manifested 
higher median SOFA scores on admission compared to IB participants. Even though this typically 
translates into a reduced likelihood of survival, it is possible that CI participants may have been 
selectively provided with additional monitoring in the ICU to account for their illness severity, 
which may influence clinical outcomes. Furthermore, clinical outcomes were evaluated by an 
independent investigator and unlike a specialized review committee, the former strategy may be 
more likely to introduce biased observations towards one of the treatment allocations. However, the 
possibility of bias in this study should be very low as the assessor had no knowledge of treatment 
allocation now role in patient management and was not working in the participating centres during 
the study period. We also acknowledge the limitation of the Cockcroft-Gault formula in estimating 
renal function in this cohort, and that measured CLCR would be more accurate [419]. Neither 
unbound plasma concentrations nor concentrations at the sites of infections were measured in this 
study, although all drugs have relatively low protein binding [99]. As MIC reporting is rare in 
Malaysia, we have used “surrogate MIC” values, using EUCAST MIC breakpoints, in our primary 
end-point analyses. Accordingly, this approach will exaggerate the magnitudes of PK/PD target 
non-attainment in the IB treatment arm relative to the CI arm if actual MIC values were used. 
Although actual MIC values would have been preferable, we believe that our approach resembles 
the real-life clinical approach where the MIC of a pathogen is rarely available upon antibiotic 
commencement [27]. Although data on concomitant antibiotics were available, we did not evaluate 
the PK/PD of those antibiotics. This study was not powered to test the effect of CI versus IB dosing 
on survival but has provided useful information that can be used for sample size determination of a 
larger multicentre RCT seeking to quantify any survival benefits of CI dosing. 
 
6.2.6 Conclusion 
In critically ill patients with severe sepsis not receiving RRT, CI administration was associated with 
higher clinical cure rates and better PK/PD target attainment compared to IB dosing for three 
common beta-lactam antibiotics. Our findings suggest that beta-lactam CI may be most beneficial 
for critically ill patients with a high level of illness severity, who are infected with less susceptible 
microorganisms and that are not receiving RRT. A large-scale, prospective, multinational clinical 
study is required to ascertain whether the potential benefits of continuous beta-lactam infusion do 
indeed translate into survival benefit in critically ill patients with severe sepsis. 
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6.3 Conclusion 
The findings in this chapter showed that CI of beta-lactam antibiotics demonstrated higher clinical 
cure rates and better PK/PD target attainment as opposed to IB dosing in a large cohort of critically 
ill patients with severe sepsis. Furthermore, data from the BLISS study further corroborates data 
from previous studies which suggest that CI may not improve outcomes for all critically ill patients, 
but only certain sub-populations. Based on the findings presented in this chapter, CI of beta-lactam 
antibiotics are likely to be advantageous for critically ill patients with a high level of illness severity 
who are not receiving RRT. Additionally, this alternative dosing strategy may improve the 
outcomes from severe infections which are more likely to be associated with less susceptible 
pathogens. Although the BLISS study was not powered to investigate survival benefit between the 
two dosing approaches, its data provides useful information that can be used for the design of a 
large-scale, prospective, multinational RCT to ascertain whether the perceived benefits of CI do 
indeed translate into mortality reduction in critically ill patients with severe sepsis. 
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Chapter 7: Optimizing antibiotic treatment in critically ill patients via 
pharmacokinetic/pharmacodynamic principles 
 
7.1 Synopsis 
The patterns of antibiotic resistance have significantly changed over the last few decades with 
increasing antibiotic resistance currently being regarded as one of the major health crises. 
Organisms such as E.coli and K. pneumoniae, which were previously considered relatively 
innocuous, are frequently becoming resistant to currently available antibiotics and therefore, 
treating these infections has become a challenge for clinicians world-wide. Furthermore, it was 
predicted that these worrying trends of increasing resistance will continue to progress with the 
biggest threats arising from Gram-negative pathogens. The rate at which these pathogens develop 
resistance is likely to far outpace the rate of development of new antibiotics. Abuse and overuse of 
antibiotics in hospitals, particularly in the ICU, has caused a dramatic increase in antibiotic 
resistance and this phenomenon currently threatens to shorten the clinical life-span of the existing 
antibiotic armamentarium. Clinicians now are forced to find new methods that optimize the use of 
presently available antibiotics. Although more commonly explored to maximize patient outcomes, 
emerging data are suggesting that the PD-based dosing approach is equally crucial to prevent the 
emergence of resistance by avoiding sub-optimal antibiotic dosing. The aims of this chapter are to 
describe the relevance of PK/PD characteristics of different antibiotic classes on the development of 
antibiotic resistance and to suggest alternative treatment strategies that can be employed not only to 
maximize patient outcomes but also to minimize the emergence of resistance. 
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7.2 Manuscript entitled “Applying pharmacokinetic/pharmacodynamic 
principles in critically ill patients: optimizing efficacy and reducing resistance 
development” 
The manuscript entitled “Applying pharmacokinetic/pharmacodynamic principles in critically ill 
patients: optimizing efficacy and reducing resistance development” has been accepted for 
publication in the Seminars in Respiratory and Critical Care Medicine (2015; 36(1): 136-153). 
 
The co-authors contributed to the manuscript as follows: Conception and development of the study 
design was performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. 
Jason A. Roberts, Prof. Jeffrey Lipman and Prof. Johan W. Mouton. Literature review was 
performed by the PhD candidate, Mohd-Hafiz Abdul-Aziz, under the guidance of Prof. Jason A. 
Roberts, Prof. Johan W. Mouton and Prof. William W. Hope. The PhD candidate took the leading 
role in manuscript preparation and all co-authors reviewed and contributed to the final draft of the 
manuscript. 
 
The accepted version of this manuscript is presented and incorporated in this chapter. However, 
some text, tables and figures may have been inserted at slightly different positions to fit the overall 
style of the thesis. Numbering of pages, tables and figures may also change to fit the thesis 
requirements. Manuscript references have been collated with all other references in the thesis. 
 
Permission has been granted by the publisher and copyright owner, Thieme, to reproduce the 
manuscript in this Thesis. 
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7.2.1 Abstract 
The recent surge in MDR pathogens combined with the diminishing antibiotic pipeline has created a 
growing need to optimize the use of our existing antibiotic armamentarium, particularly in the 
management of ICU patients. Optimal and timely PK/PD target attainment has been associated with 
an increased likelihood of clinical and microbiological success in critically ill patients. Emerging 
data, mostly from in vitro and in vivo studies, suggest that optimization of antibiotic therapy should 
not only aim to maximize clinical outcomes but to also include the suppression of resistance. The 
development of antibiotic dosing regimens that adheres to the PK/PD principles may prolong the 
clinical lifespan of our existing antibiotics by minimizing the emergence of resistance. This present 
article summarizes the relevance of PK/PD characteristics of different antibiotic classes on the 
development of antibiotic resistance. Based on the available data, we propose dosing 
recommendations that can be adopted in the clinical setting, in order to maximize therapeutic 
success and limit the emergence of resistance in the ICU. 
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7.2.2 Introduction 
Severe infections leading to severe sepsis and septic shock are prominent causes of morbidity and 
mortality in critically ill patients. In a large multicentre point prevalence study involving 1265 ICUs 
across 75 countries, 51% of ICU patients were classified as infected on the day of study with a 
mortality rate of 25.3% [31]. Data from a large European ICU study has further corroborated the 
diagnosis of severe sepsis as a global healthcare crisis, whereby the condition accounted for 26.7% 
of ICU admissions [33]. In this study, the corresponding mortality in patients with severe sepsis and 
septic shock were concerning with rates of 32.2% and 54.1%, respectively [33]. Despite an 
emerging trend for improved survival over recent years [29, 30, 32], the mortality rate in this patient 
cohort remains unacceptably high worldwide [1]. In the context of the financial burden incurred, the 
United States itself is currently spending between $121 and $263 billion annually on critically ill 
patients, which represents more than 8% of the country’s total healthcare expenditure [46]. 
 
To address these persisting poor patient outcomes, significant amounts of research have been 
directed towards optimizing the provision of care for the critically ill patient. Indeed improving 
antibiotic therapy is a core focus of treatment of infection-driven pathologies like sepsis. There is 
strong evidence to suggest that optimal antibiotic therapy may have a greater impact on patients’ 
survival when compared to novel treatment strategies such as the use of activated protein C [408], 
antithrombin III [420], and intensive insulin therapy in these patients [4, 421-423]. However, the 
process of optimizing antibiotic therapy can be a daunting challenge in the ICU for a variety of 
reasons. Extreme physiological derangements that can occur from either pharmacological 
interventions or the natural course of critical illness may alter antibiotic concentrations and 
consequently reduce antibiotic exposure in critically ill patients [6]. In addition, pathogens that are 
usually isolated in the ICU differ from the general wards, as they are commonly less susceptible to 
common antibiotics [334, 335]. Indeed, antibiotic dosing that does not account for these features is 
likely to lead to sub-optimal antibiotic exposure and therapeutic failures. In addition, sub-optimal 
antibiotic exposure is also highly implicated as a contributing factor to the escalation of antibiotic 
resistance. Resistance to antibiotics certainly is considered a global healthcare crisis which currently 
threatens the advances of modern medicine [148]. 
  
The recent surge in MDR pathogens combined with the diminishing antibiotic pipeline has created a 
growing need to optimize the use of the existing antibiotic armamentarium, particularly in the ICU. 
Although critically ill patients constitute fewer than 10% of all hospital admissions, their antibiotic 
consumption is 10-times greater compared to patients in all other wards [383, 424, 425]. The 
165 
 
rampant antibiotic use (or misuse) has therefore, in part, contributed to the alarming increase in the 
MDR pathogens such as the ESBL and carbapenemase-producing Gram-negative pathogens. 
Notably, Gram-negative pathogens such as A. baumannii and P. aeruginosa, as well as members of 
the Enterobacteriaceae family such as E. coli and K. pneumoniae, which were previously considered 
relatively innocuous, have impressively out-manoeuvred our current antibiotics. Previously simple 
infections have become increasingly difficult to treat over a short period of time [399]. Moreover, 
infections caused by these pathogens frequently result in poor clinical outcomes, including higher 
mortality and prolonged hospitalization [426-428]. The healthcare community concerns are 
legitimate, as the emergence of resistance is likely to far outpace the rate of development of new 
antibiotics. In light of these grim prospects, clinicians are currently forced to reintroduce older 
antibiotics as treatment options (e.g., colistin and fosfomycin) and vigorously search for new 
strategies that can optimize the use of our presently available antibiotics. 
 
The aim of this review is to describe the relevance of PK exposure and PD characteristics of 
different antibiotic classes on the development of antibiotic resistance. We will discuss the relevant 
antibiotic resistance descriptors and review how target drug exposures differ between predicting 
treatment success and suppressing resistance development. Based on the current data, we will also 
suggest dosing strategies that ultimately exploit antibiotic PD, which increase the likelihood of 
treatment success as well as minimizing the emergence of resistance. 
 
7.2.3 Applied clinical pharmacology of antibiotics 
Pharmacology is the science of drugs including the study of drug actions. Two principle areas of 
pharmacology are PK and PD. Traditionally, antibiotic dosing and administration were only 
optimized, in accordance to the PK/PD principles, for clinical efficacy (i.e., clinical and 
microbiological cure) with an associated collateral damage being the selection of resistant 
pathogens. Emerging data are suggesting that the PD-based dosing approach should not only aim to 
maximize clinical outcomes but to also include the suppression of resistance. Indeed, the 
application of PK/PD principles have been shown to minimize the risk of emergence of resistance 
by avoiding ineffective antibiotic exposure, which consequently exerts a selective pressure to 
pathogens, rather than to eradicate them [149]. This selective pressure causes the elimination of 
highly susceptible, but not the more resistant phenotypes, leading to future colonization and 
potential infection with poorly susceptible pathogens. 
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7.2.3.1     Pharmacokinetic considerations 
PK refers to the study of concentration changes of a drug over a given time period. This branch of 
pharmacology describes the rates and processes from absorption to distribution of drugs to 
elimination mechanism via metabolism or excretion. Some of the examples of important PK 
parameters are; (a) Vd, (b) CL, (c) Cmax, (d) Cmin and, (e) AUC0-24. Among these however, 
alterations in the primary PK parameters, namely Vd and CL, are probably the most influential in 
determining altered antibiotic dosing and exposure. Changes in antibiotic Vd and CL have been 
commonly observed in critically ill patients and the relevance of the two phenomena in influencing 
effective antibiotic exposure has been reviewed in detail elsewhere [7]. 
 
7.2.3.2     Pharmacodynamic considerations 
PD describes the relationship between PK exposure and pharmacological effect. For antibiotics, PD 
relates the antibiotic concentration to the ability of an antibiotic to kill or inhibit the growth of a 
pathogen. Generally, this relationship is often described by linking the concentration of an antibiotic 
with the corresponding MIC of the offending pathogen. For an antibiotic, it is the free or unbound 
concentration that is responsible for the antibacterial activity [429]. Numerous studies have 
demonstrated that different antibiotics have different PD properties and can be readily categorized 
as the following; (a) fT>MIC, (b) Cmax/MIC and, (c) AUC0-24/MIC. These fundamental PK/PD indices 
for antibiotics’ activity are further illustrated in Figure 7-1. It should be noted, that the AUC/MIC 
was never considered in earlier studies, and that many data retrieved from older literature only 
established the relationship between Cmax/MIC and effect parameter. From a theoretical point of 
view most of the antibiotics should show a relationship with AUC and effect rather than Cmax. 
  
Based on the PK/PD indices, antibiotics can be classified into three categories that by and large 
reflect their modes of bacterial killing [12, 24, 430]. The first category includes antibiotics where 
the difference between the maximum effect and minimum effect is relatively large, and increasing 
concentrations result in progressively increased killing. These are therefore also sometimes called 
concentration dependent antibiotics, and include aminoglycosides and quinolones. For these 
antimicrobials AUC/MIC describes their antibiotic activity best, and, mainly because AUC/MIC is 
closely correlated to Cmax/MIC, Cmax/MIC as well [386, 431]. On the other hand, time-dependent 
antibiotics’ activity, such as the beta-lactams, is strongly correlated with fT>MIC and as such, 
prolonging the duration of effective drug exposure should be the priority when this antibiotic class 
is used [11, 28]. However, some antibiotics such as the glycopeptides are more complex where they 
are found to display both concentration- and time-dependent kill characteristics [11]. For these  
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Figure 7-1: The graphical illustration of fundamental pharmacokinetic and pharmacodynamic parameters of antibiotics on a hypothetical 
concentration-time curve 
Abbreviation:  AUC, area under the concentration-time curve; Cmax, maximum drug concentration; Cmin, minimum drug concentration; MIC, 
minimum inhibitory concentration; T>MIC, duration of time that drug concentration remains above MIC. 
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antibiotics, the ratio of AUC0-24/MIC describes their antibiotic activity best and higher thresholds 
are closely related with successful clinical outcome [432]. 
 
7.2.4 Pharmacokinetic/pharmacodynamic considerations and the resistance 
descriptors 
Most of the earlier research on optimizing antibiotic dosing was only focused on maximizing 
clinical and microbiological cure and not minimization of the emergence of antibiotic resistance. To 
date, most of the data describing PK/PD and its association with antibiotic resistance comes from 
pre-clinical, albeit advanced, PK/PD infection models. However, the antibiotic exposure required 
for clinical efficacy and resistance suppression is markedly different. For instance, the antibiotic 
exposure-response relationship for clinical efficacy is monotonic or can also be described as a 
sigmoidal relationship in which, no measurable antibiotic effect is expected at lower drug exposures 
whilst larger exposures are expected to augment the bactericidal effect up to a certain threshold. In 
contrast, the relationship between antibiotic exposure and the selection of resistant mutants is 
markedly non-monotonic and has the shape of an inverted “U” where resistant mutants are 
amplified with initial antibiotic exposure and then slowly decline with increasing exposure up to an 
optimal threshold that ultimately prevents resistance amplifications [433-436]. The inverted U-
shape seems to follow a log normal distribution [437]. Additionally, Jumbe et al., found that an 
AUC0-24/MIC of ≥110 for levofloxacin, which was twice that was necessary for optimal bactericidal 
effect, was required to suppress drug-resistant population of P. aeruginosa in a mouse-thigh 
infection model [401]. This information, among other similar observations, has indicated that the 
magnitude of the PK/PD indices for resistance suppression is generally different and higher than the 
thresholds required for clinical success [405, 434, 438, 439]. Therefore, antibiotic dosing that only 
aims to optimize clinical efficacy may potentially amplify resistance formation by selecting mutant 
bacterial strains with reduced drug susceptibility. With enhanced knowledge on antibiotic PK/PD 
over recent years, important hypotheses and concepts, such as the mutant selection window (MSW) 
and mutant prevention concentrations (MPC), have been proposed to provide potential explanations 
as to how sub-optimal antibiotic exposure may amplify the selection of resistant bacterial strains. 
Additionally, the dynamics of bacterial population under various dosing regimen can be described 
using mixture models, where changes in susceptible and resistant sub-populations in relation to 
drug concentrations are quantified [401, 435, 438, 440, 441]. 
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7.2.4.1     Mutant selection window 
The term “selective window” (SW) which was firstly coined by Baquero [442, 443] refers to a 
critical range of antibiotic concentrations in which drug-resistant bacterial mutants could be 
selectively enriched and amplified when exposed to concentrations in this zone. Subsequent in vitro 
studies, utilizing mycobacteria treated with fluoroquinolones, were able to define the boundaries for 
the critical zone of antibiotic concentrations and this concept was later renamed as the MSW [444-
446]. The studies that attempted to describe MSW further suggested that these concentration zones 
are those between the MIC of the susceptible pathogens and that of the least susceptible mutants. 
Figure 7-2 graphically illustrate the concept of MSW and its relevance in the development of 
resistant mutants. The MSW describes the range of antibiotic concentrations where resistant 
mutants may be selectively amplified and these concentration zones are those between the MIC of 
the susceptible pathogens and that of the least susceptible mutants i.e., MPC. In area (A) of Figure 
7-2, which is below the MIC, no resistant mutants are expected to grow, as there is no selective 
pressure in this area. In area (C) of Figure 7-2, which is above the MPC, the growth of resistant 
mutants is severely restricted and highly unlikely as the exposure in the area is able to suppress the 
growth of the least susceptible pathogens. On the contrary, the selection of resistant mutants would 
be most intense in area (B) of Figure 7-2, which is also known as MSW. Conversely, the longer the 
time spent by an antibiotic in this concentration zone, the greater the opportunity for resistant 
mutants to be selected and amplified. In addition to this, the formation of the resistant mutants was 
observed to be most intense in the bottom portion as opposed to the upper portion of the selection 
window [447]. The existence of such “dangerous” concentration zones was further corroborated by 
several in vitro [436, 448-450] and in vivo experimental studies [451-454]. 
 
The MSW hypothesis is potentially important, as contemporary antibiotic dosing tends to produce 
drug concentrations within the critical zone where they selectively amplify the growth of resistant 
mutants. Essentially, the higher the percentage of time (t) spent by an antibiotic within the MSW 
(tMSW), the greater the opportunity for resistant mutants to be selected and amplified. Furthermore, 
the continuous and prolonged “careless” practice of “dosing to only cure” in the ICU eventually 
leads to the resistant mutants being the dominant bacterial population and it is only at this point that 
surveillance studies would be alerted to the emergent resistant isolates. The MSW has been defined 
for many of the fluoroquinolones and some of the beta-lactams against various microorganisms 
[455-457]. Nevertheless, this concept is currently considered as a relatively new idea and has not 
been investigated in many infective pathologies, nor its relevance at the site of infection. Hence, its 
170 
 
clinical relevance in optimizing antibiotic dosing to avoid the MSW remains unclear and warrants 
further investigation. 
 
 
Figure 7-2: Graphical illustration of the mutant selection window and mutant prevention 
concentration on a hypothetical concentration-time curve 
Abbreviation: Cmax, maximum drug concentration; Cmin, minimum drug concentration; MIC, 
minimum inhibitory concentration; MPC, mutant prevention concentration; MSW, mutant selection 
window. 
 
7.2.4.2     Mutant prevention concentration 
The concept of MPC, which was derived from the MSW hypothesis, refers to the antibiotic 
concentration that corresponds to the MIC of the least susceptible mutants in a colony [444, 446]. 
While MIC refers to the lower boundary, the MPC essentially represents the upper boundary of 
concentrations in the MSW in which the enrichment of resistant mutants are expected to be severely 
hindered. Conversely, antibiotic dosing that aims to achieve concentrations higher than the MPC, as 
opposed to MIC, theoretically provides both an optimal bactericidal effect as well as resistance 
suppression. Furthermore, the ratio of AUC0-24 to MPC (AUC0-24/MPC) as opposed to AUC0-24/MIC 
is also suggested as a predictor of the development of resistance in several in vitro and in vivo 
evaluations as MIC quantifications generally ignore mutant sub-populations [433, 455, 458, 459]. 
The argument has been mostly tested in in vitro studies for fluoroquinolones where the mutant-
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restrictive thresholds of AUC0-24/MPC were approximately one-third of those AUC0-24/MIC values 
[436, 460]. 
  
The MPC has been described mostly for fluoroquinolones, although data for other classes of 
antibiotics are emerging [455, 461, 462]. Quantifying MPC thresholds for individual antibiotics 
should be one of the priorities in the development of dosing guidelines especially earlier in the 
process of evaluation and screening of new compounds. Although the concept seems appealing, the 
application however is not straightforward as the doses needed to achieve the MPC are usually 
higher than those for curing patients and exceed those that are registered for those antibiotics. There 
are also examples where these concentrations are unattainable for some antibiotic-pathogen 
combination [445, 462]. In addition, a trade-off between an increased risk of adverse effects with 
minimizing antibiotic resistance is a difficult consideration in clinical practice. In such cases, 
combining two or three antibiotics with overlapping PD properties may be warranted. 
 
7.2.4.3     Application of experimental mixture models 
A mixture models examine resistance development by describing the population dynamics of 
antibiotic-susceptible and -resistant bacteria during the course of treatment. Susceptible and 
resistant sub-populations respond differently to different antibiotic concentrations. In a murine-
thigh infection model, Jumbe et al., investigated the impact of bacterial inoculum on the required 
levofloxacin exposure in the eradication of total P. aeruginosa population [401]. The mice were 
inoculated with either 107 or 108 bacteria per thigh and levofloxacin was initiated after 2 hours. The 
investigators demonstrated that the exposure intensity which is required for maximal levofloxacin 
activity increases (by 2-5 fold) as the size of the inoculum increases by 1-log. This phenomenon 
occurs as a larger bacterial challenge constitutes larger population of resistant mutants, which are 
less susceptible to antibiotic therapy. The investigators also employed a complex mathematical 
model to analyse their findings simultaneously in order to calculate an exposure that would amplify 
resistant population and also, exposure that would restrict the enrichment of the population. A free 
AUC/MIC ratio of 110 and 36 was predicted to prevent the emergence and amplify resistant P. 
aeruginosa mutants in the study, respectively. 
 
7.2.5 Specific antibiotic classes   
This section discusses individual antibiotic classes and their pharmacodynamic characteristics, 
which influence antibiotic activity and the prevention of resistance. The relevant PD indices that 
have been shown to correlate with both outcomes are presented in Table 7-1.  
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7.2.5.1     Quinolones 
Quinolones are mostly lipophilic antibiotics and display largely concentration-dependent kill 
characteristics but with some time-dependent effects. Previous in vitro studies have shown that the 
achievement of a Cmax/MIC ratio of at least 8-12 is important for its optimal bactericidal activity 
[463, 464]. Given the half-life of most quinolones, this corresponds to AUC0-24/MIC values that 
correlate to efficacy. More importantly however, is that the index has also been associated with the 
reduction of resistant mutants in several experimental studies [389, 465, 466]. 
 
Several studies found that the ratio of AUC0-24/MIC is important for its bactericidal effect, as an 
even more significant index as compared to the Cmax/MIC ratio, and a ratio of ≥125 and ≥30 has 
been advocated for clinical success in the treatment of Gram-negative and -positive infections, 
respectively [389, 467-471]. In the context of antibiotic resistance, an inverse relationship has been 
described between this index and the probability of developing resistance [402]. Accordingly, 
quinolone dosing regimens that ensure higher ratios of AUC0-24/MIC are currently recommended to 
maximize bactericidal exposure as well as minimizing the development of resistance [401, 402, 
435]. Several investigators have further elucidated the critical AUC0-24/MIC thresholds as being 
between >100 to 200 in order to suppress the formation of resistant mutants when these antibiotics 
are used for Gram-negative infections [401, 402, 472]. However, due to intrinsic differences 
between various quinolones in selecting resistant strains, the suggested AUC0-24/MIC ratio for 
resistance suppression may vary between individual agent [389, 473]. 
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Table 7-1: Optimal pharmacokinetic/pharmacodynamic indices for antibiotic activity and the magnitudes associated with maximal therapeutic outcomes and resistance suppressiona 
Antibiotic class Optimal PK/PD index PK/PD magnitude for bacterial killingb PK/PD magnitude for clinical efficacyc Optimal PK/PD index for 
resistance suppression 
PK/PD magnitude for 
resistance suppressiond 
Aminoglycosides AUC0-24/MIC AUC0-24/MIC: 80-160  
[229, 474, 475]  
AUC0-24/MIC: 50-100  
[476] 
Cmax/MIC Cmax/MIC ≥20  
[477] 
Cmax/MIC 
- 
Cmax/MIC ≥8  
[431, 461, 478]  
 Cmax/MIC ≥30 
[477] 
Penicillins T>MIC ≥40-50% T>MIC 
[11, 12] 
≥40-50% T>MIC T>MIC ≥40-50% T>MIC 
[457] 
Cephalosporins T>MIC ≥60-70% T>MIC 
[11, 12] 
≥45-100% T>MIC 
[20, 21]  
tMSW ≤40% tMSW 
[479] 
Carbapenems T>MIC ≥40% T>MIC 
[11] 
≥50-75% T>MIC 
[25, 152] 
T>MIC ≥40% T>MIC 
[480] 
   tMSW ≤45% tMSW 
[481] 
Fluoroquinolones AUC0-24/MIC AUC0-24/MIC: 30-200
  
[430, 470, 471] 
AUC0-24/MIC: 35-250
 
[389, 467-469]  
AUC0-24/MIC AUC0-24/MIC: 100-200
 
[401, 435] 
Cmax/MIC Cmax/MIC ≥8 
[463, 464, 466] 
Cmax/MIC ≥8 
[474] 
Cmax/MIC Cmax/MIC ≥4 
[465] 
   AUC0-24/MPC AUC0-24/MPC ≥22 
[455] 
   tMSW ≤30% tMSW  
[448, 450, 454, 482] 
Vancomycin AUC0-24/MIC AUC0-24/MIC: 86-460
 
[11] 
AUC0-24/MIC: 400-600
  
[11, 483] 
AUC0-24/MIC AUC0-24/MIC: 200
 
[448] 
Linezolid AUC0-24/MIC AUC0-24/MIC: 50-80
 
[484] 
AUC0-24/MIC ≥80 
[485] 
- - 
T>MIC ≥40% T>MIC  
[484, 486] 
≥85% T>MIC 
[485] 
- - 
Daptomycine AUC0-24/MIC AUC0-24/MIC: 388-537
 
[487] 
- 
AUC0-24/MIC AUC0-24/MIC: 200
 
[448] 
Cmax/MIC Cmax/MIC: 59-94
 
[487] 
- - - 
Fosfomycin Unknown - - - - 
Colistin AUC0-24/MIC AUC0-24/MIC: 50-65 
[488, 489]  
- - - 
Abbreviation: AUC0-24/MIC, ratio of area under the concentration-time curve during a 24-hour period to minimum inhibitory concentration; Cmax/MIC, ratio of maximum drug concentration to minimum inhibitory 
concentration; T>MIC, duration of time that drug concentration remains above the minimum inhibitory concentration during a dosing interval; tMSW, percentage of time spent by an antibiotic within the mutant selection 
window; AUC0-24/MPC, ratio of area under the concentration-time curve during a 24-hour period to the concentration that prevents mutation. 
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Legend: 
aAll values refer to the non-protein bound, free fraction except when indicated otherwise. 
bData have been summarized from in vivo animal studies and may utilize different infection models employing different bacteria. Where the index is reported as a range, specific data for the contributing indices, which may 
have been derived from different studies, can be found in the associated references. The data also reflect the 2-log kill and in some cases 1-log kill which may or may not coincide with maximum kill. 
cData have been summarized from clinical studies and may recruit different patient population. Where the index is reported as a range, specific data for the contributing indices, which may represent PK/PD thresholds for 
clinical or microbiological cure, can be found in the associated references. 
dData have been summarized from pre-clinical studies, which may include in vitro and in vivo experimental infection models employing different bacteria. Specific data for the contributing indices can be found in the 
associated references. 
eValues reported here refer to total drug concentration. 
175 
 
The AUC0-24/MPC index is also being investigated and the advantages over AUC0-24/MIC in the 
prediction of resistance development have been documented in several in vitro studies [455, 458, 
459]. To date, this remains a controversial argument as most authors found that both indices were 
similar in their predictive potentials of resistance development [452, 490]. Nevertheless, higher 
ratios of AUC0-24/MPC are associated with minimizing the emergence of resistance. 
 
Recently, increasing interest and efforts have been focused on the application of MSW concept in 
the evaluation of quinolones dosing regimens. Based on the current data, tMSW of ≤30% should 
restrict mutant amplification and the index has been studied in several in vitro [450, 482] and in 
vivo studies [452, 456]. Khachman et al., further extended this concept into clinical practice by 
investigating the appropriateness of the currently recommended ciprofloxacin dosing in 102 
critically ill patients [491]. Using Monte Carlo simulations, the PTA (i.e., ≤20% tMSW) for the 
currently recommended ciprofloxacin dosing regimens (i.e., 800 mg or 1200 mg/daily) was less 
than 50% and when higher doses such as 2400 mg/daily were used, only minor improvements were 
observed i.e., PTA of 61%. More importantly, the risk of selecting resistant A. baumannii and P. 
aeruginosa strains were extremely high with the recommended regimens thus challenging their 
appropriateness in critically ill patients. As it stands, a quinolone-dosing regimen that maximizes 
the AUC0-24/MIC ratio should be considered in critically ill patients and by citing ciprofloxacin as 
an example; the objective may be achieved with a 400 mg 8-hourly or 600 mg 12-hourly regimen. 
When treating pathogens with high MICs, dose escalation should be considered whilst being 
observant of possible dose-related adverse effects occurrence. 
 
7.2.5.2     Aminoglycosides 
Aminoglycosides are hydrophilic in nature and they demonstrate concentration-dependent kill 
characteristics [431, 492]. Although previous studies have mainly suggested that achieving a high 
Cmax/MIC ratio predicts optimal outcome [229, 386, 474, 478, 493], Craig et al., argued that the 
ratio of AUC0-24/MIC would be more appropriate in describing the antibiotic’s activity [11]. In the 
1980s, Moore et al., [386] suggested that an aminoglycoside dose that provided a Cmax/MIC ratio of 
8-10 was associated with a higher probability of clinical success against Gram-negative infections. 
However, the investigators chose the index due to their sparse PK sampling times and consequently, 
AUC0-24/MIC ratio was not considered in the study. Importantly, high collinearity existed between 
Cmax and AUC. Several investigators have since suggested that the ratio of AUC0-24/MIC is more 
likely to be a “better” PD descriptor for aminoglycosides activity [430, 476], in which an AUC0-
24/MIC ratio of 80-160 has been advocated for its efficacy [475, 476]. 
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Although higher concentrations enhance aminoglycoside activity, prolonged exposure of such 
concentrations may lead to drug toxicity as well as the development of bacterial resistance. This 
type of resistance is known as adaptive resistance and is characterized by a slow but reversible, 
concentration-independent killing [494-496]. Maximizing the Cmax/MIC ratio seems to reduce the 
development of adaptive resistance and the objective is likely achieved with extended-daily dosing 
(EDD) as opposed to the traditional dosing schemes (i.e., twice or thrice daily dosing) [496]. In a 
PD model designed to predict aminoglycosides activity against A. baumannii and P. aeruginosa, 
Tam et al., further quantified the required Cmax/MIC ratio to prevent the resistance development 
[477]. In this study, a Cmax/MIC ratio of 20 for a once-daily amikacin dosing regimen and 30 for a 
12-hourly gentamicin dosing regimen was required for suppressing A. baumannii and P. aeruginosa 
regrowth, respectively. Based on these results, it could be then inferred that the Cmax/MIC ratio and 
AUC0-24/MIC are the PD indices to consider in order to suppress A. baumannii and P. aeruginosa 
resistant mutants, respectively. 
 
Based on the available data, EDD rather than the traditional multiple daily dosing of 
aminoglycosides is currently advocated in an attempt to maximize their therapeutic potential and 
minimize resistance development. Furthermore, it has been shown in numerous clinical studies 
[497, 498] and several meta-analyses [499, 500] that the dosing recommendation is indeed 
appropriate and valid in reducing aminoglycosides toxicity and may increase the likelihood of 
successful treatment outcomes. Clinical data on these dosing effects on development of resistance 
remains sparse.  
 
7.2.5.3     Beta-lactams 
The beta-lactam antibiotics are made up of penicillins, cephalosporins and monobactams and 
carbapenems but the latter will be considered separately in the section below because of their 
different spectrum and PD properties. Beta-lactam antibiotics are generally hydrophilic in nature 
and display time-dependent kill characteristics. The fT>MIC is regarded as the optimal PD index for 
their activity and as such, maintaining effective drug exposure above the MIC should be the priority 
when this antibiotic class is used [12]. It has been generally suggested that % fT>MIC required for 
bactericidal effect is 50%, 60-70% and 40% for penicillins, cephalosporins and carbapenems, 
respectively [22, 393, 501]. Additionally, relatively higher fT>MIC exposures are needed for maximal 
activity against the Gram-negatives as opposed to the Gram-positive pathogens. However, clinical 
data from critically ill patients have not consistently supported these targets. Some data suggest that 
these in vitro exposures to be the minimum antibiotic exposures required, with patients potentially 
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benefitting from higher and longer antibiotic exposures than those previously described in in vitro 
and in vivo studies [20, 21, 25, 27, 28, 152]. It has also been demonstrated that maximal bactericidal 
activity occurs when drug concentrations are maintained at 4-5 x MIC, with higher concentrations 
providing little added benefit [23, 26, 152]. Therefore, it has been suggested that beta-lactam 
concentrations should be maintained at least 4-5 x MIC for extended periods during each dosing 
interval to ensure clinical success, particularly in severely ill patients [13]. 
 
It is still inconclusive whether the fT>MIC index predicts beta-lactams resistance although the 
potential link has been described in several in vitro [405] and in vivo experimental studies [404, 
457]. Fantin et al., utilized an in vivo animal model to suggest that the development of resistance 
against ceftazidime might arise should the drug concentration fall below the MIC for more than half 
of the dosing interval [404]. The risk of developing resistance against a cephalosporin has also been 
linked to a low AUC0-24/MIC ratio [502]. This was further demonstrated by Stearne et al., who 
found that an AUC0-24/MIC of 1000 was required with ceftizoxime to prevent the emergence of 
resistant Enterobacter cloacae strains [437]. In another murine lung infection model, Goessens et 
al., found that the growth of resistant E. cloacae strains was correlated with prolonged ceftazidime’s 
tMSW [479]. 
  
Based on the limited data on resistance suppression, beta-lactams dosing that targets concentrations 
greater than 4 x MIC for extended periods would be most appropriate [503]. Importantly, research 
has shown that the objective can be obtained via frequent dosing or by utilizing EI or CI. However, 
the altered dosing schemes may potentially drive the emergence of resistance with sub-optimal 
dosing, at least in theory, as these approaches tend to increase beta-lactams tMSW. In a recent in 
vitro hollow-fibre infection model (HFIM) of P. aeruginosa, Felton et al., suggested that EI of 
piperacillin/tazobactam was equivalent to IB dosing in terms of the bactericidal effect and the 
prevention of resistance [504]. However, the target concentration for the two approaches should be 
different in which the ratio of Cmin/MIC of 10.4 and 3.4 was required by EI and IB to suppress 
resistant mutants, respectively. 
 
7.2.5.4     Carbapenems 
Generally, carbapenems have similar PK/PD characteristics when compared to other beta-lactam 
antibiotics. Some studies have suggested that unlike other beta-lactams, carbapenems possess a 
PAE against Gram-negative bacilli, including P. aeruginosa strains [157] although this could not be 
confirmed in another study [505]. This PAE property of carbapenems may explain a shorter % 
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fT>MIC for optimal bactericidal activity. Li et al., further quantified the % fT>MIC as >54% in order to 
achieve optimal microbiological outcome when meropenem is used in patients with lower 
respiratory tract infections [23]. Additionally, only a ratio of Cmin/MIC of >5 was significantly 
associated with clinical and microbiological cure in this cohort of patients. Further, Tam et al., used 
an in vitro HFIM to demonstrate that a Cmin/MIC of >6.2 was required to suppress the development 
of resistant P. aeruginosa mutants [405]. The finding was later corroborated by the same group of 
investigators in a neutropenic mouse infection model and in this current analysis, % fT>MIC of >40% 
was also associated with the selection of resistant mutants [480]. More recently in an in vitro 
dynamic model simulating doripenem concentrations, Zinner et al., found that resistant P. 
aeruginosa mutants were likely to be selected at drug concentrations that fell ≥45% within the 
MSW (≥45% tMSW) [481]. 
 
Similar to the other beta-lactam antibiotics, maintaining carbapenem concentrations at 4-6 x MIC 
for extended periods is currently advocated to suppress resistant mutants selection. To achieve this 
objective, prolonging the duration of infusion is generally recommended when the antibiotic is 
used. However, EI as opposed to CI is the currently preferred dosing method when carbapenems are 
used considering the group’s inherent drug instability in aqueous solutions. With increasing 
information and emerging data, clear distinction, in the context of stability problems, needs to be 
emphasized between the different members of the carbapenem group. Whilst imipenem is indeed 
less stable, there are currently no practical reasons to oppose continuous meropenem infusion as it 
has been successfully administered up to 8 hours (under hospital environment) in numerous clinical 
studies without drug instability or degradation reports [86, 276, 506]. In an in vitro HFIM 
examining cell-kill and resistance suppression for three P. aeruginosa strains, Louie et al., 
demonstrated that a doripenem dosing regimen of 1 g infused over 4 hours was the solitary regimen 
that was able to completely suppress resistance for the full period of 10 days for wild-type isolates 
[507]. Importantly, the investigators also reported that the dosing regimen produces concentrations 
at >6.2 x MIC which were significantly associated with maximal resistance suppression in other 
evaluations [405, 481]. In addition, Chastre et al., also observed lower occurrence of resistant P. 
aeruginosa strains arising in patients treated with EI of doripenem when compared to patients who 
received conventional imipenem dosing in a multicentre, RCT of critically ill patients with VAP 
[336]. 
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7.2.5.5     Vancomycin 
Vancomycin is a glycopeptide antibiotic and is a relatively hydrophilic drug. Some in vitro [508, 
509] and in vivo animal studies [510] suggest that the bactericidal activity of the antibiotic is time-
dependent whereas some have shown the ratio of Cmax/MIC to be equally important [511]. More 
recently, it has been generally accepted that achieving a high ratio of AUC0-24/MIC would be more 
predictive of its clinical success. Studies by Moise-Broder et al., were the earliest to quantify that a 
ratio of AUC0-24/MIC of ≥400 is needed for an optimal bacteriological and clinical outcome when 
treating patients with S. aureus respiratory infections [432, 512]. The findings are consistent with 
Zelenitsky et al., retrospective data evaluation and the investigators also described that higher 
exposures are needed, specifically a ratio of AUC0-24/MIC of ≥578, when treating critically ill 
patients with septic shock [483]. Due to common clinical practice of measuring trough 
concentrations when vancomycin is used, a trough concentration ranging between 15-20 mg/L is 
recommended for optimal outcome in hospital-acquired pneumonia and complicated infections 
[513, 514]. 
 
Although scarce data exist, it could be assumed that the development of resistance is linked to sub-
optimal vancomycin exposure. Through their in vitro PD model, Tsuji et al., was able to conclude 
that the development of vancomycin-intermediately susceptible S. aureus (VISA) strains was driven 
by sub-optimal vancomycin exposure in the setting of dysfunctional agr locus in S. aureus [515]. 
Additionally, the investigators also found that the AUC0-24/MIC ratio needed to suppress resistance 
for the strains was four-fold higher than that in the parent strains. Charles et al., observed that 
patients with VISA infections were more likely to present with low vancomycin trough 
concentrations (i.e., <10 mg/L) [516]. Based on similar findings to Charles et al., retrospective data 
evaluation [517, 518], and considering the recommended trough concentrations for successful 
clinical outcomes in severe infections, vancomycin trough concentrations should also be maintained 
between ≥15-20 mg/L at all times to suppress resistance emergence [513]. Thus, loading doses of 
25-30 mg/kg should be considered in critically ill patients to rapidly attain the target concentration 
and certainly, higher vancomycin doses of up to 40 mg/kg may be important to minimize resistance 
development. In addition, doses in excess of 5 g/daily were estimated to be necessary to achieve the 
target AUC0-24/MIC ratio when treating VISA infections [107]. Increasing knowledge of the 
relationship between higher vancomycin exposures and drug toxicities may limit the dosing of this 
drug to limit the emergence of resistance. 
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7.2.5.6     Linezolid 
Linezolid belongs to a class of antibiotics known as oxazolidinones, which was developed for the 
treatment of Gram-positive infections. In a murine infection model, Andes et al., demonstrated that 
optimal linezolid activity correlates well with the ratio of AUC0-24/MIC, with a ratio of between 50 
and 80 predicting the likelihood of successful treatment outcome [484]. However, higher clinical 
success rates may occur at AUC0-24/MIC ratio of 80-120 for bacteraemia, lower respiratory tract 
infections and skin structure infections as reported by Rayner et al., in their retrospective clinical 
PD evaluation of 288 patients [485]. Importantly, the investigators also showed that the drug 
exposure required for optimal treatment outcome was also dependent on the site and types of 
infection. Additionally, the probability of treatment success appeared likely when linezolid 
concentrations were maintained above the MIC for the entire dosing interval. The finding 
corroborated two earlier rabbit endocarditis experimental models, which described linezolid as a 
time-dependent antibiotic where an fT>MIC of 40% is needed for optimal antibiotic activity [484, 
486]. A 600 mg 12-hourly dose is currently suggested to achieve these PD indices and hence, 
predicts successful treatment outcome. However, it is also imperative to emphasize that the 
antibiotic’s PK is highly variable [429, 505, 519-521], particularly in patients with severe 
infections, and the phenomenon has, in part, contributed to treatment failures as well as the 
increased occurrence of adverse events in such patients [485, 522]. As such, TDM of linezolid is 
beneficial in this respect and emerging data are suggesting that general TDM may optimize patient 
outcomes when linezolid is used in critically ill patients. In the context of antibiotic resistance, low 
dose linezolid (200 mg 12-hourly) has been associated with the development of E. faecium and E. 
faecalis resistant strains [523]. In addition, prior exposure and prolonged linezolid administration 
have been suggested to increase the likelihood of resistance development [524-526]. Nevertheless, 
the development of resistance against the antibiotic has not been widely reported [527, 528].  
 
7.2.5.7     Daptomycin 
Daptomycin is the first approved member of the cyclic lipopeptides with a potent activity against 
Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) and vancomycin-
resistant enterococci (VRE). In vivo experimental studies describe daptomycin to be a 
concentration-dependent antibiotic. The ratio of Cmax/MIC in concert with AUC0-24/MIC has been 
correlated with its efficacy in several in vivo animal studies [487, 529, 530]. Safdar et al., used a 
neutropenic murine thigh infection model to characterize the PD characteristics of the antibiotic 
[487]. In the infection model, the Cmax/MIC and AUC0-24/MIC ratio required for bacteriostasis 
ranged from 59-94 and 388-537 (total drug concentration), respectively. Similar ratios were 
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required for bacteriostasis in two other clinical studies, which recruited healthy volunteers [531, 
532]. Based on these suggested indices, optimal daptomycin exposure could be expected in most 
patients with modest dosing (4-6 mg/kg per day). However, the emergence of daptomycin-resistant 
strains has been reported with such dosing regimens [533, 534] and some experts recommend the 
use of higher dosing to curb this issue (i.e., 8-12 mg/kg per day) [535], which was shown to be safe 
in one retrospective data evaluation [536] and several case reports [537, 538]. A duration of therapy 
exceeding 2 weeks has also been documented to increase the likelihood of daptomycin resistance 
[534].    
 
7.2.5.8      Fosfomycin 
Fosfomycin, which was discovered more than 40 years ago but then forgotten, is a phosphonic acid 
derivative that possesses promising in vitro activity against carbapenem-resistant K. pneumoniae 
[539]. The introduction of fosfomycin into our current armamentarium of antibiotics was greeted 
with some scepticism due to major setbacks in its initial in vitro evaluation and this has in part, 
contributed to its limited acceptance for clinical use. Although there are suggestions that 
fosfomycin’s bacterial killing appears to be driven by fT>MIC, the optimal PK/PD index relating to 
its activity remains to be established and requires further investigations [540]. In addition, rapid 
bacterial killing was observed in several static-time kill studies when drug concentrations were 
maintained at 2-8 x MIC. Similar to the beta-lactams, the development of fosfomycin resistance is 
driven by low drug exposures and prolonged duration of antibiotic course [541]. There has also 
been some debate concerning the rapid development of fosfomycin resistance when it is used as a 
monotherapy particularly in non-urinary tract infections. In a murine endocarditis model, Thauvin et 
al., found that the combination of fosfomycin and pefloxacin was more effective in suppressing 
resistant S. aureus strains emergence when compared to fosfomycin alone [542]. In several in vitro 
and in vivo experimental studies, instances of synergism were also demonstrated against MRSA 
when fosfomycin was combined with the beta-lactams [543, 544], linezolid [545], and moxifloxacin 
[546]. Combining fosfomycin with beta-lactams is also strongly supported by in vitro data, which 
describe synergism between the two antibiotics against P. aeruginosa infections [547-549]. 
However, whether the in vitro synergism would translate to increased clinical efficacy remains to be 
demonstrated. In a recent prospective study, fosfomycin, in combination with colistin, gentamicin 
or piperacillin/tazobactam, provided promising bacteriological and clinical outcome data in the 
treatment of 11 critically ill patients with ICU-acquired infections caused by carbapenem-resistant 
K. pneumoniae [550]. Based on limited clinical data in treating serious infections in the ICU and its 
182 
 
high tendency for developing resistance, fosfomycin should not be used as a single agent and the 
choice of adjunctive antibiotic should be appropriately evaluated in future studies. 
 
7.2.5.9      Colistin 
Colistin is a polymyxin antibiotic, which is administered parenterally as colistin methanesulfonate 
(CMS). The antibiotic has concentration-dependent kill characteristics with a significant in vitro 
PAE against Gram-negative pathogens [551]. In vivo murine studies suggested that the most 
predictive PD index for its bacterial activity, particularly against A. baumannii and P. aeruginosa, is 
AUC0-24/MIC [552, 553]. Based on observations in several lung infection models, the ratio of 
AUC0-24/MIC between 50 and 65 has been suggested as the optimal PD target although higher 
exposures were also described in thigh infection models [488]. The heteroresistance phenomenon, 
the situation whereby resistant sub-populations are present within a strain considered susceptible 
based on MIC, is an emerging problem for the antibiotic and has been observed in clinical isolates 
of A. baumannii [489, 554], K. pneumoniae [555], and P. aeruginosa [556]. Further to this, rapid 
resistant mutants formation was demonstrated following colistin exposure in two recent in vitro 
PK/PD studies mimicking clinical dosing regimens in humans [557, 558]. This is particularly 
worrying as Garonzik et al., suggested that the currently recommended CMS dosing regimen is sub-
optimal in a population PK analysis of 105 critically ill patients [559] and their findings were 
corroborated by other investigators who recruited smaller number of patients [560, 561]. With 
increasing PK knowledge on the drug, Garonzik et al., [559] and Plachouras et al., [561] further 
described optimized CMS dosing regimens in patients with varying degrees of renal function. The 
dosing proposed by Plachouras et al., [561] has now been validated in a critical care setting by 
Dalfino et al., [562] in the treatment of MDR infections. Among the relevant recommendations 
concerning CMS dosing is the need for an initial loading dose as the conversion of the prodrug 
CMS to the active entity of colistin is very slow and adequate colistin exposure may be delayed for 
a few days. Although theoretically plausible based on its PD characteristics, the adoption of EDD is 
not suitable on the basis of the resultant prolonged periods of low colistin concentrations leading to 
the formation of heteroresistance [552, 553, 557]. Based on current PK data of critically ill patients 
[559-561, 563, 564] and in vivo PK/PD experimental studies [552, 553] colistin monotherapy would 
not be beneficial in maximizing therapeutic success and preventing resistance, particularly in 
patients with moderate-to-good renal function and for pathogens with MICs of ≥1. In addition, a 
treatment course lasting more than 12 days has been found to be associated with the development of 
colistin resistance in two recent clinical studies [565, 566]. 
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7.2.6      Modifying treatment approaches to prevent emergence of resistance 
7.2.6.1     Combination antibiotic therapy 
Although combining antibiotics is common during the treatment of infection, the relevance of the 
practice has been the matter of debate with conflicting conclusions. Proponents of combination 
therapy will strongly suggest that the approach will increase antibiotic exposure via extending 
coverage across a wider range of potential pathogens and in some clinical evaluations, has been 
found to improve survival in severely ill patients [567-570]. Further strong theoretical reasons to 
seriously consider a combination antibiotic approach include; antibiotic synergism which enhances 
killing potency; combined activity against biofilm-growing pathogens; increasing tissue 
penetration; inhibition of pathogen’s toxin and enzyme production; and prevention of resistance 
development. However, there is also clinical evidence indicating that combination therapy may not 
be superior, even harmful in some instances [571-573], as opposed to monotherapy in the treatment 
of Gram-negative bacilli infections [574-576]. Based on the current data, it could be deduced that 
combination antibiotic therapy may not benefit all patients but rather a select patient population 
with select infections. While monotherapy may be sufficient for most patients, critically ill patients 
with severe infections may benefit the most from rationally optimized combination therapy. 
Although some in vitro infection models [577, 578] and animal studies [579] clearly indicated 
benefits behind the approach, unfortunately, the vast majority of combination schemes were chosen 
randomly without considering the pre-clinical findings [580]. 
 
In the context of resistance suppression, rationally optimized combination therapy may restrict the 
amplification of resistant mutants. Epstein et al., [581] suggests that the presence of more than two 
antibiotics at the infection loci (with drug concentrations above the MIC), each with a different 
killing mechanism, would “shut” the MSW and thereby suppressing mutant growth [582-584]. 
Apart from several pre-clinical studies [448, 577, 579, 585, 586], no RCTs to date have shown that 
the approach reduces the emergence of resistance. Furthermore, the benefit is particularly difficult 
to be demonstrated in clinical evaluations, which frequently recruit heterogeneous patient 
population and are not conducted long enough to detect the emergence of resistance. In the face of 
rapidly evolving resistance phenomenon, it is likely that we have to turn our attention to the concept 
of rationally optimized combination antibiotic therapy, particularly in the treatment of severely ill 
patients in the ICU. In addition, the approach is likely to be important early in the course of 
infection when the inoculum of the infecting pathogens is the highest. 
 
184 
 
7.2.6.2     Duration of therapy 
It has been increasingly shown in pre-clinical studies that prolonged antibiotic administration may 
play an important role in the formation of resistant mutants. Conversely, the longer antibiotic 
therapy persists, the more challenging it is to curtail the emergence of resistant pathogens. It has 
been suggested that an antibiotic regimen that lasts for only 4-5 days should be sufficient to produce 
maximal bactericidal effect with an added benefit of resistance suppression. Extending antibiotic 
exposure to more than 10 days is risky on the basis of resistance development whereby higher drug 
exposures are needed to suppress resistant mutants in this situation and if this threshold is not 
achieved, treatment failure ensues as the resistant population dominates. This phenomenon has been 
described by Tam et al., in their in vitro model of S. aureus infection which investigated two 
garenoxin dosing regimens with different intensity; one with an AUC0-24/MIC ratio of 280 and the 
other with 100 [438]. The investigators demonstrated that once the duration of garenoxin exposure 
increased beyond 5 days, the magnitude of dosing needed for suppressing resistant mutants also 
increased. The higher dosing regimen was found to suppress resistance amplification for 10 days 
whilst the less intense regimen was only able to demonstrate the ability for 4-5 days. 
 
At best, the common practice of administering an antibiotic for 10-14 days is currently based on 
limited data and expert opinion rather than it being an evidence-based approach. However, for some 
deep-seated infections such as osteomyelitis and endocarditis, prolonged antibiotic courses are 
essential. Instances of potential benefits from shortening the duration of antibiotic therapy in 
reducing the emergence of resistance while maintaining clinical efficacy have been increasingly 
described [587-590]. Among these findings, Singh et al., demonstrated that patients who received 
shortened antibiotic courses (i.e., ≤3 days) had reduced ICU stays, lower superinfection and 
resistance rates as well as lower mortality rates compared to patients who received standard courses 
[590]. Further investigations are warranted to elucidate the exact duration of therapy that maximizes 
therapeutic outcome and suppresses resistance development. Until conclusive findings are made, 
antibiotic therapy should “hit hard” in the early course of infection and “stop early” to assist in 
resistance prevention. 
 
7.2.6.3     Altered dosing approaches 
Optimal and timely PK/PD target attainment has been associated with the likelihood of clinical 
success and resistance suppression in critically ill patients [1]. However, organ function changes 
that may result from either infectious or non-infectious pathologic processes may alter antibiotics 
exposure. For example, the increase in Vd for hydrophilic antibiotics such as the aminoglycosides 
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[591, 592], beta-lactams [56], glycopeptides [107], and linezolid [87], have been extensively 
documented in critically ill patients. Importantly, this phenomenon leads to sub-optimal antibiotic 
concentration and may impair the attainment of desired PK/PD targets for optimal activity, 
particularly in the early phase of severe sepsis and septic shock. In this setting, higher initial loading 
doses of hydrophilic antibiotics should be applied to compensate for the volume expansion. In the 
context of resistance prevention, the approach may have the potential utility to rapidly reduce 
bacterial burden in the early stage of infection. Tsuji et al., recently tested the impact of a front-
loaded linezolid-dosing regimen on bacterial killing and resistance suppression in a HFIM of 
MRSA infection [593]. From a PD standpoint of bacterial eradication, their findings suggest 
potential benefits of increasing doses of linezolid early in therapy although no differences were 
observed in terms of resistance suppression. Further pre-clinical studies are necessary to investigate 
this promising dosing strategy particularly in the context of resistance suppression, before it can be 
fully applied in clinical practice. 
 
For the beta-lactams, maintaining effective exposure for extended periods or increasing % fT>MIC 
would be especially appropriate in the prevention of resistance particularly in critically ill patients. 
Research has shown that the traditional bolus dosing produces sub-optimal antibiotic concentrations 
for much of the dosing interval, which may consequently favour resistant bacterial strains 
development [13]. Numerous pre-clinical and clinical PK/PD studies have demonstrated that 
improved beta-lactams exposure could be achieved via EI or CI administration [14]. These altered 
dosing approaches may be especially important in patients who develop severe pathophysiological 
derangements and when less susceptible pathogens are present. However, more clinical studies are 
urgently needed to evaluate the relative ability of EI and CI versus IB dosing of beta-lactam 
antibiotics in reducing the emergence of resistance if a global practice change is to be expected.   
 
7.2.7 Conclusion 
For decades now, clinicians have overused antibiotics and apparently did so with the notion of our 
continuous supply of new antibiotics would adequately address any emerging resistance concerns. 
That thought didn’t materialize and on the contrary, as our current antibiotic pipeline is nearly dry, 
infecting pathogens have tremendously outperform our existing armamentarium thus far and they 
are becoming increasingly difficult to treat. The current situation that we are in is not surprising as 
most of our treatment goals were previously focused on maximizing clinical and microbiological 
cure and not minimization of the emergence of antibiotic resistance. With numerous pre-clinical 
data indicating that the magnitude of the PK/PD indices for resistance suppression is generally 
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higher than the thresholds required for clinical success, antibiotic dosing that only aims to optimize 
clinical efficacy may potentially amplify resistance formation by selecting mutant bacterial strains 
with reduced drug susceptibility. Furthermore, the relevance of commonly prescribed antibiotic 
dosing is questionable in severely-ill patients as most dosing recommendations have been derived 
from studies that do not consider the occurrence of pathophysiological changes in critical illness. 
Therefore, with enhanced knowledge on antibiotic PK/PD over recent years, emerging data are 
suggesting that the PD-based dosing approach should not only aim to maximize clinical outcomes 
but to also include the suppression of resistance. In some antibiotics such as the fluoroquinolones, 
the PD thresholds needed to prevent the emergence of resistance is readily described but 
unfortunately, is often neglected and not implemented in clinical practice; whilst for most antibiotic 
classes, specific research is urgently needed. To curb the development of resistance, it is likely that 
we have to administer “the highest tolerated antibiotic dose” via alternative dosing strategies and 
should also consider the combined use of multiple antibiotics (that are rationally optimized), 
particularly early in the course of infection in severely ill patients. 
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7.3 Conclusion  
Previous studies of optimization of antibiotic dosing only focused on maximizing clinical and 
microbiological cure and not minimization of the emergence of antibiotic resistance. The data 
presented in this chapter showed that most of the information describing PK/PD and its association 
with antibiotic resistance were derived from pre-clinical studies. The application of PK/PD 
principles for dosing antibiotics have been shown to reduce the risk of antibiotic resistance and 
increasing data are suggesting that the dosing approach should not only be explored to maximize 
patient outcomes but to also include the suppression of resistance. To minimize the development of 
antibiotic resistance in critically ill patients, it is likely that clinicians will have to administer “the 
highest tolerated antibiotic dose” via alternative dosing strategies.  
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Chapter 8: Summary of findings, general discussion, conclusion and 
future directions 
8.1 Summary of findings and general discussion 
Critically ill patients are markedly different from those in general ward settings as they are 
associated with higher morbidity and mortality rates. These patients commonly demonstrate a high 
level of illness severity which causes profound physiological changes that can alter the PK of 
antibiotics. Antibiotic dosing that does not account for these changes may lead to therapeutic failure 
and the emergence of antibiotic resistance.  
 
The issue of critical illness-related alterations affecting beta-lactam dosing requirements was 
described in Chapter 2. Chapter 2 aimed to describe the population PK of doripenem in critically ill 
patients with sepsis and use Monte Carlo dosing simulations to provide clinically relevant dosing 
guidelines for these patients. The typical Vd of doripenem in this cohort was 0.47 L/kg, which was 
two-fold greater than that previously described in healthy volunteers and non-critically ill patients. 
The finding is expected and it is in agreement with other currently available data investigating the 
PK of doripenem in critically ill patients with sepsis. Extreme fluid extravasation related to critical 
illness and aggressive medical interventions have been suggested to cause these increases in Vd. 
The typical CL in this cohort was 0.14 L/kg/hr and this estimate was significantly influenced by 
CLCR such that a 30 mL/min increase in estimated CLCR would increase doripenem CL by 52%.The 
importance of BOV on CL in the PK model, which is also described in Chapter 2, suggests a certain 
degree of variability in CL exists between treatment days. This means that dosing requirements in 
this population may be dynamic and highlights that regular dosing review and potentially, use of 
TDM to maximize therapeutic outcomes. It is likely that conventional dosing of doripenem does not 
consider these pathophysiological perturbations and as such, the licensed “one-dose-fits-all” dosing 
strategy is likely to be flawed in critically ill patients. Data presented in Chapter 2 showed that for 
pathogens with a MIC of 8 mg/L, a dose of 1000 mg 8-hourly as a 4-hour infusion is optimal for 
patients with CLCR of 30-100 mL/min whilst a dose of 2000 mg 8-hourly as a 4-hour infusion is 
required for patients manifesting a CLCR >100 mL/min. This, in a way, highlights that an alternative 
dosing approach such as the empirical use of EI of doripenem should be strongly considered in this 
patient population, particularly when pathogens with higher MICs are involved. 
 
The primary aims of the Thesis was to investigate the potential benefits of PI dosing (i.e., CI and 
EI) as an alternative dosing method to conventional IB administration in critically ill patients. Based 
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on the structured review of published literature presented in Chapter 3 and 5, current evidence 
suggest that CI of beta-lactam antibiotics may not be advantageous for all critically ill patients but 
may only be meritorious to a specific cohort of patients with severe infections. The niche benefits of 
PI dosing was further explored in Chapter 4, which presented the findings of a post hoc analysis on 
the database of the DALI study. The primary aims of the analysis was to compare the PK/PD target 
attainment and clinical outcomes between PI (i.e., CI and EI) and IB dosing of two commonly used 
beta-lactams (i.e., piperacillin/tazobactam and meropenem) in a large cohort of critically ill patients 
who were not receiving RRT. In this analysis, the use of PI dosing significantly increased the target 
attainment for most PK/PD end-points. The data presented in Chapter 4 further specified the sub-
group of patients who are more likely to benefit from PI dosing. In the sub-group of patients who 
had respiratory infection, those who received beta-lactams via PI dosing demonstrated significantly 
better 30-day survival as opposed to IB patients (86.2% versus 56.7%; p = 0.012). Additionally, in 
patients with a SOFA score of ≥9, administration by PI as compared to IB dosing was significantly 
associated with better clinical cure (73.3% versus 35.0%; p = 0.035) and higher survival rates 
(73.3% versus 25.0%; p = 0.025). These findings further corroborate similar claims of previous 
studies which suggested potential benefits of PI dosing of beta-lactam antibiotics in critically ill 
patients with severe pneumonia. Accordingly, future clinical studies should seek to test the potential 
clinical superiority of altered beta-lactam dosing strategies in a specific cohort of critically ill 
patients with severe infections, particularly in those with respiratory infection and not receiving 
RRT. 
 
Although numerous pre-clinical and PK/PD data support CI of beta-lactam antibiotics in critically 
ill patients, the current evidence, presented in Chapter 3 and 5, suggest neither superiority nor 
inferiority of IB dosing with regards to patient outcomes. The lack of clinical outcome data to 
support the pre-clinical data may be because the existing studies are underpowered to detect 
differences in patient-centred outcomes (e.g., mortality) between the two dosing approaches. 
Chapter 5 aimed to scrutinize the published clinical studies for their methodological shortcomings 
in the comparison of CI and IB of beta-lactam antibiotics in hospitalized patients. As described in 
that chapter, most of the published clinical studies used inconsistent study designs and treatment 
arms, and mostly recruited heterogeneous patient populations which mainly consist non-critically ill 
patients. Furthermore, most studies were found to recruit patients with highly susceptible pathogens 
and this patient selection may mask the potential advantages of CI administration. If many patients 
with highly susceptible pathogens are included in a study, the sample size required to show a 
clinical difference between CI and IB dosing will rise dramatically. The findings in Chapter 5 also 
suggest that these patients should be the focus of future clinical studies: (a) critically ill patients; (b) 
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patients with higher level of illness severity (e.g., APACHE II ≥15); (c) patients infected with less 
susceptible microorganism; (d) patients infected with Gram-negative infections and; (e) patients 
who are not receiving RRT. 
 
The BLISS study, which was presented in Chapter 6, was designed to address most of the 
limitations of previous studies. The BLISS study is a prospective, two-centre, RCT of CI versus IB 
dosing of beta-lactam antibiotics which was conducted in two Malaysian ICUs. This study recruited 
140 critically ill patients with severe sepsis who were not on RRT prior to study inclusion. The 
primary outcome evaluated in the study was clinical cure at 14 days after antibiotic cessation and 
secondary outcomes included PK/PD target attainment, ICU-free days and ventilator-free days at 
Day 28 post-randomization, 14- and 30-day survival, and time to WCC normalization. In this study, 
CI of beta-lactam antibiotics demonstrated higher clinical cure rates (56% versus 34%; p = 0.011) 
and better PK/PD target attainment compared to IB dosing. CI participants were ten-times more 
likely to achieve 100% fT>MIC on Day 1 (p <0.001) and nine-times more likely to achieve 100% 
fT>MIC on Day 3 (p <0.001) post-randomization. Furthermore, CI participants also demonstrated 
increased ventilator-free days (22 versus 14; p = 0.043) and a reduced time to WCC normalization 
(3 days versus 8 days; p <0.001) as compared to IB participants. Essentially, the findings presented 
in Chapter 6 highlight that CI of beta-lactam antibiotics may be highly advantageous in those with a 
high level of illness severity and not receiving RRT. The findings of the BLISS study also suggest 
that CI dosing may be highly important in the management of patients who are infected with 
pathogens with higher MICs considering that this study was conducted in a geographical region 
which is mostly implicated with less susceptible pathogens. Although actual MIC values were not 
available, 41% of the causative pathogens isolated from the BLISS study were either A. baumannii 
or P. aeruginosa which mostly have higher MICs to the study antibiotics, thereby reducing the 
likelihood of achieving therapeutic concentrations with IB dosing. Importantly, CI participants in 
this study were three-times more likely to achieve clinical cure even after controlling for 
confounding variables (OR 3.21, 95% confidence interval 1.48-6.94; p = 0.003). 
 
A final area of study which presented in this Thesis was a structured review of published literature 
describing the relevance of PK/PD characteristics of different antibiotic classes on the development 
of resistance. Findings presented in Chapter 7 showed that the risk of antibiotic resistance 
dramatically increases with sub-optimal dosing and this phenomenon is frequently described with 
the fluoroquinolones. Traditionally, most of our treatment goals were focused on maximizing 
clinical outcomes and have not included minimization of the emergence of resistance and this 
strategy has indirectly contributed to rapid development of bacterial resistance. The data in Chapter 
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7 also suggest that PK/PD principles should be highly considered when dosing antibiotics in 
critically ill patients as the strategy has been shown to minimize the risk of antibiotic resistance. To 
prevent the emergence of resistance, it is likely that clinicians need to administer “the highest 
tolerated antibiotic dose” via alternative dosing strategies particularly early in the course of 
infection in critically ill patients. 
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8.2 Future directions for research 
Based on the findings presented in this Thesis, there are several areas for further research to address 
the following gaps in knowledge: 
 
 The theoretical basis for CI administration of beta-lactam antibiotics in critically ill patients 
are currently well established. However, numerous studies lacked a design that was 
sufficient to explore the effect of CI and IB dosing and this may have prevented them from 
obtaining a definitive answer as to which beta-lactam dosing method should be preferred in 
critically ill patients. Therefore, a large-scale, prospective, multinational RCT (n = 700) is 
now required to ascertain whether the potential benefits of CI dosing of beta-lactam 
antibiotics do indeed translate into survival benefit in critically ill patients. The proposed 
RCT should also focus on these patients: (a) critically ill patients with severe sepsis; (b) 
patients who are not receiving RRT; (c) patients with severe pneumonia and; (e) patients 
who are likely to be infected with less susceptible Gram-negative pathogens. 
 
 Although numerous studies have been performed to determine the optimal beta-lactam 
PK/PD targets for clinical success, very little data exist describing their roles in the 
prevention of bacterial resistance. Therefore, appropriate PK/PD targets are urgently 
required for this antibiotic class before a dosing regimen that minimizes the emergence of 
resistance can be suggested. It follows that, once these PK/PD targets are defined, they can 
be employed as one of the main end-points in future RCTs in order evaluate the relative 
ability of CI versus IB dosing in reducing the emergence of resistance associated with the 
use of beta-lactam antibiotics. 
    
 Most antibiotic dosage suggestion in Malaysia does not appear to be based on any published 
studies in Malaysian patients but rather PK/PD analyses of healthy Caucasian volunteers and 
therefore, its “suitability” and “appropriateness” for the local critically ill population is yet 
to be confirmed. Accordingly, there comes the need to evaluate the effectiveness of the 
current antibiotic dosing regimen in the Malaysian critically ill population via PK/PD 
analysis.    
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8.3 Conclusion 
Profound pathophysiological changes in critically ill patients may significantly alter the PK of beta-
lactam antibiotics and consequently reduce PK/PD target attainment. Conventional beta-lactam 
dosing does not address these alterations and as such, increases the likelihood of therapeutic failure 
and the emergence of resistance in critically ill patients. Altered dosing approaches (i.e., CI and EI) 
may be needed to ensure optimal beta-lactam exposure and may produce better therapeutic 
outcomes than IB administration, particularly in critically ill patients with severe sepsis.  
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